USPatent applicationPatented

Data structures and methods for modeling Saccharomyces cerevisiae metabolism

Granted 1 May 2012 · 2 office actions

Life of the application

10 dated events
⤢ drag to zoom200520102015202020252030ProsecutionOwnershipTerm & fees
ProsecutionOwnershipTerm & feeshover for detail · click to open

Abstract

The invention provides an in silico model for determining a S. cerevisiae physiological function. The model includes a data structure relating a plurality of S. cerevisiae reactants to a plurality of S. cerevisiae reactions, a constraint set for the plurality of S. cerevisiae reactions, and commands for determining a distribution of flux through the reactions that is predictive of a S. cerevisiae physiological function. A model of the invention can further include a gene database containing information characterizing the associated gene or genes. The invention further provides methods for making an in silico S. cerevisiae model and methods for determining a S. cerevisiae physiological function using a model of the invention.

Description

29 parts
›CROSS REFERENCE TO RELATED APPLICATION

This application is a continuation application of U.S. application Ser. No. 10/263,901 filed Oct. 2, 2002 now U.S. Pat. No. 7,751,981, which claims the benefit under 35 USC §119(e) to U.S. Application Ser. No. 60/344,447 filed Oct. 26, 2001. The disclosure of each of the prior applications is considered part of and is incorporated by reference in the disclosure of this application.

›GRANT INFORMATION

This invention was made with government support under Grant No. RO1HL59234 awarded by the National Institutes of Health. The government has certain rights in this invention.

›BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates generally to analysis of the activity of a chemical reaction network and, more specifically, to computational methods for simulating and predicting the activity of Saccharomyces cerevisiae ( S. cerevisiae ) reaction networks.

2. Background Information

Saccharomyces cerevisiae is one of the best-studied microorganisms and in addition to its significant industrial importance it serves as a model organism for the study of eukaryotic cells (Winzeler et al. Science 285: 901-906 (1999)). Up to 30% of positionally cloned genes implicated in human disease have yeast homologs.

The first eukaryotic genome to be sequenced was that of S. cerevisiae , and about 6400 open reading frames (or genes) have been identified in the genome. S. cerevisiae was the subject of the first expression profiling experiments and a compendium of expression profiles for many different mutants and different growth conditions has been established. Furthermore, a protein-protein interaction network has been defined and used to study the interactions between a large number of yeast proteins.

S. cerevisiae is used industrially to produce fuel ethanol, technical ethanol, beer, wine, spirits and baker's yeast, and is used as a host for production of many pharmaceutical proteins (hormones and vaccines). Furthermore, S. cerevisiae is currently being exploited as a cell factory for many different bioproducts including insulin.

Genetic manipulations, as well as changes in various fermentation conditions, are being considered in an attempt to improve the yield of industrially important products made by S. cerevisiae . However, these approaches are currently not guided by a clear understanding of how a change in a particular parameter, or combination of parameters, is likely to affect cellular behavior, such as the growth of the organism, the production of the desired product or the production of unwanted by-products. It would be valuable to be able to predict how changes in fermentation conditions, such as an increase or decrease in the supply of oxygen or a media component, would affect cellular behavior and, therefore, fermentation performance. Likewise, before engineering the organism by addition or deletion of one or more genes, it would be useful to be able to predict how these changes would affect cellular behavior.

However, it is currently difficult to make these sorts of predictions for S. cerevisiae because of the complexity of the metabolic reaction network that is encoded by the S. cerevisiae genome. Even relatively minor changes in media composition can affect hundreds of components of this network such that potentially hundreds of variables are worthy of consideration in making a prediction of fermentation behavior. Similarly, due to the complexity of interactions in the network, mutation of even a single gene can have effects on multiple components of the network. Thus, there exists a need for a model that describes S. cerevisiae reaction networks, such as its metabolic network, which can be used to simulate many different aspects of the cellular behavior of S. cerevisiae under different conditions. The present invention satisfies this need, and provides related advantages as well.

›SUMMARY OF THE INVENTION

The invention provides a computer readable medium or media, including: (a) a data structure relating a plurality of reactants in S. cerevisiae to a plurality of reactions in S. cerevisiae , wherein each of the S. cerevisiae reactions includes a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product, (b) a constraint set for the plurality of S. cerevisiae reactions, and (c) commands for determining at least one flux distribution that minimizes or maximizes an objective function when the constraint set is applied to the data representation, wherein at least one flux distribution is predictive of a physiological function of S. cerevisiae . In one embodiment, at least one of the cellular reactions in the data structure is annotated to indicate an associated gene and the computer readable medium or media further includes a gene database including information characterizing the associated gene. In another embodiment, at least one of the cellular reactions in the data structure is annotated with an assignment of function within a subsystem or a compartment within the cell.

The invention also provides a method for predicting physiological function of S. cerevisiae , including: (a) providing a data structure relating a plurality of S. cerevisiae to a plurality of S. cerevisiae reactions, wherein each of the S. cerevisiae reactions includes a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product; (b) providing a constraint set for the plurality of S. cerevisiae reactions; (c) providing an objective function, and (d) determining at least one flux distribution that minimizes or maximizes the objective function when the constraint set is applied to the data structure, thereby predicting a S. cerevisiae physiological function. In one embodiment, at least one of the S. cerevisiae reactions in the data structure is annotated to indicate an associated gene and the method predicts a S. cerevisiae physiological function related to the gene.

Also provided by the invention is a method for making a data structure relating a plurality of S. cerevisiae reactants to a plurality of S. cerevisiae reactions in a computer readable medium or media, including: (a) identifying a plurality of S. cerevisiae reactions and a plurality of reactants that are substrates and products of the reactions; (b) relating the plurality of reactants to the plurality of reactions in a data structure, wherein each of the reactions includes a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product; (c) determining a constraint set for the plurality of S. cerevisiae reactions; (d) providing an objective function; (e) determining at least one flux distribution that minimizes or maximizes the objective function when the constraint set is applied to the data structure, and (f) if at least one flux distribution is not predictive of a physiological function of S. cerevisiae , then adding a reaction to or deleting a reaction from the data structure and repeating step (e), if at least one flux distribution is predictive of a physiological function of the eukaryotic cell, then storing the data structure in a computer readable medium or media. The invention further provides a data structure relating a plurality of S. cerevisiae reactants to a plurality of reactions, wherein the data structure is produced by the method.

›BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a schematic representation of a hypothetical metabolic network.

FIG. 2 shows the stoichiometric matrix (S) for the hypothetical metabolic network shown in FIG. 1 .

FIG. 3 shows mass balance constraints and flux constraints (reversibility constraints) that can be placed on the hypothetical metabolic network shown in FIG. 1 . (∞, infinity; Y 1 , uptake rate value)

FIG. 4 shows an exemplary metabolic reaction network in S. cerevisiae.

FIG. 5 shows a method for reconstruction of the metabolic network of S. cerevisiae . Based on the available information from the genome annotation, biochemical pathway databases, biochemistry textbooks and recent publications, a genome-scale metabolic network for S. cerevisiae was designed. Additional physiological constraints were considered and modeled, such as growth, non-growth dependent ATP requirements and biomass composition.

FIGS. 6A and 6B show a Phenotypic Phase Plane (PhPP) diagram for S. cerevisiae revealing a finite number of qualitatively distinct patterns of metabolic pathway utilization divided into discrete phases. The characteristics of these distinct phases are interpreted using ratios of shadow prices in the form of isoclines. The isoclines can be used to classify these phases into futile, single and dual substrate limitation and to define the line of optimality. FIG. 6A shows a 3-dimensional S. cerevisiae Phase Plane diagram. FIG. 6B shows a 2-dimensional Phase Plane diagram with the line of optimality (LO) indicated.

FIG. 7 shows the respiratory quotient (RQ) versus oxygen uptake rate (mmole/g-DW/hr) (upper left) on the line of optimality. The phenotypic phase plane (PhPP) illustrates that the predicted RQ is a constant of value 1.06

FIG. 8 shows phases of metabolic phenotype associated with varying oxygen availability, from completely anaerobic fermentation to aerobic growth in S. cerevisiae . The glucose uptake rate was fixed under all conditions, and the resulting optimal biomass yield, as well as respiratory quotient, RQ, are indicated along with the output fluxes associated with four metabolic by-products: acetate, succinate, pyruvate, and ethanol.

FIG. 9A shows anaerobic glucose limited continuous culture of S. cerevisiae . FIG. 9A shows the utilization of glucose at varying dilution rates in anaerobic chemostat culture. The data-point at the dilution rate of 0.0 is extrapolated from the experimental results. The shaded area or the infeasible region contains a set of stoichiometric constraints that cannot be balanced simultaneously with growth demands. The model produces the optimal glucose uptake rate for a given growth rate on the line of optimal solution (indicated by Model (optimal)). Imposition of additional constraints drives the solution towards a region where more glucose is needed (i.e. region of alternative sub-optimal solution). At the optimal solution, the in silico model does not secrete pyruvate and acetate. The maximum difference between the model and the experimental points is 8% at the highest dilution rate. When the model is forced to produce these by-products at the experimental level (Model (forced)), the glucose uptake rate is increased and becomes closer to the experimental values. FIGS. 9B and 9C show the secretion rate of anaerobic by-products in chemostat culture. (q, secretion rate; D, dilution rate).

FIGS. 10A and 10B show aerobic glucose-limited continuous culture of S. cerevisiae in vivo and in silico. FIG. 10A shows biomass yield (Y X ), and secretion rates of ethanol (Eth), and glycerol (Gly). FIG. 10B shows CO 2 secretion rate (q CO2 ) and respiratory quotient (RQ; i.e. q CO2 /q O2 ) of the aerobic glucose-limited continuous culture of S. cerevisiae . (exp, experimental).

›DETAILED DESCRIPTION OF THE INVENTION · 1 of 12

The present invention provides an in silico model of the baker's and brewer's yeast, S. cerevisiae , that describes the interconnections between the metabolic genes in the S. cerevisiae genome and their associated reactions and reactants. The model can be used to simulate different aspects of the cellular behavior of S. cerevisiae under different environmental and genetic conditions, thereby providing valuable information for industrial and research applications. An advantage of the model of the invention is that it provides a holistic approach to simulating and predicting the metabolic activity of S. cerevisiae.

As an example, the S. cerevisiae metabolic model can be used to determine the optimal conditions for fermentation performance, such as for maximizing the yield of a specific industrially important enzyme. The model can also be used to calculate the range of cellular behaviors that S. cerevisiae can display as a function of variations in the activity of one gene or multiple genes. Thus, the model can be used to guide the organismal genetic makeup for a desired application. This ability to make predictions regarding cellular behavior as a consequence of altering specific parameters will increase the speed and efficiency of industrial development of S. cerevisiae strains and conditions for their use.

The S. cerevisiae metabolic model can also be used to predict or validate the assignment of particular biochemical reactions to the enzyme-encoding genes found in the genome, and to identify the presence of reactions or pathways not indicated by current genomic data. Thus, the model can be used to guide the research and discovery process, potentially leading to the identification of new enzymes, medicines or metabolites of commercial importance.

The models of the invention are based on a data structure relating a plurality of S. cerevisiae reactants to a plurality of S. cerevisiae reactions, wherein each of the S. cerevisiae reactions includes a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product.

As used herein, the term “ S. cerevisiae reaction” is intended to mean a conversion that consumes a substrate or forms a product that occurs in or by a viable strain of S. cerevisiae . The term can include a conversion that occurs due to the activity of one or more enzymes that are genetically encoded by a S. cerevisiae genome. The term can also include a conversion that occurs spontaneously in a S. cerevisiae cell. Conversions included in the term include, for example, changes in chemical composition such as those due to nucleophilic or electrophilic addition, nucleophilic or electrophilic substitution, elimination, isomerization, deamination, phosphorylation, methylation, glycolysation, reduction, oxidation or changes in location such as those that occur due to a transport reaction that moves a reactant within the same compartment or from one cellular compartment to another. In the case of a transport reaction, the substrate and product of the reaction can be chemically the same and the substrate and product can be differentiated according to location in a particular cellular compartment. Thus, a reaction that transports a chemically unchanged reactant from a first compartment to a second compartment has as its substrate the reactant in the first compartment and as its product the reactant in the second compartment. It will be understood that when used in reference to an in silico model or data structure, a reaction is intended to be a representation of a chemical conversion that consumes a substrate or produces a product.

As used herein, the term “ S. cerevisiae reactant” is intended to mean a chemical that is a substrate or a product of a reaction that occurs in or by a viable strain of S. cerevisiae . The term can include substrates or products of reactions performed by one or more enzymes encoded by S. cerevisiae gene(s), reactions occurring in S. cerevisiae that are performed by one or more non-genetically encoded macromolecule, protein or enzyme, or reactions that occur spontaneously in a S. cerevisiae cell. Metabolites are understood to be reactants within the meaning of the term. It will be understood that when used in reference to an in silico model or data structure, a reactant is intended to be a representation of a chemical that is a substrate or a product of a reaction that occurs in or by a viable strain of S. cerevisiae.

As used herein the term “substrate” is intended to mean a reactant that can be converted to one or more products by a reaction. The term can include, for example, a reactant that is to be chemically changed due to nucleophilic or electrophilic addition, nucleophilic or electrophilic substitution, elimination, isomerization, deamination, phosphorylation, methylation, reduction, oxidation or that is to change location such as by being transported across a membrane or to a different compartment.

As used herein, the term “product” is intended to mean a reactant that results from a reaction with one or more substrates. The term can include, for example, a reactant that has been chemically changed due to nucleophilic or electrophilic addition, nucleophilic or electrophilic substitution, elimination, isomerization, deamination, phosphorylation, methylation, reduction or oxidation or that has changed location such as by being transported across a membrane or to a different compartment.

As used herein, the term “stoichiometric coefficient” is intended to mean a numerical constant correlating the number of one or more reactants and the number of one or more products in a chemical reaction. Typically, the numbers are integers as they denote the number of molecules of each reactant in an elementally balanced chemical equation that describes the corresponding conversion. However, in some cases the numbers can take on non-integer values, for example, when used in a lumped reaction or to reflect empirical data.

›DETAILED DESCRIPTION OF THE INVENTION · 2 of 12

As used herein, the term “plurality,” when used in reference to S. cerevisiae reactions or reactants is intended to mean at least 2 reactions or reactants. The term can include any number of S. cerevisiae reactions or reactants in the range from 2 to the number of naturally occurring reactants or reactions for a particular strain of S. cerevisiae . Thus, the term can include, for example, at least 10, 20, 30, 50, 100, 150, 200, 300, 400, 500, 600 or more reactions or reactants. The number of reactions or reactants can be expressed as a portion of the total number of naturally occurring reactions for a particular strain of S. cerevisiae such as at least 20%, 30%, 50%, 60%, 75%, 90%, 95% or 98% of the total number of naturally occurring reactions that occur in a particular strain of S. cerevisiae.

As used herein, the term “data structure” is intended to mean a physical or logical relationship among data elements, designed to support specific data manipulation functions. The term can include, for example, a list of data elements that can be added combined or otherwise manipulated such as a list of representations for reactions from which reactants can be related in a matrix or network. The term can also include a matrix that correlates data elements from two or more lists of information such as a matrix that correlates reactants to reactions. Information included in the term can represent, for example, a substrate or product of a chemical reaction, a chemical reaction relating one or more substrates to one or more products, a constraint placed on a reaction, or a stoichiometric coefficient.

As used herein, the term “constraint” is intended to mean an upper or lower boundary for a reaction. A boundary can specify a minimum or maximum flow of mass, electrons or energy through a reaction. A boundary can further specify directionality of a reaction. A boundary can be a constant value such as zero, infinity, or a numerical value such as an integer and non-integer.

As used herein, the term “activity,” when used in reference to a reaction, is intended to mean the rate at which a product is produced or a substrate is consumed. The rate at which a product is produced or a substrate is consumed can also be referred to as the flux for the reaction.

As used herein, the term “activity,” when used in reference to S. cerevisiae is intended to mean the rate of a change from an initial state of S. cerevisiae to a final state of S. cerevisiae . The term can include, the rate at which a chemical is consumed or produced by S. cerevisiae , the rate of growth of S. cerevisiae or the rate at which energy or mass flow through a particular subset of reactions.

The invention provides a computer readable medium, having a data structure relating a plurality of S. cerevisiae reactants to a plurality of S. cerevisiae reactions, wherein each of the S. cerevisiae reactions includes a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product.

The plurality of S. cerevisiae reactions can include reactions of a peripheral metabolic pathway. As used herein, the term “peripheral,” when used in reference to a metabolic pathway, is intended to mean a metabolic pathway that includes one or more reactions that are not a part of a central metabolic pathway. As used herein, the term “central,” when used in reference to a metabolic pathway, is intended to mean a metabolic pathway selected from glycolysis, the pentose phosphate pathway (PPP), the tricarboxylic acid (TCA) cycle and the electron transfer system (ETS), associated anapleurotic reactions, and pyruvate metabolism.

A plurality of S. cerevisiae reactants can be related to a plurality of S. cerevisiae reactions in any data structure that represents, for each reactant, the reactions by which it is consumed or produced. Thus, the data structure, which is referred to herein as a “reaction network data structure,” serves as a representation of a biological reaction network or system. An example of a reaction network that can be represented in a reaction network data structure of the invention is the collection of reactions that constitute the metabolic reactions of S. cerevisiae.

The methods and models of the invention can be applied to any strain of S. cerevisiae including, for example, strain CEN.PK113.7D or any laboratory or production strain. A strain of S. cerevisiae can be identified according to classification criteria known in the art. Classification criteria include, for example, classical microbiological characteristics, such as those upon which taxonomic classification is traditionally based, or evolutionary distance as determined for example by comparing sequences from within the genomes of organisms, such as ribosome sequences.

The reactants to be used in a reaction network data structure of the invention can be obtained from or stored in a compound database. As used herein, the term “compound database” is intended to mean a computer readable medium or media containing a plurality of molecules that includes substrates and products of biological reactions. The plurality of molecules can include molecules found in multiple organisms, thereby constituting a universal compound database. Alternatively, the plurality of molecules can be limited to those that occur in a particular organism, thereby constituting an organism-specific compound database. Each reactant in a compound database can be identified according to the chemical species and the cellular compartment in which it is present. Thus, for example, a distinction can be made between glucose in the extracellular compartment versus glucose in the cytosol. Additionally each of the reactants can be specified as a metabolite of a primary or secondary metabolic pathway. Although identification of a reactant as a metabolite of a primary or secondary metabolic pathway does not indicate any chemical distinction between the reactants in a reaction, such a designation can assist in visual representations of large networks of reactions.

›DETAILED DESCRIPTION OF THE INVENTION · 3 of 12

As used herein, the term “compartment” is intended to mean a subdivided region containing at least one reactant, such that the reactant is separated from at least one other reactant in a second region. A subdivided region included in the term can be correlated with a subdivided region of a cell. Thus, a subdivided region included in the term can be, for example, the intracellular space of a cell; the extracellular space around a cell; the periplasmic space; the interior space of an organelle such as a mitochondrium, endoplasmic reticulum, Golgi apparatus, vacuole or nucleus; or any subcellular space that is separated from another by a membrane or other physical barrier. Subdivided regions can also be made in order to create virtual boundaries in a reaction network that are not correlated with physical barriers. Virtual boundaries can be made for the purpose of segmenting the reactions in a network into different compartments or substructures.

As used herein, the term “substructure” is intended to mean a portion of the information in a data structure that is separated from other information in the data structure such that the portion of information can be separately manipulated or analyzed. The term can include portions subdivided according to a biological function including, for example, information relevant to a particular metabolic pathway such as an internal flux pathway, exchange flux pathway, central metabolic pathway, peripheral metabolic pathway, or secondary metabolic pathway. The term can include portions subdivided according to computational or mathematical principles that allow for a particular type of analysis or manipulation of the data structure.

The reactions included in a reaction network data structure can be obtained from a metabolic reaction database that includes the substrates, products, and stoichiometry of a plurality of metabolic reactions of S. cerevisiae . The reactants in a reaction network data structure can be designated as either substrates or products of a particular reaction, each with a stoichiometric coefficient assigned to it to describe the chemical conversion taking place in the reaction. Each reaction is also described as occurring in either a reversible or irreversible direction. Reversible reactions can either be represented as one reaction that operates in both the forward and reverse direction or be decomposed into two irreversible reactions, one corresponding to the forward reaction and the other corresponding to the backward reaction.

Reactions included in a reaction network data structure can include intra-system or exchange reactions. Intra-system reactions are the chemically and electrically balanced interconversions of chemical species and transport processes, which serve to replenish or drain the relative amounts of certain metabolites. These intra-system reactions can be classified as either being transformations or translocations. A transformation is a reaction that contains distinct sets of compounds as substrates and products, while a translocation contains reactants located in different compartments. Thus, a reaction that simply transports a metabolite from the extracellular environment to the cytosol, without changing its chemical composition is solely classified as a translocation, while a reaction such as the phosphotransferase system (PTS) which takes extracellular glucose and converts it into cytosolic glucose-6-phosphate is a translocation and a transformation.

Exchange reactions are those which constitute sources and sinks, allowing the passage of metabolites into and out of a compartment or across a hypothetical system boundary. These reactions are included in a model for simulation purposes and represent the metabolic demands placed on S. cerevisiae . While they may be chemically balanced in certain cases, they are typically not balanced and can often have only a single substrate or product. As a matter of convention the exchange reactions are further classified into demand exchange and input/output exchange reactions.

The metabolic demands placed on the S. cerevisiae metabolic reaction network can be readily determined from the dry weight composition of the cell which is available in the published literature or which can be determined experimentally. The uptake rates and maintenance requirements for S. cerevisiae can be determined by physiological experiments in which the uptake rate is determined by measuring the depletion of the substrate. The measurement of the biomass at each point can also be determined, in order to determine the uptake rate per unit biomass. The maintenance requirements can be determined from a chemostat experiment. The glucose uptake rate is plotted versus the growth rate, and the y-intercept is interpreted as the non-growth associated maintenance requirements. The growth associated maintenance requirements are determined by fitting the model results to the experimentally determined points in the growth rate versus glucose uptake rate plot.

Input/output exchange reactions are used to allow extracellular reactants to enter or exit the reaction network represented by a model of the invention. For each of the extracellular metabolites a corresponding input/output exchange reaction can be created. These reactions can either be irreversible or reversible with the metabolite indicated as a substrate with a stoichiometric coefficient of one and no products produced by the reaction. This particular convention is adopted to allow the reaction to take on a positive flux value (activity level) when the metabolite is being produced or removed from the reaction network and a negative flux value when the metabolite is being consumed or introduced into the reaction network. These reactions will be further constrained during the course of a simulation to specify exactly which metabolites are available to the cell and which can be excreted by the cell.

A demand exchange reaction is always specified as an irreversible reaction containing at least one substrate. These reactions are typically formulated to represent the production of an intracellular metabolite by the metabolic network or the aggregate production of many reactants in balanced ratios such as in the representation of a reaction that leads to biomass formation, also referred to as growth. As set forth in the Examples, the biomass components to be produced for growth include L-Alanine, L-Arginine, L-Asparagine, L-Aspartate, L-Cysteine, L-Glutamine, L-Glutamate, Glycine, L-Histidine, L-Isoleucine, L-Leucine, L-Lysine, L-Methionine, L-Phenylalanine, L-Proline, L-Serine, L-Threonine, L-Tryptophan, L-Tyrosine, L-Valine, AMP, GMP, CMP, UMP, dAMP, dCMP, dTMP, dGMP, Glycogen, alpha,alpha-Trehalose, Mannan, beta-D-Glucan, Triacylglycerol, Ergosterol, Zymosterol, Phosphatidate, Phosphatidylcholine, Phosphatidylethanolamine, Phosphatidyl-D-myo-inositol, Phosphatidylserine, ATP, Sulfate, ADP and Orthophosphate, with exemplary values shown in Table 1.

›DETAILED DESCRIPTION OF THE INVENTION · 4 of 12

A demand exchange reaction can be introduced for any metabolite in a model of the invention. Most commonly these reactions are introduced for metabolites that are required to be produced by the cell for the purposes of creating a new cell such as amino acids, nucleotides, phospholipids, and other biomass constituents, or metabolites that are to be produced for alternative purposes. Once these metabolites are identified, a demand exchange reaction that is irreversible and specifies the metabolite as a substrate with a stoichiometric coefficient of unity can be created. With these specifications, if the reaction is active it leads to the net production of the metabolite by the system meeting potential production demands. Examples of processes that can be represented as a demand exchange reaction in a reaction network data structure and analyzed by the methods of the invention include, for example, production or secretion of an individual protein; production or secretion of an individual metabolite such as an amino acid, vitamin, nucleoside, antibiotic or surfactant; production of ATP for extraneous energy requiring processes such as locomotion; or formation of biomass constituents.

In addition to these demand exchange reactions that are placed on individual metabolites, demand exchange reactions that utilize multiple metabolites in defined stoichiometric ratios can be introduced. These reactions are referred to as aggregate demand exchange reactions. An example of an aggregate demand reaction is a reaction used to simulate the concurrent growth demands or production requirements associated with cell growth that are placed on a cell, for example, by simulating the formation of multiple biomass constituents simultaneously at a particular cellular growth rate.

A hypothetical reaction network is provided in FIG. 1 to exemplify the above-described reactions and their interactions. The reactions can be represented in the exemplary data structure shown in FIG. 2 as set forth below. The reaction network, shown in FIG. 1 , includes intrasystem reactions that occur entirely within the compartment indicated by the shaded oval such as reversible reaction R 2 which acts on reactants B and G and reaction R 3 which converts one equivalent of B to two equivalents of F. The reaction network shown in FIG. 1 also contains exchange reactions such as input/output exchange reactions A xt and E xt , and the demand exchange reaction, V growth , which represents growth in response to the one equivalent of D and one equivalent of F. Other intrasystem reactions include R 1 which is a translocation and transformation reaction that translocates reactant A into the compartment and transforms it to reactant G and reaction R 6 which is a transport reaction that translocates reactant E out of the compartment.

A reaction network can be represented as a set of linear algebraic equations which can be presented as a stoichiometric matrix S, with S being an m×n matrix where m corresponds to the number of reactants or metabolites and n corresponds to the number of reactions taking place in the network. An example of a stoichiometric matrix representing the reaction network of FIG. 1 is shown in FIG. 2 . As shown in FIG. 2 , each column in the matrix corresponds to a particular reaction n, each row corresponds to a particular reactant m, and each S mn element corresponds to the stoichiometric coefficient of the reactant m in the reaction denoted n. The stoichiometric matrix includes intra-system reactions such as R 2 and R 3 which are related to reactants that participate in the respective reactions according to a stoichiometric coefficient having a sign indicative of whether the reactant is a substrate or product of the reaction and a value correlated with the number of equivalents of the reactant consumed or produced by the reaction. Exchange reactions such as -E xt and -A xt are similarly correlated with a stoichiometric coefficient. As exemplified by reactant E, the same compound can be treated separately as an internal reactant (E) and an external reactant (E external ) such that an exchange reaction (R 6 ) exporting the compound is correlated by stoichiometric coefficients of −1 and 1, respectively. However, because the compound is treated as a separate reactant by virtue of its compartmental location, a reaction, such as R 5 , which produces the internal reactant (E) but does not act on the external reactant (E external ) is correlated by stoichiometric coefficients of 1 and 0, respectively. Demand reactions such as V growth can also be included in the stoichiometric matrix being correlated with substrates by an appropriate stoichiometric coefficient.

As set forth in further detail below, a stoichiometric matrix provides a convenient format for representing and analyzing a reaction network because it can be readily manipulated and used to compute network properties, for example, by using linear programming or general convex analysis. A reaction network data structure can take on a variety of formats so long as it is capable of relating reactants and reactions in the manner exemplified above for a stoichiometric matrix and in a manner that can be manipulated to determine an activity of one or more reactions using methods such as those exemplified below. Other examples of reaction network data structures that are useful in the invention include a connected graph, list of chemical reactions or a table of reaction equations.

A reaction network data structure can be constructed to include all reactions that are involved in S. cerevisiae metabolism or any portion thereof. A portion of S. cerevisiae metabolic reactions that can be included in a reaction network data structure of the invention includes, for example, a central metabolic pathway such as glycolysis, the TCA cycle, the PPP or ETS; or a peripheral metabolic pathway such as amino acid biosynthesis, amino acid degradation, purine biosynthesis, pyrimidine biosynthesis, lipid biosynthesis, fatty acid metabolism, vitamin or cofactor biosynthesis, transport processes and alternative carbon source catabolism. Examples of individual pathways within the peripheral pathways are set forth in Table 2, including, for example, the cofactor biosynthesis pathways for quinone biosynthesis, riboflavin biosynthesis, folate biosynthesis, coenzyme A biosynthesis, NAD biosynthesis, biotin biosynthesis and thiamin biosynthesis.

›DETAILED DESCRIPTION OF THE INVENTION · 5 of 12

Depending upon a particular application, a reaction network data structure can include a plurality of S. cerevisiae reactions including any or all of the reactions listed in Table 2. Exemplary reactions that can be included are those that are identified as being required to achieve a desired S. cerevisiae specific growth rate or activity including, for example, reactions identified as ACO1, CDC19, CIT1, DAL7, ENO1, FBA1, FBP1, FUM1, GND1, GPM1, HXK1, ICL1, IDH1, IDH2, IDP1, IDP2, IDP3, KGD1, KGD2, LPD1, LSC1, LSC2, MDH1, MDH2, MDH3, MLS1, PDC1, PFK1, PFK2, PGI1,PGK1, PGM1, PGM2, PYC1, PYC2, PYK2, RKI1, RPE1, SOL1, TAL1, TDH1, IDH2, TDH3, TKL1, TPI1, ZWF1 in Table 2. Other reactions that can be included are those that are not described in the literature or genome annotation but can be identified during the course of iteratively developing a S. cerevisiae model of the invention including, for example, reactions identified as MET6 — 2, MNADC, MNADD1, MNADE, MNADF — 1, MNADPHPS, MNADG1, MNADG2, MNADH, MNPT1.

Standard chemical names for the acronyms used to identify the reactants in the reactions of Table 2 are provided in Table 3.

Depending upon the particular environmental conditions being tested and the desired activity, a reaction network data structure can contain smaller numbers of reactions such as at least 200, 150, 100 or 50 reactions. A reaction network data structure having relatively few reactions can provide the advantage of reducing computation time and resources required to perform a simulation. When desired, a reaction network data structure having a particular subset of reactions can be made or used in which reactions that are not relevant to the particular simulation are omitted. Alternatively, larger numbers of reactions can be included in order to increase the accuracy or molecular detail of the methods of the invention or to suit a particular application. Thus, a reaction network data structure can contain at least 300, 350, 400, 450, 500, 550, 600 or more reactions up to the number of reactions that occur in or by S. cerevisiae or that are desired to simulate the activity of the full set of reactions occurring in S. cerevisiae . A reaction network data structure that is substantially complete with respect to the metabolic reactions of S. cerevisiae provides the advantage of being relevant to a wide range of conditions to be simulated, whereas those with smaller numbers of metabolic reactions are limited to a particular subset of conditions to be simulated.

A S. cerevisiae reaction network data structure can include one or more reactions that occur in or by S. cerevisiae and that do not occur, either naturally or following manipulation, in or by another prokaryotic organism, such as Escherichia coli, Haemophilus influenzae, Bacillus subtilis, Helicobacter pylori or in or by another eukaryotic organism, such as Homo sapiens . Examples of reactions that are unique to S. cerevisiae compared at least to Escherichia coli, Haemophilus influenzae , and Helicobacter pylori include those identified in Table 4. It is understood that a S. cerevisiae reaction network data structure can also include one or more reactions that occur in another organism. Addition of such heterologous reactions to a reaction network data structure of the invention can be used in methods to predict the consequences of heterologous gene transfer in S. cerevisiae , for example, when designing or engineering man-made cells or strains.

A reaction network data structure or index of reactions used in the data structure such as that available in a metabolic reaction database, as described above, can be annotated to include information about a particular reaction. A reaction can be annotated to indicate, for example, assignment of the reaction to a protein, macromolecule or enzyme that performs the reaction, assignment of a gene(s) that codes for the protein, macromolecule or enzyme, the Enzyme Commission (EC) number of the particular metabolic reaction or Gene Ontology (GO) number of the particular metabolic reaction, a subset of reactions to which the reaction belongs, citations to references from which information was obtained, or a level of confidence with which a reaction is believed to occur in S. cerevisiae . A computer readable medium or media of the invention can include a gene database containing annotated reactions. Such information can be obtained during the course of building a metabolic reaction database or model of the invention as described below.

As used herein, the term “gene database” is intended to mean a computer readable medium or media that contains at least one reaction that is annotated to assign a reaction to one or more macromolecules that perform the reaction or to assign one or more nucleic acid that encodes the one or more macromolecules that perform the reaction. A gene database can contain a plurality of reactions some or all of which are annotated. An annotation can include, for example, a name for a macromolecule; assignment of a function to a macromolecule; assignment of an organism that contains the macromolecule or produces the macromolecule; assignment of a subcellular location for the macromolecule; assignment of conditions under which a macromolecule is being expressed or being degraded; an amino acid or nucleotide sequence for the macromolecule; or any other annotation found for a macromolecule in a genome database such as those that can be found in Saccharomyces Genome Database maintained by Stanford University, or Comprehensive Yeast Genome Database maintained by MIPS.

A gene database of the invention can include a substantially complete collection of genes and/or open reading frames in S. cerevisiae or a substantially complete collection of the macromolecules encoded by the S. cerevisiae genome. Alternatively, a gene database can include a portion of genes or open reading frames in S. cerevisiae or a portion of the macromolecules encoded by the S. cerevisiae genome. The portion can be at least 10%, 15%, 20%, 25%, 50%, 75%, 90% or 95% of the genes or open reading frames encoded by the S. cerevisiae genome, or the macromolecules encoded therein. A gene database can also include macromolecules encoded by at least a portion of the nucleotide sequence for the S. cerevisiae genome such as at least 10%, 15%, 20%, 25%, 50%, 75%, 90% or 95% of the S. cerevisiae genome. Accordingly, a computer readable medium or media of the invention can include at least one reaction for each macromolecule encoded by a portion of the S. cerevisiae genome.

›DETAILED DESCRIPTION OF THE INVENTION · 6 of 12

An in silico S. cerevisiae model according to the invention can be built by an iterative process which includes gathering information regarding particular reactions to be added to a model, representing the reactions in a reaction network data structure, and performing preliminary simulations wherein a set of constraints is placed on the reaction network and the output evaluated to identify errors in the network. Errors in the network such as gaps that lead to non-natural accumulation or consumption of a particular metabolite can be identified as described below and simulations repeated until a desired performance of the model is attained. An exemplary method for iterative model construction is provided in Example I.

Thus, the invention provides a method for making a data structure relating a plurality of S. cerevisiae reactants to a plurality of S. cerevisiae reactions in a computer readable medium or media. The method includes the steps of: (a) identifying a plurality of S. cerevisiae reactions and a plurality of S. cerevisiae reactants that are substrates and products of the S. cerevisiae reactions; (b) relating the plurality of S. cerevisiae reactants to the plurality of S. cerevisiae reactions in a data structure, wherein each of the S. cerevisiae reactions includes a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product; (c) making a constraint set for the plurality of S. cerevisiae reactions; (d) providing an objective function; (e) determining at least one flux distribution that minimizes or maximizes the objective function when the constraint set is applied to the data structure, and (f) if at least one flux distribution is not predictive of S. cerevisiae physiology, then adding a reaction to or deleting a reaction from the data structure and repeating step (e), if at least one flux distribution is predictive of S. cerevisiae physiology, then storing the data structure in a computer readable medium or media.

Information to be included in a data structure of the invention can be gathered from a variety of sources including, for example, the scientific literature or an annotated genome sequence of S. cerevisiae such as the GENBANK, a site maintained by the NCBI (ncbi.nlm.gov), the CYGD database, a site maintained by MIPS, or the SGD database, a site maintained by the School of Medicine at Stanford University, etc.

In the course of developing an in silico model of S. cerevisiae metabolism, the types of data that can be considered include, for example, biochemical information which is information related to the experimental characterization of a chemical reaction, often directly indicating a protein(s) associated with a reaction and the stoichiometry of the reaction or indirectly demonstrating the existence of a reaction occurring within a cellular extract; genetic information which is information related to the experimental identification and genetic characterization of a gene(s) shown to code for a particular protein(s) implicated in carrying out a biochemical event; genomic information which is information related to the identification of an open reading frame and functional assignment, through computational sequence analysis, that is then linked to a protein performing a biochemical event; physiological information which is information related to overall cellular physiology, fitness characteristics, substrate utilization, and phenotyping results, which provide evidence of the assimilation or dissimilation of a compound used to infer the presence of specific biochemical event (in particular translocations); and modeling information which is information generated through the course of simulating activity of S. cerevisiae using methods such as those described herein which lead to predictions regarding the status of a reaction such as whether or not the reaction is required to fulfill certain demands placed on a metabolic network.

The majority of the reactions occurring in S. cerevisiae reaction networks are catalyzed by enzymes/proteins, which are created through the transcription and translation of the genes found on the chromosome(s) in the cell. The remaining reactions occur through non-enzymatic processes. Furthermore, a reaction network data structure can contain reactions that add or delete steps to or from a particular reaction pathway. For example, reactions can be added to optimize or improve performance of a S. cerevisiae model in view of empirically observed activity. Alternatively, reactions can be deleted to remove intermediate steps in a pathway when the intermediate steps are not necessary to model flux through the pathway. For example, if a pathway contains 3 nonbranched steps, the reactions can be combined or added together to give a net reaction, thereby reducing memory required to store the reaction network data structure and the computational resources required for manipulation of the data structure. An example of a combined reaction is that for fatty acid degradation shown in Table 2, which combines the reactions for acyl-CoA oxidase, hydratase-dehydrogenase-epimerase, and acetyl-CoA C-acyltransferase of beta-oxidation of fatty acids.

The reactions that occur due to the activity of gene-encoded enzymes can be obtained from a genome database that lists genes or open reading frames identified from genome sequencing and subsequent genome annotation. Genome annotation consists of the locations of open reading frames and assignment of function from homology to other known genes or empirically determined activity. Such a genome database can be acquired through public or private databases containing annotated S. cerevisiae nucleic acid or protein sequences. If desired, a model developer can perform a network reconstruction and establish the model content associations between the genes, proteins, and reactions as described, for example, in Covert et al. Trends in Biochemical Sciences 26:179-186 (2001) and Palsson, WO 00/46405.

›DETAILED DESCRIPTION OF THE INVENTION · 7 of 12

As reactions are added to a reaction network data structure or metabolic reaction database, those having known or putative associations to the proteins/enzymes which enable/catalyze the reaction and the associated genes that code for these proteins can be identified by annotation. Accordingly, the appropriate associations for some or all of the reactions to their related proteins or genes or both can be assigned. These associations can be used to capture the non-linear relationship between the genes and proteins as well as between proteins and reactions. In some cases, one gene codes for one protein which then perform one reaction. However, often there are multiple genes which are required to create an active enzyme complex and often there are multiple reactions that can be carried out by one protein or multiple proteins that can carry out the same reaction. These associations capture the logic (i.e. AND or OR relationships) within the associations. Annotating a metabolic reaction database with these associations can allow the methods to be used to determine the effects of adding or eliminating a particular reaction not only at the reaction level, but at the genetic or protein level in the context of running a simulation or predicting S. cerevisiae activity.

A reaction network data structure of the invention can be used to determine the activity of one or more reactions in a plurality of S. cerevisiae reactions independent of any knowledge or annotation of the identity of the protein that performs the reaction or the gene encoding the protein. A model that is annotated with gene or protein identities can include reactions for which a protein or encoding gene is not assigned. While a large portion of the reactions in a cellular metabolic network are associated with genes in the organism's genome, there are also a substantial number of reactions included in a model for which there are no known genetic associations. Such reactions can be added to a reaction database based upon other information that is not necessarily related to genetics such as biochemical or cell based measurements or theoretical considerations based on observed biochemical or cellular activity. For example, there are many reactions that are not protein-enabled reactions. Furthermore, the occurrence of a particular reaction in a cell for which no associated proteins or genetics have been currently identified can be indicated during the course of model building by the iterative model building methods of the invention.

The reactions in a reaction network data structure or reaction database can be assigned to subsystems by annotation, if desired. The reactions can be subdivided according to biological criteria, such as according to traditionally identified metabolic pathways (glycolysis, amino acid metabolism and the like) or according to mathematical or computational criteria that facilitate manipulation of a model that incorporates or manipulates the reactions. Methods and criteria for subdividing a reaction database are described in further detail in Schilling et al., J. Theor. Biol. 203:249-283 (2000). The use of subsystems can be advantageous for a number of analysis methods, such as extreme pathway analysis, and can make the management of model content easier. Although assigning reactions to subsystems can be achieved without affecting the use of the entire model for simulation, assigning reactions to subsystems can allow a user to search for reactions in a particular subsystem, which may be useful in performing various types of analyses. Therefore, a reaction network data structure can include any number of desired subsystems including, for example, 2 or more subsystems, 5 or more subsystems, 10 or more subsystems, 25 or more subsystems or 50 or more subsystems.

The reactions in a reaction network data structure or metabolic reaction database can be annotated with a value indicating the confidence with which the reaction is believed to occur in S. cerevisiae . The level of confidence can be, for example, a function of the amount and form of supporting data that is available. This data can come in various forms including published literature, documented experimental results, or results of computational analyses. Furthermore, the data can provide direct or indirect evidence for the existence of a chemical reaction in a cell based on genetic, biochemical, and/or physiological data.

The invention further provides a computer readable medium, containing (a) a data structure relating a plurality of S. cerevisiae reactants to a plurality of S. cerevisiae reactions, wherein each of the S. cerevisiae reactions includes a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product, and (b) a constraint set for the plurality of S. cerevisiae reactions.

Constraints can be placed on the value of any of the fluxes in the metabolic network using a constraint set. These constraints can be representative of a minimum or maximum allowable flux through a given reaction, possibly resulting from a limited amount of an enzyme present. Additionally, the constraints can determine the direction or reversibility of any of the reactions or transport fluxes in the reaction network data structure. Based on the in vivo environment where S. cerevisiae lives the metabolic resources available to the cell for biosynthesis of essential molecules for can be determined. Allowing the corresponding transport fluxes to be active provides the in silico S. cerevisiae with inputs and outputs for substrates and by-products produced by the metabolic network.

Returning to the hypothetical reaction network shown in FIG. 1 , constraints can be placed on each reaction in the exemplary format, shown in FIG. 3 , as follows. The constraints are provided in a format that can be used to constrain the reactions of the stoichiometric matrix shown in FIG. 2 . The format for the constraints used for a matrix or in linear programming can be conveniently represented as a linear inequality such as

›DETAILED DESCRIPTION OF THE INVENTION · 8 of 12

β j ≦ν j ≦α j :j=1 . . . n  (Eq. 1)

where v j is the metabolic flux vector, β j is the minimum flux value and α j is the maximum flux value. Thus, α j can take on a finite value representing a maximum allowable flux through a given reaction or β j can take on a finite value representing minimum allowable flux through a given reaction. Additionally, if one chooses to leave certain reversible reactions or transport fluxes to operate in a forward and reverse manner the flux may remain unconstrained by setting β j to negative infinity and α j to positive infinity as shown for reaction R 2 in FIG. 3 . If reactions proceed only in the forward reaction β j is set to zero while α j is set to positive infinity as shown for reactions R 1 , R 3 , R 4 , R 5 , and R 6 in FIG. 3 . As an example, to simulate the event of a genetic deletion or non-expression of a particular protein, the flux through all of the corresponding metabolic reactions related to the gene or protein in question are reduced to zero by setting α j and β j to be zero. Furthermore, if one wishes to simulate the absence of a particular growth substrate, one can simply constrain the corresponding transport fluxes that allow the metabolite to enter the cell to be zero by setting α j and β j to be zero. On the other hand if a substrate is only allowed to enter or exit the cell via transport mechanisms, the corresponding fluxes can be properly constrained to reflect this scenario.

The in silico S. cerevisiae model and methods described herein can be implemented on any conventional host computer system, such as those based on Intel® microprocessors and running Microsoft Windows operating systems. Other systems, such as those using the UNIX or LINUX operating system and based on IBM®, DEC® or Motorola® microprocessors are also contemplated. The systems and methods described herein can also be implemented to run on client-server systems and wide-area networks, such as the Internet.

Software to implement a method or model of the invention can be written in any well-known computer language, such as Java, C, C++, VISUAL BASIC™, FORTRAN or COBOL and compiled using any well-known compatible compiler. The software of the invention normally runs from instructions stored in a memory on a host computer system. A memory or computer readable medium can be a hard disk, floppy disc, compact disc, magneto-optical disc, Random Access Memory, Read Only Memory or Flash Memory. The memory or computer readable medium used in the invention can be contained within a single computer or distributed in a network. A network can be any of a number of conventional network systems known in the art such as a local area network (LAN) or a wide area network (WAN). Client-server environments, database servers and networks that can be used in the invention are well known in the art. For example, the database server can run on an operating system such as UNIX, running a relational database management system, a World Wide Web application and a World Wide Web server. Other types of memories and computer readable media are also contemplated to function within the scope of the invention.

A database or data structure of the invention can be represented in a markup language format including, for example, Standard Generalized Markup Language (SGML), Hypertext markup language (HTML) or Extensible Markup language (XML). Markup languages can be used to tag the information stored in a database or data structure of the invention, thereby providing convenient annotation and transfer of data between databases and data structures. In particular, an XML format can be useful for structuring the data representation of reactions, reactants and their annotations; for exchanging database contents, for example, over a network or internet; for updating individual elements using the document object model; or for providing differential access to multiple users for different information content of a data base or data structure of the invention. XML programming methods and editors for writing XML code are known in the art as described, for example, in Ray, Learning XML O'Reilly and Associates, Sebastopol, Calif. (2001).

A set of constraints can be applied to a reaction network data structure to simulate the flux of mass through the reaction network under a particular set of environmental conditions specified by a constraints set. Because the time constants characterizing metabolic transients and/or metabolic reactions are typically very rapid, on the order of milli-seconds to seconds, compared to the time constants of cell growth on the order of hours to days, the transient mass balances can be simplified to only consider the steady state behavior. Referring now to an example where the reaction network data structure is a stoichiometric matrix, the steady state mass balances can be applied using the following system of linear equations

S·ν= 0  (Eq. 2)

where S is the stoichiometric matrix as defined above and ν is the flux vector. This equation defines the mass, energy, and redox potential constraints placed on the metabolic network as a result of stoichiometry. Together Equations 1 and 2 representing the reaction constraints and mass balances, respectively, effectively define the capabilities and constraints of the metabolic genotype and the organism's metabolic potential. All vectors, ν, that satisfy Equation 2 are said to occur in the mathematical nullspace of S. Thus, the null space defines steady-state metabolic flux distributions that do not violate the mass, energy, or redox balance constraints. Typically, the number of fluxes is greater than the number of mass balance constraints, thus a plurality of flux distributions satisfy the mass balance constraints and occupy the null space. The null space, which defines the feasible set of metabolic flux distributions, is further reduced in size by applying the reaction constraints set forth in Equation 1 leading to a defined solution space. A point in this space represents a flux distribution and hence a metabolic phenotype for the network. An optimal solution within the set of all solutions can be determined using mathematical optimization methods when provided with a stated objective and a constraint set. The calculation of any solution constitutes a simulation of the model.

›DETAILED DESCRIPTION OF THE INVENTION · 9 of 12

Objectives for activity of S. cerevisiae can be chosen to explore the improved use of the metabolic network within a given reaction network data structure. These objectives can be design objectives for a strain, exploitation of the metabolic capabilities of a genotype, or physiologically meaningful objective functions, such as maximum cellular growth. Growth can be defined in terms of biosynthetic requirements based on literature values of biomass composition or experimentally determined values such as those obtained as described above. Thus, biomass generation can be defined as an exchange reaction that removes intermediate metabolites in the appropriate ratios and represented as an objective function. In addition to draining intermediate metabolites this reaction flux can be formed to utilize energy molecules such as ATP, NADH and NADPH so as to incorporate any growth dependent maintenance requirement that must be met. This new reaction flux then becomes another constraint/balance equation that the system must satisfy as the objective function. Using the stoichiometric matrix of FIG. 2 as an example, adding such a constraint is analogous to adding the additional column V growth to the stoichiometric matrix to represent fluxes to describe the production demands placed on the metabolic system. Setting this new flux as the objective function and asking the system to maximize the value of this flux for a given set of constraints on all the other fluxes is then a method to simulate the growth of the organism.

Continuing with the example of the stoichiometric matrix applying a constraint set to a reaction network data structure can be illustrated as follows. The solution to equation 2 can be formulated as an optimization problem, in which the flux distribution that minimizes a particular objective is found. Mathematically, this optimization problem can be stated as:

Minimize Z  (Eq. 3)

where

z=Σc i ·ν i   (Eq. 4)

where Z is the objective which is represented as a linear combination of metabolic fluxes ν i using the weights c i in this linear combination. The optimization problem can also be stated as the equivalent maximization problem; i.e. by changing the sign on Z. Any commands for solving the optimization problem can be used including, for example, linear programming commands.

A computer system of the invention can further include a user interface capable of receiving a representation of one or more reactions. A user interface of the invention can also be capable of sending at least one command for modifying the data structure, the constraint set or the commands for applying the constraint set to the data representation, or a combination thereof. The interface can be a graphic user interface having graphical means for making selections such as menus or dialog boxes. The interface can be arranged with layered screens accessible by making selections from a main screen. The user interface can provide access to other databases useful in the invention such as a metabolic reaction database or links to other databases having information relevant to the reactions or reactants in the reaction network data structure or to S. cerevisiae physiology. Also, the user interface can display a graphical representation of a reaction network or the results of a simulation using a model of the invention.

Once an initial reaction network data structure and set of constraints has been created, this model can be tested by preliminary simulation. During preliminary simulation, gaps in the network or “dead-ends” in which a metabolite can be produced but not consumed or where a metabolite can be consumed but not produced can be identified. Based on the results of preliminary simulations areas of the metabolic reconstruction that require an additional reaction can be identified. The determination of these gaps can be readily calculated through appropriate queries of the reaction network data structure and need not require the use of simulation strategies, however, simulation would be an alternative approach to locating such gaps.

In the preliminary simulation testing and model content refinement stage the existing model is subjected to a series of functional tests to determine if it can perform basic requirements such as the ability to produce the required biomass constituents and generate predictions concerning the basic physiological characteristics of the particular organism strain being modeled. The more preliminary testing that is conducted the higher the quality of the model that will be generated. Typically the majority of the simulations used in this stage of development will be single optimizations. A single optimization can be used to calculate a single flux distribution demonstrating how metabolic resources are routed determined from the solution to one optimization problem. An optimization problem can be solved using linear programming as demonstrated in the Examples below. The result can be viewed as a display of a flux distribution on a reaction map. Temporary reactions can be added to the network to determine if they should be included into the model based on modeling/simulation requirements.

Once a model of the invention is sufficiently complete with respect to the content of the reaction network data structure according to the criteria set forth above, the model can be used to simulate activity of one or more reactions in a reaction network. The results of a simulation can be displayed in a variety of formats including, for example, a table, graph, reaction network, flux distribution map or a phenotypic phase plane graph.

Thus, the invention provides a method for predicting a S. cerevisiae physiological function. The method includes the steps of (a) providing a data structure relating a plurality of S. cerevisiae reactants to a plurality of S. cerevisiae reactions, wherein each of the S. cerevisiae reactions includes a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating said substrate and said product; (b) providing a constraint set for the plurality of S. cerevisiae reactions; (c) providing an objective function, and (d) determining at least one flux distribution that minimizes or maximizes the objective function when the constraint set is applied to the data structure, thereby predicting a S. cerevisiae physiological function.

›DETAILED DESCRIPTION OF THE INVENTION · 10 of 12

As used herein, the term “physiological function,” when used in reference to S. cerevisiae , is intended to mean an activity of a S. cerevisiae cell as a whole. An activity included in the term can be the magnitude or rate of a change from an initial state of a S. cerevisiae cell to a final state of the S. cerevisiae cell. An activity can be measured qualitatively or quantitatively. An activity included in the term can be, for example, growth, energy production, redox equivalent production, biomass production, development, or consumption of carbon, nitrogen, sulfur, phosphate, hydrogen or oxygen. An activity can also be an output of a particular reaction that is determined or predicted in the context of substantially all of the reactions that affect the particular reaction in a S. cerevisiae cell or substantially all of the reactions that occur in a S. cerevisiae cell. Examples of a particular reaction included in the term are production of biomass precursors, production of a protein, production of an amino acid, production of a purine, production of a pyrimidine, production of a lipid, production of a fatty acid, production of a cofactor, or transport of a metabolite. A physiological function can include an emergent property which emerges from the whole but not from the sum of parts where the parts are observed in isolation (see for example, Palsson Nat. Biotech 18:1147-1150 (2000)).

A physiological function of S. cerevisiae reactions can be determined using phase plane analysis of flux distributions. Phase planes are representations of the feasible set which can be presented in two or three dimensions. As an example, two parameters that describe the growth conditions such as substrate and oxygen uptake rates can be defined as two axes of a two-dimensional space. The optimal flux distribution can be calculated from a reaction network data structure and a set of constraints as set forth above for all points in this plane by repeatedly solving the linear programming problem while adjusting the exchange fluxes defining the two-dimensional space. A finite number of qualitatively different metabolic pathway utilization patterns can be identified in such a plane, and lines can be drawn to demarcate these regions. The demarcations defining the regions can be determined using shadow prices of linear optimization as described, for example in Chvatal, Linear Programming New York, W.H. Freeman and Co. (1983). The regions are referred to as regions of constant shadow price structure. The shadow prices define the intrinsic value of each reactant toward the objective function as a number that is either negative, zero, or positive and are graphed according to the uptake rates represented by the x and y axes. When the shadow prices become zero as the value of the uptake rates are changed there is a qualitative shift in the optimal reaction network.

One demarcation line in the phenotype phase plane is defined as the line of optimality (LO). This line represents the optimal relation between respective metabolic fluxes. The LO can be identified by varying the x-axis flux and calculating the optimal y-axis flux with the objective function defined as the growth flux. From the phenotype phase plane analysis the conditions under which a desired activity is optimal can be determined. The maximal uptake rates lead to the definition of a finite area of the plot that is the predicted outcome of a reaction network within the environmental conditions represented by the constraint set. Similar analyses can be performed in multiple dimensions where each dimension on the plot corresponds to a different uptake rate. These and other methods for using phase plane analysis, such as those described in Edwards et al., Biotech Bioeng. 77:27-36 (2002), can be used to analyze the results of a simulation using an in silica S. cerevisiae model of the invention.

A physiological function of S. cerevisiae can also be determined using a reaction map to display a flux distribution. A reaction map of S. cerevisiae can be used to view reaction networks at a variety of levels. In the case of a cellular metabolic reaction network a reaction map can contain the entire reaction complement representing a global perspective. Alternatively, a reaction map can focus on a particular region of metabolism such as a region corresponding to a reaction subsystem described above or even on an individual pathway or reaction. An example of a reaction map showing a subset of reactions in a reaction network of S. cerevisiae is shown in FIG. 4 .

The invention also provides an apparatus that produces a representation of a S. cerevisiae physiological function, wherein the representation is produced by a process including the steps of: (a) providing a data structure relating a plurality of S. cerevisiae reactants to a plurality of S. cerevisiae reactions, wherein each of the S. cerevisiae reactions includes a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating said substrate and said product; (b) providing a constraint set for the plurality of S. cerevisiae reactions; (c) providing an objective function; (d) determining at least one flux distribution that minimizes or maximizes the objective function when the constraint set is applied to the data structure, thereby predicting a S. cerevisiae physiological function, and (e) producing a representation of the activity of the one or more S. cerevisiae reactions.

The methods of the invention can be used to determine the activity of a plurality of S. cerevisiae reactions including, for example, biosynthesis of an amino acid, degradation of an amino acid, biosynthesis of a purine, biosynthesis of a pyrimidine, biosynthesis of a lipid, metabolism of a fatty acid, biosynthesis of a cofactor, transport of a metabolite and metabolism of an alternative carbon source. In addition, the methods can be used to determine the activity of one or more of the reactions described above or listed in Table 2.

›DETAILED DESCRIPTION OF THE INVENTION · 11 of 12

The methods of the invention can be used to determine a phenotype of a S. cerevisiae mutant. The activity of one or more S. cerevisiae reactions can be determined using the methods described above, wherein the reaction network data structure lacks one or more gene-associated reactions that occur in S. cerevisiae . Alternatively, the methods can be used to determine the activity of one or more S. cerevisiae reactions when a reaction that does not naturally occur in S. cerevisiae is added to the reaction network data structure. Deletion of a gene can also be represented in a model of the invention by constraining the flux through the reaction to zero, thereby allowing the reaction to remain within the data structure. Thus, simulations can be made to predict the effects of adding or removing genes to or from S. cerevisiae . The methods can be particularly useful for determining the effects of adding or deleting a gene that encodes for a gene product that performs a reaction in a peripheral metabolic pathway.

A drug target or target for any other agent that affects S. cerevisiae function can be predicted using the methods of the invention. Such predictions can be made by removing a reaction to simulate total inhibition or prevention by a drug or agent. Alternatively, partial inhibition or reduction in the activity a particular reaction can be predicted by performing the methods with altered constraints. For example, reduced activity can be introduced into a model of the invention by altering the α j or β j values for the metabolic flux vector of a target reaction to reflect a finite maximum or minimum flux value corresponding to the level of inhibition. Similarly, the effects of activating a reaction, by initiating or increasing the activity of the reaction, can be predicted by performing the methods with a reaction network data structure lacking a particular reaction or by altering the α j or β j values for the metabolic flux vector of a target reaction to reflect a maximum or minimum flux value corresponding to the level of activation. The methods can be particularly useful for identifying a target in a peripheral metabolic pathway.

Once a reaction has been identified for which activation or inhibition produces a desired effect on S. cerevisiae function, an enzyme or macromolecule that performs the reaction in S. cerevisiae or a gene that expresses the enzyme or macromolecule can be identified as a target for a drug or other agent. A candidate compound for a target identified by the methods of the invention can be isolated or synthesized using known methods. Such methods for isolating or synthesizing compounds can include, for example, rational design based on known properties of the target (see, for example, DeCamp et al., Protein Engineering Principles and Practice , Ed. Cleland and Craik, Wiley-Liss, New York, pp. 467-506 (1996)), screening the target against combinatorial libraries of compounds (see for example, Houghten et al., Nature, 354, 84-86 (1991); Dooley et al., Science, 266, 2019-2022 (1994), which describe an iterative approach, or R. Houghten et al. PCT/US91/08694 and U.S. Pat. No. 5,556,762 which describe a positional-scanning approach), or a combination of both to obtain focused libraries. Those skilled in the art will know or will be able to routinely determine assay conditions to be used in a screen based on properties of the target or activity assays known in the art.

A candidate drug or agent, whether identified by the methods described above or by other methods known in the art, can be validated using an in silico S. cerevisiae model or method of the invention. The effect of a candidate drug or agent on S. cerevisiae physiological function can be predicted based on the activity for a target in the presence of the candidate drug or agent measured in vitro or in vivo. This activity can be represented in an in silico S. cerevisiae model by adding a reaction to the model, removing a reaction from the model or adjusting a constraint for a reaction in the model to reflect the measured effect of the candidate drug or agent on the activity of the reaction. By running a simulation under these conditions the holistic effect of the candidate drug or agent on S. cerevisiae physiological function can be predicted.

The methods of the invention can be used to determine the effects of one or more environmental components or conditions on an activity of S. cerevisiae . As set forth above, an exchange reaction can be added to a reaction network data structure corresponding to uptake of an environmental component, release of a component to the environment, or other environmental demand. The effect of the environmental component or condition can be further investigated by running simulations with adjusted α j or β j values for the metabolic flux vector of the exchange reaction target reaction to reflect a finite maximum or minimum flux value corresponding to the effect of the environmental component or condition. The environmental component can be, for example an alternative carbon source or a metabolite that when added to the environment of S. cerevisiae can be taken up and metabolized. The environmental component can also be a combination of components present for example in a minimal medium composition. Thus, the methods can be used to determine an optimal or minimal medium composition that is capable of supporting a particular activity of S. cerevisiae.

The invention further provides a method for determining a set of environmental components to achieve a desired activity for S. cerevisiae . The method includes the steps of (a) providing a data structure relating a plurality of S. cerevisiae reactants to a plurality of S. cerevisiae reactions, wherein each of the S. cerevisiae reactions includes a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product; (b) providing a constraint set for the plurality of S. cerevisiae reactions; (c) applying the constraint set to the data representation, thereby determining the activity of one or more S. cerevisiae reactions (d) determining the activity of one or more S. cerevisiae reactions according to steps (a) through (c), wherein the constraint set includes an upper or lower bound on the amount of an environmental component and (e) repeating steps (a) through (c) with a changed constraint set, wherein the activity determined in step (e) is improved compared to the activity determined in step (d).

›DETAILED DESCRIPTION OF THE INVENTION · 12 of 12

The following examples are intended to illustrate but not limit the present invention.

›EXAMPLE I

Reconstruction of the Metabolic Network of S. cerevisiae

This example shows how the metabolic network of S. cerevisiae can be reconstructed.

The reconstruction process was based on a comprehensive search of the current knowledge of metabolism in S. cerevisiae as shown in FIG. 5 . A reaction database was built using the available genomic and metabolic information on the presence, reversibility, localization and cofactor requirements of all known reactions. Furthermore, information on non-growth-dependent and growth-dependent ATP requirements and on the biomass composition was used.

For this purpose different online reaction databases, recent publications and review papers (Table 5 and 9), and established biochemistry textbooks (Zubay, Biochemistry Wm.C. Brown Publishers, Dubuque, Iowa (1998); Stryer, Biochemistry W. H. Freeman, New York, N.Y. (1988)) were consulted. Information on housekeeping genes of S. cerevisiae and their functions were taken from three main yeast on-line resources:

The MIPS Comprehensive Yeast Genome Database (CYGD) (Mewes et al., Nucleic Acids Research 30(1): 31-34 (2002)); The Saccharomyces Genome Database (SGD) (Cherry et al., Nucleic Acids Research 26(1): 73-9 (1998)); The Yeast Proteome Database (YPD) (Costanzo et al., Nucleic Acids Research 29(1): 75-9 (2001)).

The following metabolic maps and protein databases (available online) were investigated:

Kyoto Encyclopedia of Genes and Genomes database (KEGG) (Kanehisa et al., Nucleic Acids Research 28(1): 27-30 (2000)); The Biochemical Pathways database of the Expert Protein Analysis System database (ExPASy) (Appel et al., Trends Biochem Sci. 19(6): 258-260 (1994)); ERGO from Integrated Genomics (www.integratedgenomics.com) SWISS-PROT Protein Sequence database (Bairoch et al., Nucleic Acids Research 28(1): 45-48 (2000)).

Table 5 lists additional key references that were consulted for the reconstruction of the metabolic network of S. cerevisiae .

All reactions are localized into the two main compartments, cytosol and mitochondria, as most of the common metabolic reactions in S. cerevisiae take place in these compartments. Optionally, one or more additional compartments can be considered. Reactions located in vivo in other compartments or reactions for which no information was available regarding localization were assumed to be cytosol. All corresponding metabolites were assigned appropriate localization and a link between cytosol and mitochondria was established through either known transport and shuttle systems or through inferred reactions to meet metabolic demands.

After the initial assembly of all the metabolic reactions the list was manually examined for resolution of detailed biochemical issues. A large number of reactions involve cofactors utilization, and for many of these reactions the cofactor requirements have not yet been completely elucidated. For example, it is not clear whether certain reactions use only NADH or only NADPH as a cofactor or can use both cofactors, whereas other reactions are known to use both cofactors. For example, a mitochondrial aldehyde dehydrogenase encoded by ALD4 can use both NADH and NADPH as a cofactor (Remize et al. Appl Environ Microbiol 66(8): 3151-3159 (2000)). In such cases, two reactions are included in the reconstructed metabolic network.

Further considerations were taken into account to preserve the unique features of S. cerevisiae metabolism. S. cerevisiae lacks a gene that encodes the enzyme transhydrogenase. Insertion of a corresponding gene from Azetobacter vinelandii in S. cerevisiae has a major impact on its phenotypic behavior, especially under anaerobic conditions (Niessen et al. Yeast 18(1): 19-32 (2001)). As a result, reactions that create a net transhydrogenic effect in the model were either constrained to zero or forced to become irreversible. For instance, the flux carried by NADH dependent glutamate dehydrogenase (Gdh2p) was constrained to zero to avoid the appearance of a net transhydrogenase activity through coupling with the NADPH dependent glutamate dehydrogenases (Gdh1p and Gdh3p).

Once a first generation model is prepared, microbial behavior can be modeled for a specific scenario, such as anaerobic or aerobic growth in continuous cultivation using glucose as a sole carbon source. Modeling results can then be compared to experimental results. If modeling and experimental results are in agreement, the model can be considered as correct, and it is used for further modeling and predicting S. cerevisiae behavior. If the modeling and experimental results are not in agreement, the model has to be evaluated and the reconstruction process refined to determine missing or incorrect reactions, until modeling and experimental results are in agreement. This iterative process is shown in FIG. 5 and exemplified below.

›EXAMPLE II

Calculation of the P/O Ratio

This example shows how the genome-scale reconstructed metabolic model of S. cerevisiae was used to calculate the P/O ratio, which measures the efficiency of aerobic respiration. The P/O ratio is the number of ATP molecules produced per pair of electrons donated to the electron transport system (ETS).

Linear optimization was applied, and the in silico P/O ratio was calculated by first determining the maximum number of ATP molecules produced per molecule of glucose through the electron transport system (ETS), and then interpolating the in silico P/O ratio using the theoretical relation (i.e. in S. cerevisiae for the P/O ratio of 1.5, 18 ATP molecules are produced).

Experimental studies of isolated mitochondria have shown that S. cerevisiae lacks site I proton translocation (Verduyn et al., Antonie Van Leeuwenhoek 59(1): 49-63 (1991)). Consequently, estimation of the maximum theoretical or “mechanistic” yield of the ETS alone gives a P/O ratio of 1.5 for oxidation of NADH in S. cerevisiae grown on glucose (Verduyn et al., supra (1991)). However, based on experimental measurements, it has been determined that the net in vivo P/O ratio is approximately 0.95 (Verduyn et al., supra (1991)). This difference is generally thought to be due to the use of the mitochondrial transmembrane proton gradient needed to drive metabolite exchange, such as the proton-coupled translocation of pyruvate, across the inner mitochondrial membrane. Although simple diffusion of protons (or proton leakage) would be surprising given the low solubility of protons in the lipid bilayer, proton leakage is considered to contribute to the lowered P/O ratio due to the relatively high electrochemical gradient across the inner mitochondrial membrane (Westerhoff and van Dam, Thermodynamics and control of biological free - energy transduction Elsevier, New York, N.Y. (1987)).

Using the reconstructed network, the P/O ratio was calculated to be 1.04 for oxidation of NADH for growth on glucose by first using the model to determine the maximum number of ATP molecules produced per molecule of glucose through the electron transport system (ETS) (YATP,max=12.5 ATP molecules/glucose molecule via ETS in silico). The in silico P/O ratio was then interpolated using the theoretical relation (i.e. 18 ATP molecules per glucose molecule are produced theoretically when the P/O ratio is 1.5). The calculated P/O ratio was found to be close to the experimentally determined value of 0.95. Proton leakage, however, was not included in the model, which suggests that the major reason for the lowered P/O ratio is the use of the proton gradient for solute transport across the inner mitochondrial membrane. This result illustrates the importance of including the complete metabolic network in the analysis, as the use of the proton gradient for solute transport across the mitochondrial membrane contributes significantly to the operational P/O ratio.

›EXAMPLE III

Phenotypic Phase Plane Analysis

This example shows how the S. cerevisiae metabolic model can be used to calculate the range of characteristic phenotypes that the organism can display as a function of variations in the activity of multiple reactions.

For this analysis, O 2 and glucose uptake rates were defined as the two axes of the two-dimensional space. The optimal flux distribution was calculated using linear programming (LP) for all points in this plane by repeatedly solving the LP problem while adjusting the exchange fluxes defining the two-dimensional space. A finite number of quantitatively different metabolic pathway utilization patterns were identified in the plane, and lines were drawn to demarcate these regions. One demarcation line in the phenotypic phase plane (PhPP) was defined as the line of optimality (LO), and represents the optimal relation between the respective metabolic fluxes. The LO was identified by varying the x-axis (glucose uptake rate) and calculating the optimal y-axis (O 2 uptake rate), with the objective function defined as the growth flux. Further details regarding Phase-Plane Analysis are provided in Edwards et al., Biotechnol. Bioeng. 77:27-36 (2002) and Edwards et al., Nature Biotech. 19:125-130 (2001)).

As illustrated in FIG. 6 , the S. cerevisiae PhPP contains 8 distinct metabolic phenotypes. Each region (P 1 -P 8 ) exhibits unique metabolic pathway utilization that can be summarized as follows:

The left-most region is the so-called “infeasible” steady state region in the PhPP, due to stoichiometric limitations. From left to right: P 1 : Growth is completely aerobic. Sufficient oxygen is available to complete the oxidative metabolism of glucose to support growth requirements. This zone represents a futile cycle. Only CO 2 is formed as a metabolic by-product. The growth rate is less than the optimal growth rate in region P 2 . The P 1 upper limit represents the locus of points for which the carbon is completely oxidized to eliminate the excess electron acceptor, and thus no biomass can be generated. P 2 : Oxygen is slightly limited, and all biosynthetic cofactor requirements cannot be optimally satisfied by oxidative metabolism. Acetate is formed as a metabolic by-product enabling additional high-energy phosphate bonds via substrate level phosphorylation. With the increase of O 2 supply, acetate formation eventually decreases to zero. P 3 : Acetate is increased and pyruvate is decreased with increase in oxygen uptake rate. P 4 : Pyruvate starts to increase and acetate is decreased with increase in oxygen uptake rate. Ethanol production eventually decreases to zero. P 5 : The fluxes towards acetate formation are increasing and ethanol production is decreasing. P 6 : When the oxygen supply increases, acetate formation increases and ethanol production decreases with the carbon directed toward the production of acetate. Besides succinate production, malate may also be produced as metabolic by-product. P 7 : The oxygen supply is extremely low, ethanol production is high and succinate production is decreased. Acetate is produced at a relatively low level. P 8 : This region is along the Y-axis and the oxygen supply is zero. This region represents completely anaerobic fermentation. Ethanol and glycerol are secreted as a metabolic by-product. The role of NADH-consuming glycerol formation is to maintain the cytosol redox balance under anaerobic conditions (Van Dijken and Scheffers Yeast 2(2): 123-7 (1986)). Line of Optimality: Metabolically, the line of optimality (LO) represents the optimal utilization of the metabolic pathways without limitations on the availability of the substrates. On an oxygen/glucose phenotypic phase plane diagram, LO represents the optimal aerobic glucose-limited growth of S. cerevisiae metabolic network to produce biomass from unlimited oxygen supply for the complete oxidation of the substrates in the cultivation processes. The line of optimality therefore represents a completely respiratory metabolism, with no fermentation by-product secretion and the futile cycle fluxes equals zero.

Thus, this example demonstrates that Phase Plane Analysis can be used to determine the optimal fermentation pattern for S. cerevisiae , and to determine the types of organic byproducts that are accumulated under different oxygenation conditions and glucose uptake rates.

›EXAMPLE IV

Calculation of Line of Optimality and Respiratory Quotient

This example shows how the S. cerevisiae metabolic model can be used to calculate the oxygen uptake rate (OUR), the carbon dioxide evolution rate (CER) and the respiration quotient (RQ), which is the ratio of CER over OUR.

The oxygen uptake rate (OUR) and the carbon dioxide evolution rate (CER) are direct indicators of the yeast metabolic activity during the fermentation processes. RQ is a key metabolic parameter that is independent of cell number. As illustrated in FIG. 7 , if the S. cerevisiae is grown along the line of optimality, LO, its growth is at optimal aerobic rate with all the carbon sources being directed to biomass formation and there are no metabolic by-products secreted except CO 2 . The calculated RQ along the LO is a constant value of 1.06; the RQ in P 1 region is less than 1.06; and the RQ in the remaining regions in the yeast PhPP are greater than 1.06. The RQ has been used to determine the cell growth and metabolism and to control the glucose feeding for optimal biomass production for decades (Zeng et al. Biotechnol. Bioeng. 44:1107-1114 (1994)). Empirically, several researchers have proposed the values of 1.0 (Zigova, J Biotechnol 80: 55-62 (2000). Journal of Biotechnology), 1.04 (Wang et al., Biotechnol & Bioeng 19:69-86 (1977)) and 1.1 (Wang et al., Biotechnol . & Bioeng. 21:975-995 (1979)) as optimal RQ which should be maintained in fed-batch or continuous production of yeast's biomass so that the highest yeast biomass could be obtained (Dantigny et al., Appl. Microbiol. Biotechnol. 36:352-357 (1991)). The constant RQ along the line of optimality for yeast growth by the metabolic model is thus consistent with the empirical formulation of the RQ through on-line measurements from the fermentation industry.

›EXAMPLE V

Computer Simulations

This example shows computer simulations for the change of metabolic phenotypes described by the yeast PhPP.

A piece-wise linearly increasing function was used with the oxygen supply rates varying from completely anaerobic to fully aerobic conditions (with increasing oxygen uptake rate from 0 to 20 mmol per g cell-hour). A glucose uptake rate of 5 mmol of glucose per g (dry weight)-hour was arbitrarily chosen for these computations. As shown in FIG. 8A , the biomass yield of the in silico S. cerevisiae strain was shown to increase from P 8 to P 2 , and become optimal on the LO. The yield then started to slowly decline in P 1 (futile cycle region). At the same time, the RQ value declines in relation to the increase of oxygen consumption rate, reaching a value of 1.06 on the LO1 and then further declining to become less than 1.

FIG. 8B shows the secretion rates of metabolic by-products; ethanol, succinate, pyruvate and acetate with the change of oxygen uptake rate from 0 to 20 mmol of oxygen per g (dry weight)-h. Each one of these by-products is secreted in a fundamentally different way in each region. As oxygen increases from 0 in P 7 , glycerol production (data not shown in this figure) decreases and ethanol production increases. Acetate and succinate are also secreted.

›EXAMPLE VI

Modeling of Phenotypic Behavior in Chemostat Cultures

This example shows how the S. cerevisiae metabolic model can be used to predict optimal flux distributions that would optimize fermentation performance, such as specific product yield or productivity. In particular, this example shows how flux based analysis can be used to determine conditions that would minimize the glucose uptake rate of S. cerevisiae grown on glucose in a continuous culture under anaerobic and under aerobic conditions.

In a continuous culture, growth rate is equivalent to the dilution rate and is kept at a constant value. Calculations of the continuous culture of S. cerevisiae were performed by fixing the in silico growth rate to the experimentally determined dilution rate, and minimizing the glucose uptake rate. This formulation is equivalent to maximizing biomass production given a fixed glucose uptake value and was employed to simulate a continuous culture growth condition. Furthermore, a non growth dependent ATP maintenance of 1 mmol/gDW, a systemic P/O ratio of 1.5 (Verduyn et al. Antonie Van Leeuwenhoek 59(1): 49-63 (1991)), a polymerization cost of 23.92 mmol ATP/gDW, and a growth dependent ATP maintenance of 35.36 mmol ATP/gDW, which is simulated for a biomass yield of 0.51 gDW/h, are assumed. The sum of the latter two terms is included into the biomass equation of the genome-scale metabolic model.

Optimal growth properties of S. cerevisiae were calculated under anaerobic glucose-limited continuous culture at dilution rates varying between 0.1 and 0.4 h −1 . The computed by-product secretion rates were then compared to the experimental data (Nissen et al. Microbiology 143(1): 203-18 (1997)). The calculated uptake rates of glucose and the production of ethanol, glycerol, succinate, and biomass are in good agreement with the independently obtained experimental data ( FIG. 9 ). The relatively low observed acetate and pyruvate secretion rates were not predicted by the in silico model since the release of these metabolites does not improve the optimal solution of the network.

It is possible to constrain the in silico model further to secrete both, pyruvate and acetate at the experimental level and recompute an optimal solution under these additional constraints. This calculation resulted in values that are closer to the measured glucose uptake rates ( FIG. 9A ). This procedure is an example of an iterative data-driven constraint-based modeling approach, where the successive incorporation of experimental data is used to improve the in silico model. Besides the ability to describe the overall growth yield, the model allows further insight into how the metabolism operates. From further analysis of the metabolic fluxes at anaerobic growth conditions the flux through the glucose-6-phosphate dehydrogenase was found to be 5.32% of the glucose uptake rate at dilution rate of 0.1 h −1 , which is consistent with experimentally determined value (6.34%) for this flux when cells are operating with fermentative metabolism (Nissen et al., Microbiology 143(1): 203-218 (1997)).

Optimal growth properties of S. cerevisiae were also calculated under aerobic glucose-limited continuous culture in which the Crabtree effect plays an important role. The molecular mechanisms underlying the Crabtree effect in S. cerevisiae are not known. The regulatory features of the Crabtree effect (van Dijken et al. Antonie Van Leeuwenhoek 63 (3-4):343-52 (1993)) can, however, be included in the in silico model as an experimentally determined growth rate-dependent maximum oxygen uptake rate (Overkamp et al. J. of Bacteriol 182(10): 2823-30 (2000))). With this additional constraint and by formulating growth in a chemostat as described above, the in silico model makes quantitative predictions about the respiratory quotient, glucose uptake, ethanol, CO2, and glycerol secretion rates under aerobic glucose-limited continuous condition ( FIG. 10 ).

›EXAMPLE VII

Analysis of Deletion of Genes Involved in Central Metabolism in S. cerevsiae

This example shows how the S. cerevisiae metabolic model can be used to determine the effect of deletions of individual reactions in the network.

Gene deletions were performed in silico by constraining the flux(es) corresponding to a specific gene to zero. The impact of single gene deletions on growth was analysed by simulating growth on a synthetic complete medium containing glucose, amino acids, as well as purines and pyrimidines.

In silico results were compared to experimental results as supplied by the Saccharomyces Genome Database (SOD) (Cherry et al., Nucleic Acids Research 26(1):73-79 (1998)) and by the Comprehensive Yeast Genome Database (Mewes et al., Nucleic Acids Research 30(1):31-34 (2002)). In 85.6% of all considered cases (499 out of 583 cases), the in silico prediction was in qualitative agreement with experimental results. An evaluation of these results can be found in Example VIII. For central metabolism, growth was predicted under various experimental conditions and 81.5% (93 out of 114 cases) of the in silico predictions were in agreement with in vivo phenotypes.

Table 6 shows the impact of gene deletions on growth in S. cerevisiae . Growth on different media was considered, including defined complete medium with glucose as the carbon source, and minimal medium with glucose, ethanol or acetate as the carbon source. The complete reference citations for Table 6 can be found in Table 9.

Thus, this example demonstrates that the in silico model can be used to uncover essential genes to augment or circumvent traditional genetic studies.

›EXAMPLE VIII · 1 of 5

Large-Scale Gene Deletion Analysis in S. Cerevisiae

A large-scale in silico evaluation of gene deletions in S. cerevisiae was conducted using the genome-scale metabolic model. The effect of 599 single gene deletions on cell viability was simulated in silico and compared to published experimental results. In 526 cases (87.8%), the in silico results were in agreement with experimental observations when growth on synthetic complete medium was simulated. Viable phenotypes were predicted in 89.4% (496 out of 555) and lethal phenotypes are correctly predicted in 68.2% (30 out of 44) of the cases considered.

The failure modes were analyzed on a case-by-case basis for four possible inadequacies of the in silico model: 1) incomplete media composition; 2) substitutable biomass components; 3) incomplete biochemical information; and 4) missing regulation. This analysis eliminated a number of false predictions and suggested a number of experimentally testable hypotheses. The genome-scale in silico model of S. cerevisiae can thus be used to systematically reconcile existing data and fill in knowledge gaps about the organism.

Growth on complete medium was simulated under aerobic condition. Since the composition of a complete medium is usually not known in detail, a synthetic complete medium containing glucose, twenty amino acids (alanine, arginine, asparagine, aspartate, cysteine, glutamine, glutamate, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophane, tyrosine, valine) and purines (adenine and guanine) as well as pyrimidines (cytosine and thymine) was defined for modeling purposes. Furthermore, ammonia, phosphate, and sulphate were supplied. The in silico results were initially compared to experimental data from a competitive growth assay (Winzeler et al., Science 285:901-906 (1999)) and to available data from the MIPS and SGD databases (Mewes et al., Nucleic Acids Research 30(1):31-34 (2002); Cherry et al., Nucleic Acids Research 26(1):73-79 (1998)). Gene deletions were simulated by constraining the flux through the corresponding reactions to zero and optimizing for growth as previously described (Edwards and Palsson, Proceedings of the National Academy of Sciences 97(10):5528-5533 (2000)). For this analysis, a viable phenotype was defined as a strain that is able to meet all the defined biomass requirements and thus grow. Single gene deletion mutants that have a reduced growth rate compared to the wild type simulation are referred to as growth retarded mutants.

The analysis of experimental data was approached in three steps: The initial simulation using the synthetic medium described above, referred to as simulation 1 .

False predictions of simulation 1 were subsequently examined to determine if the failure was due to incomplete information in the in silico model, such as missing reactions, the reversibility of reactions, regulatory events, and missing substrates in the synthetic complete medium. In simulation 2 , any such additional information was introduced into the in silico model and growth was re-simulated for gene deletion mutants whose in silico phenotype was not in agreement with its in vivo phenotype.

A third simulation was carried out, in which dead end pathways (i.e. pathways leading to intracellular metabolites that were not further connected into the overall network), were excluded from the analysis (simulation 3 ).

The effect of single gene deletions on the viability of S. cerevisiae was investigated for each of the 599 single gene deletion mutants. The in silica results were categorized into four groups:

1. True negatives (correctly predicted lethal phenotype);

2. False negatives (wrongly predicted lethal phenotype);

3. True positives (correctly predicted viable phenotypes);

4. False positives (wrongly predicted viable phenotypes).

In simulation 1 , 509 out of 599 (85%) simulated phenotypes were in agreement with experimental data. The number of growth retarding genes in simulation 1 was counted to be 19, a surprisingly low number. Only one deletion, the deletion of TPI1, had a severe impact on the growth rate. Experimentally, a deletion in TPI1 is lethal (Ciriacy and Breitenbach, J Bacteriol 139(1):152-60 (1979)). In silico, a tpi1 mutant could only sustain a specific growth rate of as low as 17% of the wild type. All other growth retarding deletions sustained approximately 99% of wild type growth, with the exception of a deletion of the mitochondrial ATPase that resulted in a specific growth rate of approximately 90% of wild type.

Predictions of simulation 1 were evaluated in a detailed manner on a case-by-case basis to determine whether the false predictions could be explained by:

1. Medium composition used for the simulation;

2. The biomass composition used in the simulation;

3. Incomplete biochemical information; and

4. Effects of gene regulation.

Analysis of the false predictions from simulation 1 based on these possible failure modes resulted in model modifications that led to 526 out of 599 correctly predicted phenotypes (87.8%), i.e., simulation 2 .

Simulation 3 uncovered some 220 reactions in the reconstructed network that are involved in dead end pathways. Removing these reactions and their corresponding genes from the genome-scale metabolic flux balance model, simulation 3 resulted in 473 out of 530 (89.6%) correctly predicted phenotypes of which 91.4% are true positive and 69.8% are true negative predictions.

Table 7 provides a summary of the large-scale evaluation of the effect of in silico single gene deletions in S. cerevisiae on viability.

A comprehensive list of all the genes used in the in silica deletion studies and results of the analysis are provided in Table 8. Table 8 is organized according to the categories true negative, false negative, true positive and false positive predictions. Genes highlighted in grey boxes, such as  corresponded initially to false predictions (simulation 1 ); however, evaluation of the false prediction and simulation 2 identified these cases as true predictions. ORFs or genes that are in an open box, such as  were excluded in simulation 3 , as the corresponding reactions catalysed steps in dead end pathways.

›EXAMPLE VIII · 2 of 5

The following text describes the analysis of the initially false predictions of simulation 1 that were performed, leading to simulation 2 results.

Influence of Media Composition on Simulation Results:

A rather simple synthetic complete medium composition was chosen for simulation 1 . The in silico medium contained only glucose, amino acids and nucleotides as the main components. However, complete media often used for experimental purposes, e.g. the YPD medium containing yeast extract and peptone, include many other components, which are usually unknown.

False Negative Predictions: The phenotype of the following deletion mutants: ecm1Δ, yil145cΔ, erg2 Δ, erg24 Δ, fas1 Δ, ura1 Δ, ura2 Δ, ura3 Δ and ura4 Δ were falsely predicted to be lethal in simulation 1 . In simulation 2 , an additional supplement of specific substrate could rescue a viable phenotype in silico and as the supplemented substrate may be assumed to be part of a complex medium, the predictions were counted as true positive predictions in simulation 2 . For example, both Ecm1 and Yil145c are involved in pantothenate synthesis. Ecm1 catalyses the formation of dehydropantoate from 2-oxovalerate, whereas Yil145c catalyses the final step in pantothenate synthesis from β-alanine and panthoate. In vivo, ecm1Δ, and yil145c A mutants require pantothenate for growth (White et al., J Biol Chem 276(14): 10794-10800 (2001)). By supplying pantothenate to the synthetic complete medium in silico, the model predicted a viable phenotype and the growth rate was similar to in silico wild type S. cerevisiae.

Similarly other false predictions could be traced to medium composition:

Mutants deleted in ERG2 or ERG24 are auxotroph for ergosterol (Silve et al., Mol Cell Biol 16(6): 2719-2727 (1996); Bourot and Karst, Gene 165(1): 97-102 (1995)). Simulating growth on a synthetic complete medium supplemented with ergosterol allowed the model to accurately predict viable phenotypes. A deletion of FAS1 (fatty acid synthase) is lethal unless appropriate amounts of fatty acids are provided, and by addition of fatty acids to the medium, a viable phenotype was predicted. Strains deleted in URA1, URA2, URA3, or URA4 are auxotroph for uracil (Lacroute, J Bacterial 95(3): 824-832 (1968)), and by supplying uracil in the medium the model predicted growth.

The above cases were initially false negative predictions, and simulation 2 demonstrated that these cases were predicted as true positive by adjusting the medium composition.

False Positive Predictions: Simulation 1 also contained false positive predictions, which may be considered as true negatives or as true positives. Contrary to experimental results from a competitive growth assay (Winzeler et al., Science 285: 901-906 (1999)), mutants deleted in ADE13 are viable in vivo on a rich medium supplemented with low concentrations of adenine, but grow poorly (Guetsova et al., Genetics 147(2): 383-397 (1997)). Adenine was supplied in the in silico synthetic complete medium. By not supplying adenine, a lethal mutant was predicted. Therefore, this case was considered as a true negative prediction.

A similar case was the deletion of GLN1, which codes a glutamine synthase, the only pathway to produce glutamine from ammonia. Therefore, gln1 Δ mutants are glutamine auxotroph (Mitchell, Genetics 111(2):243-58 (1985)). In a complex medium, glutamine is likely to be deaminated to glutamate, particularly during autoclaving. Complex media are therefore likely to contain only trace amounts of glutamine, and gln1Δ mutants are therefore not viable. However, in silico, glutamine was supplied in the complete synthetic medium and growth was predicted. By not supplying glutamine to the synthetic complete medium, the model predicted a lethal phenotype resulting in a true negative prediction.

Ilv3 and Ilv5 are both involved in branched amino acid metabolism. One may expect that a deletion of ILV3 or ILV5 could be rescued with the supply of the corresponding amino acids. For this, the model predicted growth. However, contradictory experimental data exists. In a competitive growth assay lethal phenotypes were reported. However, earlier experiments showed that ilv3Δ and ilv5Δ mutants could sustain growth when isoleucine and valine were supplemented to the medium, as for the complete synthetic medium. Hence, these two cases were considered to be true positive predictions.

Influence of the Definition of the Biomass Equation

The genome-scale metabolic model contains the growth requirements in the form of biomass composition. Growth is defined as a drain of building blocks, such as amino acids, lipids, nucleotides, carbohydrates, etc., to form biomass. The number of biomass components is 44 (see Table 1). These building blocks are essential for the formation of cellular components and they have been used as a fixed requirement for growth in the in silico simulations. Thus, each biomass component had to be produced by the metabolic network otherwise the organism could not grow in silico. In vivo, one often finds deletion mutants that are not able to produce the original biomass precursor or building block; however, other metabolites can replace these initial precursors or building blocks. Hence, for a number of strains a wrong phenotype was predicted in silico for this reason.

Phosphatidylcholine is synthesized by three methylation steps from phosphatidylethanolamine (Dickinson and Schweizer, The metabolism and molecular physiology of Saccharomyces cerevisiae Taylor & Francis, London; Philadelphia (1999)). The first step in the synthesis of phosphatidylcholine from phosphatidylethanolamine is catalyzed by a methyltransferase encoded by CHO2 and the latter two steps are catalyzed by phospholipid methyltransferase encoded by OPI3. Strains deleted in CHO2 or OPI3 are viable (Summers et al., Genetics 120(4): 909-922 (1988); Daum et al., Yeast 14(16): 1471-1510 (1998)); however, either null mutant accumulates mono- and dimethylated phosphatidylethanolamine under standard conditions and display greatly reduced levels of phosphatidylcholine (Daum et al., Yeast 15(7): 601-614 (1999)). Hence, phosphatidylethanolamine can replace phosphatidylcholine as a biomass component. In silico, phosphatidylcholine is required for the formation of biomass. One may further speculate on whether an alternative pathway for the synthesis of phosphatidylcholine is missing in the model, since Daum et al., supra (1999) detected small amounts of phosphatidylcholine in cho2Δ mutants. An alternative pathway, however, was not included in the in silico model.

›EXAMPLE VIII · 3 of 5

Deletions in the ergosterol biosynthetic pathways of ERG3, ERG4, ERG5 or ERG6 lead in vivo to viable phenotypes. The former two strains accumulate ergosta-8,22,24 (28)-trien-3-beta-ol (Bard et al., Lipids 12(8): 645-654 (1977); Zweytick et al., FEBS Lett 470(1): 83-87 (2000)), whereas the latter two accumulate ergosta-5,8-dien-3beta-ol (Hata et al., J Biochem (Tokyo) 94(2): 501-510 (1983)), or zymosterol and smaller amounts of cholesta-5,7,24-trien-3-beta-ol and cholesta-5,7,22,24-trien-3-beta-ol (Bard et al., supra (1977); Parks et al., Crit Rev Biochem Mol Biol 34(6): 399-404 (1999)), respectively, components that were not included in the biomass equations.

The deletion of the following three genes led to false positive predictions: RER2, SEC59 and QIR1. The former two are involved in glycoprotein synthesis and the latter is involved in chitin metabolism. Both chitin and glycoprotein are biomass components. However, for simplification, neither of the compounds was considered in the biomass equation. Inclusion of these compounds into the biomass equation may improve the prediction results.

Incomplete Biochemical Information

For a number of gene deletion mutants (inm1Δ, met6Δ, ynk1Δ, pho84Δ, psd2Δ, tps2Δ), simulation 1 produced false predictions that could not be explained by any of the two reasons discussed above nor by missing gene regulation (see below). Further investigation of the metabolic network including an extended investigation of biochemical data from the published literature showed that some information was missing initially in the in silico model or information was simply not available.

Inm1 catalyses the ultimate step in inositol biosynthesis from inositol 1-phosphate to inositol (Murray and Greenberg, Mol Microbiol 36(3): 651-661 (2000)). Upon deleting INM1, the model predicted a lethal phenotype in contrary to the experimentally observed viable phenotype. An isoenzyme encoded by IMP2 was initially not included in the model, which may take over the function of INM1 and this addition would have led to a correct prediction. However, an inm1 Δimp2Δ in vivo double deletion mutant is not inositol auxotroph (Lopez et al., Mol Microbiol 31(4): 1255-1264 (1999)). Hence, it appears that alternative routes for the production of inositol probably exist. Due to the lack of comprehensive biochemical knowledge, effects on inositol biosynthesis and the viability of strains deleted in inositol biosynthetic genes could not be explained.

Met6Δ mutants are methionine auxotroph (Thomas and Surdin-Kerjan, Microbiol Mol Biol Rev 61(4):503-532 (1997)), and growth may be sustained by the supply of methionine or S-adenosyl-L-methionine. In silico growth was supported neither by the addition of methionine nor by the addition of S-adenosyl-L-methionine. Investigation of the metabolic network showed that deleting MET6 corresponds to deleting the only possibility for using 5-methyltetrahydrofolate. Hence, the model appears to be missing certain information. A possibility may be that the carbon transfer is carried out using 5-methyltetrahydropteroyltri-L-glutamate instead of 5-methyltetrahydrofolate. A complete pathway for such a by-pass was not included in the genome-scale model.

The function of Ynk1p is the synthesis of nucleoside triphosphates from nucleoside diphosphates. YNK1Δ mutants have a 10-fold reduced Ynk1p activity (Fukuchi et al., Genes 129(1):141-146 (1993)), though this implies that there may either be an alternative route for the production of nucleoside triphosphates or a second nucleoside diphosphate kinase, even though there is no ORF in the genome with properties that indicates that there is a second nucleoside diphosphate kinase. An alternative route for the production of nucleoside triphosphate is currently unknown (Dickinson et al., supra (1999)), and was therefore not included in the model, hence a false negative prediction.

PHO84 codes for a high affinity phosphate transporter that was the only phosphate transporter included in the model. However, at least two other phosphate transporters exist, a second high affinity and Na + dependent transporter Pho89 and a low affinity transporter (Persson et al., Biochim Biophys Acta 1422(3): 255-72 (1999)). Due to exclusion of these transporters a lethal pho84□ mutant was predicted. Including PHO89 and a third phosphate transporter, the model predicted a viable deletion mutant.

In a null mutant of PSD2, phosphatidylethanolamine synthesis from phosphatidylserine is at the location of Psd1 (Trotter et al., J Biol Chem 273(21): 13189-13196 (1998)), which is located in the mitochondria. It has been postulated that phosphatidylserine can be transported into the mitochondria and phosphatidylethanolamine can be transported out of the mitochondria. However, transport of phosphatidylethanolamine and phosphatidylserine over the mitochondrial membrane was initially not included in the model. Addition of these transporters to the genome-scale flux balance model allowed in silico growth of a PSD2 deleted mutant.

Strains deleted in TPS2 have been shown to be viable when grown on glucose (Bell et al., J Biol Chem 273(50): 33311-33319 (1998)). The reaction carried out by Tps2p was modeled as essential and as the final step in trehalose synthesis from trehalose 6-phosphate. However, the in vivo viable phenotype shows that other enzymes can take over the hydrolysis of trehalose 6-phosphate to trehalose from Tps2p (Bell et al., supra (1998)). The corresponding gene(s) are currently unknown. Inclusion of a second reaction catalyzing the final step of trehalose formation allowed for the simulation of a viable phenotype.

Strains deleted in ADE3 (C1-tetrahydrofolate synthase) and ADK1 (Adenylate kinase) could not be readily explained. It is possible that alternative pathways or isoenzyme-coding genes for both functions exist among the many orphan genes still present in the S. cerevisiae.

The reconstruction process led to some incompletely modeled parts of metabolism. Hence, a number of false positive predictions may be the result of gaps (missing reactions) within pathways or between pathways, which prevent the reactions to completely connect to the overall pathway structure of the reconstructed model. Examples include:

›EXAMPLE VIII · 4 of 5

Sphingolipid metabolism. It has not yet been fully elucidated and therefore was not included completely into the model nor were sphingolipids considered as building blocks in the biomass equation. Formation of tRNA. During the reconstruction process some genes were included responsible for the synthesis of tRNA (DED81, HTS1, KRS1, YDR41C, YGL245W). However, pathways of tRNA synthesis were not fully included. Heme synthesis was considered in the reconstructed model (HEM1, HEM12, HEM13, HEM15, HEM2, HEM3, HEM4). However no reaction was included that metabolized heme in the model. Hence, the incomplete structure of metabolic network may be a reason for false prediction of the phenotype of aur1Δ, lcb1Δ, lcb2Δ, tsc10Δ, ded81Δ, hts1Δ, krs1Δ, ydr41cΔ, ygl245wΔ, hem1Δ, hem12Δ, hem13Δ, hem15Δ, hem2Δ, hem3Δ, and hem4Δ deletion mutants. Reaction reversibility. The CHO1 gene encodes a phosphatidylserine synthase, an integral membrane protein that catalyses a central step in cellular phospholipid biosynthesis. In vivo, a deletion in CHO1 is viable (Winzeler et al., Science 285: 901-906 (1999)). However, mutants are auxotrophic for choline or ethanolamine on media containing glucose as the carbon source (Birner et al., Mol Biol Cell 12(4): 997-1007 (2001)). Nevertheless, the model did not predict growth when choline and/or ethanolamine were supplied. Further investigation of the genome-scale model showed that this might be due to defining reactions leading from phosphatidylserine to phosphatidylcholine via phosphatidylethanolamine exclusively irreversible. By allowing these reactions to be reversible, either supply of choline and ethanolamine could sustain growth in silico.

Gene Regulation

Whereas many false negative predictions could be explained by either simulation of growth using the incorrect in silico synthetic complete medium or by initially missing information in the model, many false positives may be explained by in vivo catabolite expression, product inhibition effects or by repressed isoenzymes, as kinetic and other regulatory constraints were not included in the genome-scale metabolic model.

A total of 17 false positive predictions could be related to regulatory events. For a deletion of CDC19, ACS2 or ENO2 one may usually expect that the corresponding isoenzymes may take over the function of the deleted genes. However, the corresponding genes, either PYK2, ACS1 or ENO1, respectively, are subject to catabolite repression (Boles et al., J Bacteriol 179(9): 2987-2993 (1997); van den Berg and Steensma, Eur J Biochem 231(3): 704-713 (1995); Zimmerman et al., Yeast sugar metabolism: biochemistry, genetics, biotechnology, and applications Technomic Pub., Lancaster, Pa. (1997)). A deletion of GPM1 should be replaced by either of the two other isoenzymes, Gpm2 and Gpm3; however for the two latter corresponding gene products usually no activity is found (Heinisch et al., Yeast 14(3): 203-13 (1998)).

Falsely predicted growth phenotypes can often be explained when the corresponding deleted metabolic genes are involved in several other cell functions, such as cell cycle, cell fate, communication, cell wall integrity, etc. The following genes whose deletions yielded false positive predictions were found to have functions other than just metabolic function: ACS2, BET2, CDC19, CDC8, CYR1, DIM1, ENO2, FAD1, GFA1, GPM1, HIP1, MSS4, PET9, PIK1, PMA1, STT4, TOR2. Indeed, a statistical analysis of the MIPS functional catalogue (http://mips.gsf.de/proj/yeast/) showed that in general it was more likely to have a false prediction when the genes that had multiple functions were involved in cellular communication, cell cycling and DNA processing or control of cellular organization.

Table 9. Reference List for Table 2

Boles, E., Liebetrau, W., Hofmann, M. and Zimmermann, F. K. A Family of Hexosephosphate Mutases in Saccharomyces cerevisiae. Eur. J. Biochem. 220, 83-96 (1994).

Boles, E. Yeast Sugar Metabolism. Zimmermann, F. K. and Entian, K. D. (eds.), pp. 81-96 (Technomic Publishing Co., Inc., Lancaster, 1997).

Boles, E., Jong-Gubbels, P. and Pronk, J. T. Identification and Characterization of MAE1, the Saccharomyces cerevisiae Structural Gene Encoding Mitochondrial Malic Enzyme. J. Bacteriol. 180, 2875-2882 (1998).

Clifton, D., Weinstock, S. B. and Fraenkel, D. G. Glycolysis Mutants in Saccharomyces cerevisiae . Genetics 88, 1-11 (1978).

Clifton, D. and Fraenkel, D. G. Mutant Studies of Yeast Phosphofructokinase. Biochemistry 21, 1935-1942 (1982).

Cupp, J. R. and McAlister-Henn, L. Cloning and Characterization of the Gene Encoding the IDH1 Subunit of NAD(+)-Dependent Isocitrate Dehydrogenase from Saccharomyces cerevisiae . J. Biol. Chem. 267, 16417-16423 (1992).

Flikweert, M. T. et al. Pyruvate Decarboxylase: an Indispensable Enzyme for Growth of Saccharomyces cerevisiae on Glucose. Yeast 12, 247-257 (1996).

Gancedo, C. and Delgado, M. A. Isolation and Characterization of a Mutant from Saccharomyces cerevisiae Lacking Fructose 1,6-Bisphosphatase. Eur. J. Biochem. 139, 651-655 (1984).

Gangloff, S. P., Marguet, D. and Lauquin, G. J. Molecular Cloning of the Yeast Mitochondrial Aconitase Gene (ACO1) and Evidence of a Synergistic Regulation of Expression by Glucose Plus Glutamate. Mol Cell Biol 10, 3551-3561 (1990).

Hartig, A. et al. Differentially Regulated Malate Synthase Genes Participate in Carbon and Nitrogen Metabolism of S. cerevisiae . Nucleic Acids Res. 20, 5677-5686 (1992).

Heinisch, J. J., Muller, S., Schluter, E., Jacoby, J. and Rodicio, R. Investigation of Two Yeast Genes Encoding Putative Isoenzymes of Phosphoglycerate Mutase. Yeast 14, 203-213 (1998).

Kim, K. S., Rosenkrantz, M. S, and Guarente, L. Saccharomyces cerevisiae Contains Two Functional Citrate Synthase Genes. Mol. Cell. Biol. 6, 1936-1942 (1986).

Loftus, T. M., Hall, L. V., Anderson, S. L. and McAlister-Henn, L. Isolation, Characterization, and Disruption of the Yeast Gene Encoding Cytosolic NADP-Specific Isocitrate Dehydrogenase. Biochemistry 33, 9661-9667 (1994).

›EXAMPLE VIII · 5 of 5

McAlister-Henn, L. and Thompson, L. M. Isolation and Expression of the Gene Encoding Yeast Mitochondrial Malate Dehydrogenase. J. Bacteriol. 169, 5157-5166 (1987).

Müller, S, and Entian, K.-D. Yeast Sugar Metabolism. Zimmermann, F. K. and Entian, K. D. (eds.), pp. 157-170 (Technomic Publishing Co., Inc., Lancaster, 1997).

Ozcan, S., Freidel, K., Leuker, A. and Ciriacy, M. Glucose Uptake and Catabolite Repression in Dominant HTR1Mutants of Saccharomyces cerevisiae . J. Bacteriol. 175, 5520-5528 (1993).

Przybyla-Zawislak, B., Dennis, R. A., Zakharkin, S. O. and McCammon, M. T. Genes of Succinyl-CoA Ligase from Saccharomyces cerevisiae . Eur. J. Biochem. 258, 736-743 (1998).

Repetto, B. and Tzagoloff, A. In vivo Assembly of Yeast Mitochondrial Alpha-Ketoglutarate Dehydrogenase Complex. Mol. Cell. Biol. 11, 3931-3939 (1991).

Schaaff-Gerstenschlager, I. and Zimmermann, F. K. Pentose-Phosphate Pathway in Saccharomyces cerevisiae : Analysis of Deletion Mutants for Transketolase, Transaldolase, and Glucose 6-Phosphate Dehydrogenase. Curr. Genet. 24, 373-376 (1993).

Schaaff-Gerstenschlager, I. and Miosga, T. Yeast Sugar Metabolism. Zimmermann, F. K. and Entian, K. D. (eds.), pp. 271-284 (Technomic Publishing Co., Inc., Lancaster, 1997).

Sedivy, J. M. and Fraenkel, D. G. Fructose Bisphosphatase of Saccharomyces cerevisiae . Cloning, Disruption and Regulation of the FBP1 Structural Gene. J. Mol. Biol. 186, 307-319 (1985).

Smith, V., Chou, K. N., Lashkari, D., Botstein, D. and Brown, P. O. Functional Analysis of the Genes of Yeast Chromosome V by Genetic Footprinting. Science 274, 2069-2074 (1996).

Swartz, J. A Pure Approach to Constructive Biology. Nat. Biotechnol. 19, 732-733 (2001).

Wills, C. and Melham, T. Pyruvate Carboxylase Deficiency in Yeast: a Mutant Affecting the Interaction between the Glyoxylate and Krebs Cycles. Arch. Biochem. Biophys. 236, 782-791 (1985).

Throughout this application various publications have been referenced. The disclosures of these publications in their entireties are hereby incorporated by reference in this application in order to more fully describe the state of the art to which this invention pertains.

Although the invention has been described with reference to the examples provided above, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is only limited by the claims.

›Tables in the description — 5
TABLE 1 — Cellular components of S. cerevisiae (mmol/gDW).
ALA0.459CMP0.05
ARG0.161dAMP0.0036
ASN0.102dCMP0-0024
ASP0.297dGMP0.0024
CYS0.007DTMP0.0036
GLU0.302TAGLY0.007
GLN0.105ERGOST0.0007
GLY0.290ZYMST0.015
HIS0.066PA0.0006
ILE0.193PINS0.005
LEU0.296PS0.002
LYS0.286PE0.005
MET0.051PC0.006
PHE0.134GLYCOGEN0.519
PRO0.165TRE0.023
SER0.185Mannan0.809
THR0.19113GLUCAN1.136
TRP0.028SLF0.02
TYR0.102ATP23.9166
VAL0.265ADP23.9166
AMP0.051PI23.9456
GMP0.051Biomass1
UMP0.067
TABLE 2
Locus #E.C. #GeneGene DescriptionReactionRxn Name
Carbohydrate Metabolism
Glycolysis/Gluconeogenesis
YCL040W2.7.1.2GLK1GlucokinaseGLC + ATP -> G6P + ADPglk1_1
YCL040W2.7.1.2GLK1GlucokinaseMAN + ATP -> MAN6P + ADPglk1_2
YCL040W2.7.1.2GLK1GlucokinasebDGLC + ATP -> bDG6P + ADPglk1_3
YFR053C2.7.1.1HXK1Hexokinase I (PI) (also called Hexokinase A)bDGLC + ATP -> G6P + ADPhxk1_1
YFR053C2.7.1.1HXK1Hexokinase I (PI) (also called Hexokinase A)GLC + ATP -> G6P + ADPhxk1_2
YFR053C2.7.1.1HXK1Hexokinase I (PI) (also called Hexokinase A)MAN + ATP -> MAN6P + ADPhxk1_3
YFR053C2.7.1.1HXK1Hexokinase I (PI) (also called Hexokinase A)ATP + FRU -> ADP + F6Phxk1_4
YGL253W2.7.1.1HXK2Hexokinase II (PII) (also called Hexokinase B)bDGLC + ATP -> G6P + ADPhxk2_1
YGL253W2.7.1.1HXK2Hexokinase II (PII) (also called Hexokinase B)GLC + ATP -> G6P + ADPhxk2_2
YGL253W2.7.1.1HXK2Hexokinase II (PII) (also called Hexokinase B)MAN + ATP -> MAN6P + ADPhxk2_3
YGL253W2.7.1.1HXK2Hexokinase II (PII) (also called Hexokinase B)ATP + FRU -> ADP + F6Phxk2_4
YBR196C5.3.1.9PGI1Glucose-6-phosphate isomeraseG6P <-> F6Ppgi1_1
YBR196C5.3.1.9PGI1Glucose-6-phosphate isomeraseG6P <-> bDG6Ppgi1_2
YBR196C5.3.1.9PGI1Glucose-6-phosphate isomerasebDG6P <-> F6Ppgi1_3
YMR205C2.7.1.11PFK2phosphofructokinase beta subunitF6P + ATP -> FDP + ADPpfk2
YGR240C2.7.1.11PFK1phosphofructokinase alpha subunitF6P + ATP -> FDP + ADPpfk1_1
YGR240C2.7.1.11PFK1phosphofructokinase alpha subunitATP + TAG6P -> ADP + TAG16Ppfk1_2
YGR240C2.7.1.11PFK1phosphofructokinase alpha subunitATP + S7P -> ADP + S17Ppfk1_3
YKL060C4.1.2.13FBA1fructose-bisphosphate aldolaseFDP <-> T3P2 + T3P1fba1_1
YDR050C5.3.1.1TPI1triosephosphate isomeraseT3P2 <-> T3P1tpi1
YJL052W1.2.1.12TDH1Glyceraldehyde-3-phosphate dehydrogenase 1T3P1 + PI + NAD <-> NADH + 13PDGtdh1
YJR009C1.2.1.12TDH2glyceraldehyde 3-phosphate dehydrogenaseT3P1 + PI + NAD <-> NADH + 13PDGtdh2
YGR192C1.2.1.12TDH3Glyceraldehyde-3-phosphate dehydrogenase 3T3P1 + PI + NAD <-> NADH + 13PDGtdh3
YCR012W2.7.2.3PGK1phosphoglycerate kinase13PDG + ADP <-> 3PG + ATPpgk1
YKL152C5.4.2.1GPM1Phosphoglycerate mutase13PDG <-> 23PDGgpm1_1
YKL152C5.4.2.1GPM1Phosphoglycerate mutase3PG <-> 2PGgpm1_2
YDL021W5.4.2.1GPM2Similar to GPM1 (phosphoglycerate mutase)3PG <-> 2PGgpm2
YOL056W5.4.2.1GPM3phosphoglycerate mutase3PG <-> 2PGgpm3
YGR254W4.2.1.11ENO1enolase I2PG <-> PEPeno1
YHR174W4.2.1.11ENO2enolase2PG <-> PEPeno2
YMR323W4.2.1.11ERR1Protein with similarity to enolases2PG <-> PEPeno3
YPL281C4.2.1.11ERR2enolase related protein2PG <-> PEPeno4
YOR393W4.2.1.11ERR1enolase related protein2PG <-> PEPeno5
YAL038W2.7.1.40CDC19Pyruvate kinasePEP + ADP -> PYR + ATPcdc19
YOR347C2.7.1.40PYK2Pyruvate kinase, glucose-repressed isoformPEP + ADP -> PYR + ATPpyk2
YER178w1.2.4.1PDA1pyruvate dehydrogenase (lipoamide) alphaPYRm + COAm + NADm -> NADHm + CO2m +pda1
chain precursor, E1 component, alpha unitACCOAm
YBR221c1.2.4.1PDB1pyruvate dehydrogenase (lipoamide) beta chain
precursor, E1 component, beta unit
YNL071w2.3.1.12LAT1dihydrolipoamide S-acetyltransferase, E2
component
Citrate cycle (TCA cycle)
YNR001C4.1.3.7CIT1Citrate synthase, Nuclear encodedACCOAm + OAm -> COAm + CITmcit1
mitochondrial protein.
YCR005C4.1.3.7CIT2Citrate synthase, non-mitochondrial citrateACCOA + OA -> COA + CITcit2
synthase
YPR001W4.1.3.7cit3Citrate synthase, Mitochondrial isoform ofACCOAm + OAm -> COAm + CITmcit3
citrate synthase
YLR304C4.2.1.3aco1Aconitase, mitochondrialCITm <-> ICITmaco1
YJL200C4.2.1.3YJL200Caconitate hydratase homologCITm <-> ICITmaco2
YNL037C1.1.1.41IDH1Isocitrate dehydrogenase (NAD+) mito,ICITm + NADm -> CO2m + NADHm + AKGmidh1
subuint1
YOR136W1.1.1.41IDH2Isocitrate dehydrogenase (NAD+) mito,
subunit2
YDL066W1.1.1.42IDP1Isocitrate dehydrogenase (NADP+)ICITm + NADPm -> NADPHm + OSUCmidp1_1
YLR174W1.1.1.42IDP2Isocitrate dehydrogenase (NADP+)ICIT + NADP -> NADPH + OSUCidp2_1
YNL009W1.1.1.42IDP3Isocitrate dehydrogenase (NADP+)ICIT + NADP -> NADPH + OSUCidp3_1
YDL066W1.1.1.42IDP1Isocitrate dehydrogenase (NADP+)OSUCm -> CO2m + AKGmidp1_2
YLR174W1.1.1.42IDP2Isocitrate dehydrogenase (NADP+)OSUC -> CO2 + AKGidp2_2
YNL009W1.1.1.42IDP3Isocitrate dehydrogenase (NADP+)OSUC -> CO2 + AKGidp3_2
YIL125W1.2.4.2kgd1alpha-ketoglutarate dehydrogenase complex,AKGm + NADm + COAm -> CO2m + NADHm +kgd1a
E1 componentSUCCOAm
YDR148C2.3.1.61KGD2Dihydrolipoamide S-succinyltransferase, E2
component
YGR244C6.2.1.4/LSC2Succinate--CoA ligase (GDP-forming)ATPm + SUCCm + COAm <-> ADPm + PIm +lsc2
6.2.1.5SUCCOAm
YOR142W6.2.1.4/LSC1succinate-CoA ligase alpha subunitATPm + ITCm + COAm <-> ADPm + PIm +lsc1
6.2.1.5ITCCOAm
Electron Transport System, Complex II
YKL141w1.3.5.1SDH3succinate dehydrogenase cytochrome bSUCCm + FADm <-> FUMm + FADH2msdh3
YKL148c1.3.5.1SDH1succinate dehydrogenase cytochrome b
YLL041c1.3.5.1SDH2Succinate dehydrogenase (ubiquinone) iron-
sulfur protein subunit
YDR178w1.3.5.1SDH4succinate dehydrogenase membrane anchor
subunit
YLR164w1.3.5.1YLR164wstrong similarity to SDH4P
YMR118c1.3.5.1YMR118cstrong similarity to succinate dehydrogenase
YJL045w1.3.5.1YJL045wstrong similarity to succinate dehydrogenase
flavoprotein
YEL047c1.3.99.1YEL047csoluble fumarate reductase, cytoplasmicFADH2m + FUM -> SUCC + FADmfrds1
YJR051W1.3.99.1osm1Mitochondrial soluble fumarate reductaseFADH2m + FUMm -> SUCCm + FADmosm1
involved in osmotic regulation
YPL262W4.2.1.2FUM1FumarataseFUMm <-> MALmfum1_1
YPL262W4.2.1.2FUM1FumarataseFUM <-> MALfum1_2
YKL085W1.1.1.37MDH1mitochondrial malate dehydrogenaseMALm + NADm <-> NADHm + OAmmdh1
YDL078C1.1.1.37MDH3MALATE DEHYDROGENASE,MAL + NAD <-> NADH + OAmdh3
PEROXISOMAL
YOL126C1.1.1.37MDH2malate dehydrogenase, cytoplasmicMAL + NAD <-> NADH + OAmdh2
Anaplerotic Reactions
YER065C4.1.3.1ICL1isocitrate lyaseICIT -> GLX + SUCCicl1
YPR006C4.1.3.1ICL2Isocitrate lyase, may be nonfunctionalICIT -> GLX + SUCCicl2
YIR031C4.1.3.2dal7Malate synthaseACCOA + GLX -> COA + MALdal7
YNL117W4.1.3.2MLS1Malate synthaseACCOA + GLX -> COA + MALmls1
YKR097W4.1.1.49pck1phosphoenolpyruvate carboxylkinaseOA + ATP -> PEP + CO2 + ADPpck1
YLR377C3.1.3.11FBP1fructose-1,6-bisphosphataseFDP -> F6P + PIfbp1
YGL062W6.4.1.1PYC1pyruvate carboxylasePYR + ATP + CO2 -> ADP + OA + PIpyc1
YBR218C6.4.1.1PYC2pyruvate carboxylasePYR + ATP + CO2 -> ADP + OA + PIpyc2
YKL029C1.1.1.38MAE1mitochondrial malic enzymeMALm + NADPm -> CO2m + NADPHm + PYRmmae1
Pentose phosphate cycle
YNL241C1.1.1.49zwf1Glucose-6-phosphate-1-dehydrogenaseG6P + NADP <-> D6PGL + NADPHzwf1
YNR034W3.1.1.31SOL1Possible 6-phosphogluconolactonaseD6PGL -> D6PGCsol1
YCR073W-A3.1.1.31SOL2Possible 6-phosphogluconolactonaseD6PGL -> D6PGCsol2
YHR163W3.1.1.31SOL3Possible 6-phosphogluconolactonaseD6PGL -> D6PGCsol3
YGR248W3.1.1.31SOL4Possible 6-phosphogluconolactonaseD6PGL -> D6PGCsol4
YGR256W1.1.1.44GND26-phophogluconate dehydrogenaseD6PGC + NADP -> NADPH + CO2 + RL5Pgnd2
YHR183W1.1.1.44GND16-phophogluconate dehydrogenaseD6PGC + NADP -> NADPH + CO2 + RL5Pgnd1
YJL121C5.1.3.1RPE1ribulose-5-P 3-epimeraseRL5P <-> X5Prpe1
YOR095C5.3.1.6RKI1ribose-5-P isomeraseRL5P <-> R5Prki1
YBR117C2.2.1.1TKL2transketolaseR5P + X5P <-> T3P1 + S7Ptkl2_1
YBR117C2.2.1.1TKL2transketolaseX5P + E4P <-> F6P + T3P1tkl2_2
YPR074C2.2.1.1TKL1transketolaseR5P + X5P <-> T3P1 + S7Ptkl1_1
YPR074C2.2.1.1TKL1transketolaseX5P + E4P <-> F6P + T3P1tkl1_2
YLR354C2.2.1.2TAL1transaldolaseT3P1 + S7P <-> E4P + F6Ptal1_1
YGR043C2.2.1.2YGR043CtransaldolaseT3P1 + S7P <-> E4P + F6Ptal1_2
YCR036W2.7.1.15RBK1RibokinaseRIB + ATP -> R5P + ADPrbk1_1
YCR036W2.7.1.15RBK1RibokinaseDRIB + ATP -> DR5P + ADPrbk1_2
YKL127W5.4.2.2pgm1phosphoglucomutaseR1P <-> R5Ppgm1_1
YKL127W5.4.2.2pgm1phosphoglucomutase 1G1P <-> G6Ppgm1_2
YMR105C5.4.2.2pgm2phosphoglucomutaseR1P <-> R5Ppgm2_1
YMR105C5.4.2.2pgm2PhosphoglucomutaseG1P <-> G6Ppgm2_2
Mannose
YER003C5.3.1.8PMI40mannose-6-phosphate isomeraseMAN6P <-> F6Ppmi40
YFL045C5.4.2.8SEC53phosphomannomutaseMAN6P <-> MAN1Psec53
YDL055C2.7.7.13PSA1mannose-1-phosphate guanyltransferase, GDP-GTP + MAN1P -> PPI + GDPMANpsa1
mannose pyrophosphorylase
Fructose
YIL107C2.7.1.105PFK266-Phosphofructose-2-kinaseATP + F6P -> ADP + F26Ppfk26
YOL136C2.7.1.105pfk276-phosphofructo-2-kinaseATP + F6P -> ADP + F26Ppfk27
YJL155C3.1.3.46FBP26Fructose-2,6-biphosphataseF26P -> F6P + PIfbp26
—2.7.1.56—1-Phosphofructokinase (Fructose 1-phosphateF1P + ATP -> FDP + ADPfrc3
kinase)
SorboseS.c. does not metabolize sorbitol, erythritol, mannitol,
xylitol, ribitol, arabinitol, galactinol
YJR159W1.1.1.14SOR1sorbitol dehydrogenase (L-iditol 2-SOT + NAD -> FRU + NADHsor1
dehydrogenase)
Galactose metabolism
YBR020W2.7.1.6gal1galactokinaseGLAC + ATP -> GAL1P + ADPgal1
YBR018C2.7.7.10gal7galactose-1-phosphate uridyl transferaseUTP + GAL1P <-> PPI + UDPGALgal7
YBR019C5.1.3.2gal10UDP-glucose 4-epimeraseUDPGAL <-> UDPGgal10
YHL012W2.7.7.9YHL012WUTP--Glucose 1-Phosphate UridylyltransferaseG1P + UTP <-> UDPG + PPIugp1_2
YKL035W2.7.7.9UGP1Uridinephosphoglucose pyrophosphorylaseGIP + UTP <-> UDPG + PPIugp1_1
YBR184W3.2.1.22YBR184WAlpha-galactosidase (melibiase)MELI -> GLC + GLACmel1_1
YBR184W3.2.1.22YBR184WAlpha-galactosidase (melibiase)DFUC -> GLC + GLACmel1_2
YBR184W3.2.1.22YBR184WAlpha-galactosidase (melibiase)RAF -> GLAC + SUCmel1_3
YBR184W3.2.1.22YBR184WAlpha-galactosidase (melibiase)GLACL <-> MYOI + GLACmel1_4
YBR184W3.2.1.22YBR184WAlpha-galactosidase (melibiase)EPM <-> MAN + GLACmel1_5
YBR184W3.2.1.22YBR184WAlpha-galactosidase (melibiase)GGL <-> GL + GLACmel1_6
YBR184W3.2.1.22YBR184WAlpha-galactosidase (melibiase)MELT <-> SOT + GLACmel1_7
YBR299W3.2.1.20MAL32MaltaseMLT -> 2 GLCmal32a
YGR287C3.2.1.20YGR287Cputative alpha glucosidaseMLT -> 2 GLCmal32b
YGR292W3.2.1.20MAL12MaltaseMLT -> 2 GLCmal12a
YIL172C3.2.1.20YIL172Cputative alpha glucosidaseMLT -> 2 GLCmal12b
YJL216C3.2.1.20YJL216Cprobable alpha-glucosidase (MALTase)MLT -> 2 GLCmal12c
YJL221C3.2.1.20FSP2homology to maltase(alpha-D-glucosidase)MLT -> 2 GLCfsp2a
YJL221C3.2.1.20FSP2homology to maltase(alpha-D-glucosidase)6DGLC -> GLAC + GLCfsp2b
YBR018C2.7.7.12GAL7UDPglucose--hexose-1-phosphateUDPG + GAL1P <-> G1P + UDPGALunkrx10
uridylytransferase
Trehalose
YBR126C2.4.1.15TPS1trehalose-6-P synthetase, 56 kD synthaseUDPG + G6P -> UDP + TRE6Ptps1
subunit of trehalose-6-phosphate
synthase\/phosphatase complex
YML100W2.4.1.15tsl1trehalose-6-P synthetase, 123 kD regulatoryUDPG + G6P -> UDP TRE6Ptsl1
subunit of trehalose-6-phosphate
synthase\/phosphatase complex\; homologous
to TPS3 gene product
YMR261C2.4.1.15TPS3trehalose-6-P synthetase, 115 kD regulatoryUDPG + G6P -> UDP + TRE6Ptps3
subunit of trehalose-6-phosphate
synthase\/phosphatase complex
YDR074W3.1.3.12TPS2Trehalose-6-phosphate phosphataseTRE6P -> TRE + PItps2
YPR026W3.2.1.28ATH1Acid trehalaseTRE -> 2 GLCath1
YBR001C3.2.1.28NTH2Neutral trehalase, highly homologous to NthIpTRE -> 2 GLCnth2
YDR001C3.2.1.28NTH1neutral trehalaseTRE -> 2 GLCnth1
Glycogen Metabolism (sucorose and sugar metabolism)
YEL011W2.4.1.18glc3Branching enzyme, 1,4-glucan-6-(1,4-glucano)-GLYCOGEN + PI -> G1Pglc3
transferase
YPR160W2.4.1.1GPH1Glycogen phosphorylaseGLYCOGEN + PI -> G1Pgph1
YFR015C2.4.1.11GSY1Glycogen synthase (UDP-gluocse--starchUDPG -> UDP + GLYCOGENgsy1
glucosyltransferase)
YLR258W2.4.1.11GSY2Glycogen synthase (UDP-gluocse--starchUDPG -> UDP + GLYCOGENgsy2
glucosyltransferase)
Pyruvate Metabolism
YAL054C6.2.1.1acs1acetyl-coenzyme A synthetaseATPm + ACm + COAm -> AMPm + PPIm +acs1
ACCOAm
YLR153C6.2.1.1ACS2acetyl-coenzyme A synthetaseATP + AC + COA -> AMP + PPI + ACCOAacs2
YDL168W1.2.1.1SFA1Formaldehyde dehydrogenase/long-chainFALD + RGT + NAD <-> FGT + NADHsfa1_1
alcohol dehydrogenase
YJL068C3.1.2.12—S-Formylglutathione hydrolaseFGT <-> RGT + FORunkrx11
YGR087C4.1.1.1PDC6pyruvate decarboxylasePYR -> CO2 + ACALpdc6
YLR134W4.1.1.1PDC5pyruvate decarboxylasePYR -> CO2 + ACALpdc5
YLR044C4.1.1.1pdc1pyruvate decarboxylasePYR -> CO2 + ACALpdc1
YBL015W3.1.2.1ACH1acetyl CoA hydrolaseCOA + AC -> ACCOAach1_1
YBL015W3.1.2.1ACH1acetyl CoA hydrolaseCOAm + ACm -> ACCOAmach1_2
YDL131W4.1.3.21LYS21probable homocitrate synthase, mitochondrialACCOA + AKG -> HCIT + COAlys21
isozyme precursor
YDL182W4.1.3.21LYS20homocitrate synthase, cytosolic isozymeACCOA + AKG -> HCIT + COAlys20
YDL182W4.1.3.21LYS20Homocitrate synthaseACCOAm + AKGm -> HCITm + COAmlys20a
YGL256W1.1.1.1adh4alcohol dehydrogenase isoenzyme IVETH + NAD <-> ACAL + NADHadh4
YMR083W1.1.1.1adh3alcohol dehydrogenase isoenzyme IIIETHm + NADm <-> ACALm + NADHmadh3
YMR303C1.1.1.1adh2alcohol dehydrogenase IIETH + NAD <-> ACAL + NADHadh2
YBR145W1.1.1.1ADH5alcohol dehydrogenase isoenzyme VETH + NAD <-> ACAL + NADHadh5
YOL086C1.1.1.1adh1Alcohol dehydrogenase IETH + NAD <-> ACAL + NADHadh1
YDL168W1.1.1.1SFA1Alcohol dehydrogenase IETH + NAD <-> ACAL + NADHsfa1_2
Glyoxylate and dicarboxylate metabolism
Glyoxal Pathway
YML004C4.4.1.5GLO1Lactoylglutathione lyase, glyoxalase IRGT + MTHGXL <-> LGTglo1
YDR272W3.1.2.6GLO2Hydroxyacylglutathione hydrolaseLGT -> RGT + LACglo2
YOR040W3.1.2.6GLO4glyoxalase II (hydroxyacylglutathioneLGTm -> RGTm + LACmglo4
hydrolase)
Energy Metabolism
Oxidative Phosphorylation
YBR011C3.6.1.1ipp1Inorganic pyrophosphatasePPI -> 2 PIipp1
YMR267W3.6.1.1ppa2mitochondrial inorganic pyrophosphatasePPIm -> 2 PImppa2
1.2.2.1FDNGFormate dehydrogenaseFOR + Qm -> QH2m + CO2 + 2 HEXTfdng
YML120C1.6.5.3NDI1NADH dehydrogenase (ubiquinone)NADHm + Qm -> QH2m + NADmndi1
YDL085W1.6.5.3NDH2Mitochondrial NADH dehydrogenase thatNADH + Qm -> QH2m + NADndh2
catalyzes the oxidation of cytosolic NADH
YMR145C1.6.5.3NDH1Mitochondrial NADH dehydrogenase thatNADH + Qm -> QH2m + NADndh1
catalyzes the oxidation of cytosolic NADH
YHR042W1.6.2.4NCP1NADPH--ferrihemoprotein reductaseNADPH + 2 FERIm -> NADP + 2 FEROmncp1
YKL141w1.3.5.1SDH3succinate dehydrogenase cytochrome bFADH2m + Qm <-> FADm + QH2mfad
YKL148c1.3.5.1SDH1succinate dehydrogenase cytochrome b
YLL041c1.3.5.1SDH2succinate dehydrogenase cytochrome b
YDR178w1.3.5.1SDH4succinate dehydrogenase cytochrome b
Electron Transport System, Complex III
YEL024W1.10.2.2RIP1ubiquinol-cytochrome c reductase iron-sulfurO2m + 4 FEROm + 6 Hm -> 4 FERImcyto
subunit
Q01051.10.2.2CYTBubiquinol-cytochrome c reductase cytochrome
b subunit
YOR065W1.10.2.2CYT1ubiquinol-cytochrome c reductase cytochrome
c1 subunit
YBL045C1.10.2.2COR1ubiquinol-cytochrome c reductase core subunit 1
YPR191W1.10.2.2QCR1ubiquinol-cytochrome c reductase core subunit 2
YPR191W1.10.2.2QCR2ubiquinol-cytochrome c reductase
YFR033C1.10.2.2QCR6ubiquinol-cytochrome c reductase subunit 6
YDR529C1.10.2.2QCR7ubiquinol-cytochrome c reductase subunit 7
YJL166W1.10.2.2QCR8ubiquinol-cytochrome c reductase subunit 8
YGR183C1.10.2.2QCR9ubiquinol-cytochrome c reductase subunit 9
YHR001W-A1.10.2.2QCR10ubiquinol-cytochrome c reductase subunit 10
Electron Transport System, Complex IV
Q00451.9.3.1COX1cytochrome c oxidase subunit IQH2m + 2 FERIm + 1.5 Hm -> Qm + 2 FEROmcytr
Q02501.9.3.1COX2cytochrome c oxidase subunit I
Q02751.9.3.1COX3cytochrome c oxidase subunit I
YDL067C1.9.3.1COX9cytochrome c oxidase subunit I
YGL187C1.9.3.1COX4cytochrome c oxidase subunit I
YGL191W1.9.3.1COX13cytochrome c oxidase subunit I
YHR051W1.9.3.1COX6cytochrome c oxidase subunit I
YIL111W1.9.3.1COX5Bcytochrome c oxidase subunit I
YLR038C1.9.3.1COX12cytochrome c oxidase subunit I
YLR395C1.9.3.1COX8cytochrome c oxidase subunit I
YMR256C1.9.3.1COX7cytochrome c oxidase subunit I
YNL052W1.9.3.1COX5Acytochrome c oxidase subunit I
ATP Synthase
YBL099W3.6.1.34ATP1F1F0-ATPase complex, F1 alpha subunitADPm + PIm -> ATPm + 3 Hmatp1
YPL271W3.6.1.34ATP15F1F0-ATPase complex, F1 epsilon subunit
YDL004W3.6.1.34ATP16F-type H+-transporting ATPase delta chain
Q00853.6.1.34ATP6F1F0-ATPase complex, FO A subunit
YBR039W3.6.1.34ATP3F1F0-ATPase complex, F1 gamma subunit
YBR127C3.6.1.34VMA2H+-ATPase V1 domain 60 KD subunit,
vacuolar
YPL078C3.6.1.34ATP4F1F0-ATPase complex, F1 delta subunit
YDR298C3.6.1.34ATP5F1F0-ATPase complex, OSCP subunit
YDR377W3.6.1.34ATP17ATP synthase complex, subunit f
YJR121W3.6.1.34ATP2F1F0-ATPase complex, F1 beta subunit
YKL016C3.6.1.34ATP7F1F0-ATPase complex, FO D subunit
YLR295C3.6.1.34ATP14ATP synthase subunit h
Q00803.6.1.34ATP8F-type H+-transporting ATPase subunit 8
Q01303.6.1.34ATP9F-type H+-transporting ATPase subunit c
YOL077W-A3.6.1.34ATP19ATP synthase k chain, mitochondrial
YPR020W3.6.1.34ATP20subunit G of the dimeric form of mitochondrial
F1F0-ATP synthase
YLR447C3.6.1.34VMA6V-type H+-transporting ATPase subunit AC39
YGR020C3.6.1.34VMA7V-type H+-transporting ATPase subunit F
YKL080W3.6.1.34VMA5V-type H+-transporting ATPase subunit C
YDL185W3.6.1.34TFP1V-type H+-transporting ATPase subunit A
YBR127C3.6.1.34VMA2V-type H+-transporting ATPase subunit B
YOR332W3.6.1.34VMA4V-type H+-transporting ATPase subunit E
YEL027W3.6.1.34CUP5V-type H+-transporting ATPase proteolipid
subunit
YHR026W3.6.1.34PPA1V-type H+-transporting ATPase proteolipid
subunit
YPL234C3.6.1.34TFP3V-type H+-transporting ATPase proteolipid
subunit
YMR054W3.6.1.34STV1V-type H+-transporting ATPase subunit I
YOR270C3.6.1.34VPH1V-type H+-transporting ATPase subunit I
YEL051W3.6.1.34VMA8V-type H+-transporting ATPase subunit D
YHR039C-A3.6.1.34VMA10vacuolar ATP synthase subunit G
YPR036W3.6.1.34VMA13V-type H+-transporting ATPase 54 kD subunit
Electron Transport System, Complex IV
Q00451.9.3.1COX1cytochrome-c oxidase subunit I4 FEROm + O2m + 6 Hm -> 4 FERImcox1
Q02751.9.3.1COX3Cytochrome-c oxidase subunit III,
mitochondrially-coded
Q02501.9.3.1COX2cytochrome-c oxidase subunit II
YDL067C1.9.3.1COX9Cytochrome-c oxidase
YGL187C1.9.3.1COX4cytochrome-c oxidase chain IV
YGL191W1.9.3.1COX13cytochrome-c oxidase chain VIa
YHR051W1.9.3.1COX6cytochrome-c oxidase subunit VI
YIL111W1.9.3.1COX5bcytochrome-c oxidase chain Vb
YLR038C1.9.3.1COX12cytochrome-c oxidase, subunit VIB
YLR395C1.9.3.1COX8cytochrome-c oxidase chain VIII
YMR256C1.9.3.1COX7cytochrome-c oxidase, subunit VII
YNL052W1.9.3.1COX5Acytochrome-c oxidase chain V.A precursor
YML054C1.1.2.3cyb2Lactic acid dehydrogenase2 FERIm + LLACm -> PYRm + 2 FEROmcyb2
YDL174C1.1.2.4DLD1mitochondrial enzyme D-lactate2 FERIm + LACm -> PYRm + 2 FEROmdld1
ferricytochrome c oxidoreductase
Methane metabolism
YPL275W1.2.1.2YPL275Wputative formate dehydrogenase/putativeFOR + NAD -> CO2 + NADHtfo1a
pseudogene
YPL276W1.2.1.2YPL276Wputative formate dehydrogenase/putativeFOR + NAD -> CO2 + NADHtfo1b
pseudogene
YOR388C1.2.1.2FDH1Protein with similarity to formateFOR + NAD -> CO2 + NADHfdh1
dehydrogenases
Nitrogen metabolism
YBR208C6.3.4.6DUR1urea amidolyase containing urea carboxylase/ATP + UREA + CO2 <-> ADP + PI + UREACdur1
allophanate hydrolase
YBR208C3.5.1.54DUR1Allophanate hydrolaseUREAC -> 2 NH3 + 2 CO2dur2
YJL126W3.5.5.1NIT2nitrilaseACNL -> INAC + NH3nit2
Sulfur metabolism (Cystein biosynthesis maybe)
YJR137C1.8.7.1ECM17Sulfite reductaseH2SO3 + 3 NADPH <-> H2S + 3 NADPecm17
Lipid Metabolism
Fatty acid biosynthesis
YER015W6.2.1.3FAA2Long-chain-fatty-acid--CoA ligase, Acyl-CoAATP + LCCA + COA <-> AMP + PPI + ACOAfaa2
synthetase
YIL009W6.2.1.3FAA3Long-chain-fatty-acid--CoA ligase, Acyl-CoAATP + LCCA + COA <-> AMP + PPI + ACOAfaa3
synthetase
YOR317W6.2.1.3FAA1Long-chain-fatty-acid--CoA ligase, Acyl-CoAATP + LCCA + COA <-> AMP + PPI + ACOAfaa1
synthetase
YMR246W6.2.1.3FAA4Acyl-CoA synthase (long-chain fatty acid CoAATP + LCCA + COA <-> AMP + PPI + ACOAfaa4
ligase); contributes to activation of imported
myristate
YKR009C1.1.1.—FOX23-Hydroxyacyl-CoA dehydrogenaseHACOA + NAD <-> OACOA + NADHfox2b
YIL160C2.3.1.16pot13-Ketoacyl-CoA thiolaseOACOA + COA -> ACOA + ACCOApot1_1
YPL028W2.3.1.9erg10Acetyl-CoA C-acetyltransferase,2 ACCOA <-> COA + AACCOAerg10_1
ACETOACETYL-COA THIOLASE
YPL028W2.3.1.9erg10Acetyl-CoA C-acetyltransferase,2 ACCOAm <-> COAm + AACCOAmerg10_2
ACETOACETYL-COA THIOLASE (mitoch)
Fatty Acids Metabolism
Mitochondrial type II fatty acid synthase
YKL192C1.6.5.3ACP1Acyl carrier protein, component ofNADHm + Qm -> NADm + QH2mACP1
mitochondrial type II fatty acid synthase
YER061C—CEM1Beta-ketoacyl-ACP synthase, mitochondrial (3-
oxoacyl-[Acyl-carrier-protein] synthase)
YOR221C—MCT1Malonyl CoA:acyl carrier protein transferase
YKL055C—OAR13-Oxoacy-[acyl-carrier-protein] reductase
YKL192C/YER061C/1.6.5.3/—/—/—ACP1/CEM1/Type II fatty acid synthaseACACPm + 4 MALACPm + 8 NADPHm -> 8TypeII_1
YOR221C/YKL055CMCT1/NADPm + C100ACPm + 4 CO2m + 4 ACPm
OAR1
YKL192C/YER061C/1.6.5.3/—/—/—ACP1/CEM1/Type II fatty acid synthaseACACPm + 5 MALACPm + 10 NADPHm -> 10TypeII_2
YOR221C/YKL055CMCT1/NADPm + C120ACPm + 5 CO2m + 5 ACPm
OAR1
YKL192C/YER061C/1.6.5.3/—/—/—ACP1/CEM1/Type II fatty acid synthaseACACPm + 6 MALACPm + 12 NADPHm -> 12TypeII_3
YOR221C/YKL055CMCT1/NADPm + C140ACPm + 6 CO2m + 6 ACPm
OAR1
YKL192C/YER061C/1.6.5.3/—/—/—ACP1/CEM1/Type II fatty acid synthaseACACPm + 6 MALACPm + 11 NADPHm -> 11TypeII_4
YOR221C/YKL055CMCT1/NADPm + C141ACPm + 6 CO2m + 6 ACPm
OAR1
YKL192C/YER061C/1.6.5.3/—/—/—ACP1/CEM1/Type II fatty acid synthaseACACPm + 7 MALACPm + 14 NADPHm -> 14TypeII_5
YOR221C/YKL055CMCT1/NADPm + C160ACPm + 7 CO2m + 7 ACPm
OAR1
YKL192C/YER061C/1.6.5.3/—/—/—ACP1/CEM1/Type II fatty acid synthaseACACPm + 7 MALACPm + 13 NADPHm -> 13TypeII_6
YOR221C/YKL055CMCT1/NADPm + C161ACPm + 7 CO2m + 7 ACPm
OAR1
YKL192C/YER061C/1.6.5.3/—/—/—ACP1/CEM1/Type II fatty acid synthaseACACPm + 8 MALACPm + 16 NADPHm -> 16TypeII_7
YOR221C/YKL055CMCT1/NADPm + C180ACPm + 8 CO2m + 8 ACPm
OAR1
YKL192C/YER061C/1.6.5.3/—/—/—ACP1/CEM1/Type II fatty acid synthaseACACPm + 8 MALACPm + 15 NADPHm -> 15TypeII_8
YOR221C/YKL055CMCT1/NADPm + C181ACPm + 8 CO2m + 8 ACPm
OAR1
YKL192C/YER061C/1.6.5.3/—/—/—ACP1/CEM1/Type II fatty acid synthaseACACPm + 8 MALACPm + 14 NADPHm -> 14TypeII_9
YOR221C/YKL055CMCT1/NADPm + C182ACPm + 8 CO2m + 8 ACPm
OAR1
Cytosolic fatty acid synthesis
YNR016C6.4.1.2ACC1acetyl-CoA carboxylase (ACC)/biotinACCOA + ATP + CO2 <-> MALCOA + ADP + PIacc1
6.3.4.14carboxylase
YKL182w4.2.1.61;fas1fatty-acyl-CoA synthase, beta chainMALCOA + ACP <-> MALACP + COAfas1_1
1.3.1.9;
2.3.1.38;
2.3.1.39;
3.1.2.14;
2.3.1.86
YPL231w2.3.1.85;FAS2fatty-acyl-CoA synthase, alpha chain
1.1.1.100;
2.3.1.41
YKL182w4.2.1.61;fas1fatty-acyl-CoA synthase, beta chainACCOA + ACP <-> ACACP + COAfas1_2
1.3.1.9;
2.3.1.38;
2.3.1.39;
3.1.2.14;
2.3.1.86
YER061C2.3.1.41CEM13-Oxoacyl-[acyl-carrier-protein] synthaseMALACPm + ACACPm -> ACPm + CO2m +cem1
3OACPm
YGR037C/YNR016C/6.4.1.2;ACB1/ACC1/b-Ketoacyl-ACP synthase (C10,0), fatty acylACACP + 4 MALACP + 8 NADPH -> 8 NADP +c100sn
YKL182W/6.3.4.1; 4fas1/CoA synthaseC100ACP + 4 CO2 + 4 ACP
YPL231w2.3.1.85;FAS2/
1.1.1.100;
2.3.1.41;
4.2.1.61
YGR037C/YNR016C/6.4.1.2;ACB1/ACC1/b-Ketoacyl-ACP synthase (C12,0), fatty acylACACP + 5 MALACP + 10 NADPH -> 10 NADP +c120sn
YKL182W/6.3.4.1; 4fas1/CoA synthaseC120ACP + 5 CO2 + 5 ACP
YPL231w2.3.1.85;FAS2/
1.1.1.100;
2.3.1.41;
4.2.1.61
YGR037C/YNR016C/6.4.1.2;ACB1/ACC1/b-Ketoacyl-ACP synthase (C14,0)ACACP + 6 MALACP + 12 NADPH -> 12 NADP +c140sn
YKL182W/6.3.4.1; 4fas1/C140ACP + 6 CO2 + 6 ACP
YPL231w2.3.1.85;FAS2/
1.1.1.100;
2.3.1.41;
4.2.1.61
YGR037C/YNR016C/6.4.1.2;ACB1/ACC1/b-Ketoacyl-ACP synthase I (C14,1)ACACP + 6 MALACP + 11 NADPH -> 11 NADP +c141sy
YKL182W/6.3.4.1; 4fas1/C141ACP + 6 CO2 + 6 ACP
YPL231w2.3.1.85;FAS2/
1.1.1.100;
2.3.1.41;
4.2.1.61
YGR037C/YNR016C/6.4.1.2;ACB1/ACC1/b-Ketoacyl-ACP synthase I (C16,0)ACACP + 7 MALACP + 14 NADPH -> 14 NADP +c160sn
YKL182W/6.3.4.1; 4fas1/C160ACP + 7 CO2 + 7 ACP
YPL231w2.3.1.85;FAS2/
1.1.1.100;
2.3.1.41;
4.2.1.61
YGR037C/YNR016C/6.4.1.2;ACB1/ACC1/b-Ketoacyl-ACP synthase I (C16,1)ACACP + 7 MALACP + 13 NADPH -> 13 NADP +c161sy
YKL182W/6.3.4.1; 4fas1/C161ACP + 7 CO2 + 7 ACP
YPL231w2.3.1.85;FAS2/
1.1.1.100;
2.3.1.41;
4.2.1.61
YGR037C/YNR016C/6.4.1.2;ACB1/ACC1/b-Ketoacyl-ACP synthase I (C18,0)ACACP + 8 MALACP + 16 NADPH -> 16 NADP +c180sy
YKL182W/6.3.4.1; 4fas1/C180ACP + 8 CO2 + 8 ACP
YPL231w2.3.1.85;FAS2/
1.1.1.100;
2.3.1.41;
4.2.1.61
YGR037C/YNR016C/6.4.1.2;ACB1/ACC1/b-Ketoacyl-ACP synthase I (C18,1)ACACP + 8 MALACP + 15 NADPH -> 15 NADP +c181sy
YKL182W/6.3.4.1; 4fas1/C181ACP + 8 CO2 + 8 ACP
YPL231w2.3.1.85;FAS2/
1.1.1.100;
2.3.1.41;
4.2.1.61
YGR037C/YNR016C/6.4.1.2;ACB1/ACC1/b-Ketoacyl-ACP synthase I (C18,2)ACACP + 8 MALACP + 14 NADPH -> 14 NADP +c182sy
YKL182W/6.3.4.1; 4fas1/C182ACP + 8 CO2 + 8 ACP
YPL231w2.3.1.85;FAS2/
1.1.1.100;
2.3.1.41;
4.2.1.61
YKL182W4.2.1.61fas13-hydroxypalmitoyl-[acyl-carrier protein]3HPACP <-> 2HDACPfas1_3
dehydratase
YKL182W1.3.1.9fas1Enoyl-ACP reductaseAACP + NAD <-> 23DAACP + NADHfas1_4
Fatty acid degradation
YGL205VV/YKR009C/1.3.3.6/POX1/FOX2/Fatty acid degradationC140 + ATP + 7 COA + 7 FADm + 7 NAD ->c140dg
YIL160C2.3.1.18POT3AMP + PPI + 7 FADH2m + 7 NADH + 7 ACCOA
YGL205W/YKR009C/1.3.3.6/POX1/FOX2/Fatty acid degradationC160 + ATP + 8 COA + 8 FADm + 8 NAD ->c160dg
YIL160C2.3.1.18POT3AMP + PPI + 8 FADH2m + 8 NADH + 8 ACCOA
YGL205W/YKR009C/1.3.3.6/POX1/FOX2/Fatty acid degradationC180 + ATP + 9 COA + 9 FADm + 9 NAD ->c180dg
YIL160C2.3.1.18POT3AMP + PPI + 9 FADH2m + 9 NADH + 9 ACCOA
Phospholipid Biosynthesis
——Glycerol-3-phosphate acyltransferaseGL3P + 0.017 C100ACP + 0.062 C120ACP + 0.1Gat1_1
C140ACP + 0.27 C160ACP + 0.169 C161ACP +
0.055 C180ACP + 0.235 C181ACP + 0.093
C182ACP -> AGL3P + ACP
——Glycerol-3-phosphate acyltransferaseGL3P + 0.017 C100ACP + 0.062 C120ACP + 0.1Gat2_1
C140ACP + 0.27 C160ACP + 0.169 C161ACP +
0.055 C180ACP + 0.235 C181ACP + 0.093
C182ACP -> AGL3P + ACP
——Glycerol-3-phosphate acyltransferaseT3P2 + 0.017 C100ACP + 0.062 C120ACP + 0.1Gat1_2
C140ACP + 0.27 C160ACP + 0.169 C161ACP +
0.055 C180ACP + 0.235 CI81ACP + 0.093
C182ACP -> AT3P2 + ACP
——Glycerol-3-phosphate acyltransferaseT3P2 + 0.017 C100ACP + 0.062 C120ACP + 0.1Gat2_2
C140ACP + 0.27 C160ACP + 0.169 C161ACP +
0.055 C180ACP + 0.235 C181ACP + 0.093
C182ACP -> AT3P2 + ACP
——Acyldihydroxyacetonephosphate reductaseAT3P2 + NADPH -> AGL3P + NADPADHAPR
YDL052C2.3.1.51SLC11-Acylglycerol-3-phosphate acyltransferaseAGL3P + 0.017 C100ACP + 0.062 C120ACP +slc1
0.100 C140ACP + 0.270 C160ACP + 0.169
C161ACP + 0.055 C180ACP + 0.235 C181ACP +
0.093 C182ACP -> PA + ACP
—2.3.1.51—1-Acylglycerol-3-phosphate acyltransferaseAGL3P + 0.017 C100ACP + 0.062 C120ACP +AGAT
0.100 C140ACP + 0.270 C160ACP + 0.169
C161ACP + 0.055 C180ACP + 0.235 C181ACP +
0.093 C182ACP -> PA + ACP
YBR029C2.7.7.41CDS1CDP-Diacylglycerol synthetasePAm + CTPm <-> CDPDGm + PPImcds1a
YBR029C2.7.7.41CDS1CDP-Diacylglycerol synthetasePA + CTP <-> CDPDG + PPIcds1b
YER026C2.7.8.8cho1phosphatidylserine synthaseCDPDG + SER <-> CMP + PScho1a
YER026C2.7.8.8cho1Phosphatidylserine synthaseCDPDGm + SERm <-> CMPm + PSmcho1b
YGR170W4.1.1.65PSD2phosphatidylserine decarboxylase located inPS -> PE + CO2psd2
vacuole or Golgi
YNL169C4.1.1.65PSD1Phosphatidylserine Decarboxylase 1PSm -> PEm + CO2mpsd1
YGR157W2.1.1.17CHO2Phosphatidylethanolamine N-methyltransferaseSAM + PE -> SAH + PMMEcho2
YJR073C2.1.1.16OPI3Methylene-fatty-acyl-phospholipid synthase.SAM + PMME -> SAH + PDMEopi3_1
YJR073C2.1.1.16OPI3Phosphatidyl-N-methylethanolamine N-PDME + SAM -> PC + SAHopi3_2
methyltransferase
YLR133W2.7.1.32CKI1Choline kinaseATP + CHO -> ADP + PCHOcki1
YGR202C2.7.7.15PCT1Cholinephosphate cytidylyltransferasePCHO + CTP -> CDPCHO + PPIpct1
YNL130C2.7.8.2CPT1Diacylglycerol cholinephosphotransferaseCDPCHO + DAGLY -> PC + CMPcpt1
YDR147W2.7.1.82EKI1Ethanolamine kinaseATP + ETHM -> ADP + PETHMeki1
YGR007W2.7.7.14MUQ1Phosphoethanolamine cytidylyltransferasePETHM + CTP -> CDPETN + PPIect1
YHR123W2.7.8.1EPT1Ethanolaminephosphotransferase.CDPETN + DAGLY <-> CMP + PEept1
YJL153C5.5.1.4ino1myo-Inositol-1-phosphate synthaseG6P -> MI1Pino1
YHR046C3.1.3.25INM1myo-Inositol-1(or 4)-monophosphataseMI1P -> MYOI + PIimpa1
YPR113W2.7.8.11PIS1phosphatidylinositol synthaseCDPDG + MYOI -> CMP + PINSpis1
YJR066W2.7.1.137tor11-Phosphatidylinositol 3-kinaseATP + PINS -> ADP + PINSPtor1
YKL203C2.7.1.137tor21-Phosphatidylinositol 3-kinaseATP + PINS -> ADP + PINSPtor2
YLR240W2.7.1.137vps341-Phosphatidylinositol 3-kinaseATP + PINS -> ADP + PINSPvps34
YNL267W2.7.1.67PIK1Phosphatidylinositol 4-kinase (PI 4-kinase),ATP + PINS -> ADP + PINS4Ppik1
generates PtdIns 4-P
YLR305C2.7.1.67STT4Phosphatidylinositol 4-kinaseATP + PINS -> ADP + PINS4Psst4
YFR019W2.7.1.68FAB1PROBABLE PHOSPHATIDYLINOSITOL-4-PINS4P + ATP -> D45PI + ADPfab1
PHOSPHATE 5-KINASE, 1-
phosphatidylinositol-4-phosphate kinase
YDR208W2.7.1.68MSS4Phosphatidylinositol-4-phosphate 5-kinase;PINS4P + ATP -> D45PI + ADPmss4
required for proper organization of the actin
cytoskeleton
YPL268W3.1.4.11plc11-phosphatidylinositol-4,5-bisphosphateD45PI -> TPI + DAGLYplc1
phosphodiesterase
YCL004W2.7.8.8PGS1CDP-diacylglycerol--serine O-CDPDGm + GL3Pm <-> CMPm + PGPmpgs1
phosphatidyltransferase
—3.1.3.27Phosphatidylglycerol phosphate phosphatase APGPm -> PIm + PGmpgpa
YDL142C2.7.8.5CRD1Cardiolipin synthaseCDPDGm + PGm -> CMPm + CLmcrd1
YDR284CDPP1diacylglycerol pyrophosphate phosphatasePA -> DAGLY + PIdpp1
YDR503CLPP1lipid phosphate phosphataseDGPP -> PA + PIlpp1
Sphingoglycolipid Metabolism
YDR062W2.3.1.50LCB2Serine C-palmitoyltransferasePALCOA + SER -> COA + DHSPH + CO2lcb2
YMR296C2.3.1.50LCB1Serine C-palmitoyltransferasePALCOA + SER -> COA + DHSPH + CO2lcb1
YBR265w1.1.1.102TSC103-Dehydrosphinganine reductaseDHSPH + NADPH -> SPH + NADPtsc10
YDR297WSUR2SYRINGOMYCIN RESPONSE PROTEIN 2SPH + O2 + NADPH -> PSPH + NADPsur2
—Ceramide synthasePSPH + C260COA -> CER2 + COAcsyna
—Ceramide synthasePSPH + C240COA -> CER2 + COAcsynb
YMR272CSCS7Ceramide hydroxylase that hydroxylates the C-CER2 + NADPH + O2 -> CER3 + NADPscs7
26 fatty-acyl moiety of inasitol-
phosphorylceramide
YKL004WAUR1IPS synthase, AUREOBASIDIN ACER3 + PINS -> IPCaur1
RESISTANCE PROTEIN
YBR036CCSG2Protein required for synthesis of theIPC + GDPMAN -> MIPCcsg2
mannosylated sphingolipids
YPL057CSUR1Protein required for synthesis of theIPC + GDPMAN -> MIPCsur1
mannosylated sphingolipids
YDR072C2.—.—.—IPT1MIP2C synthase, MANNOSYLMIPC + PINS -> MIP2Cipt1
DIPHOSPHORYLINOSITOL CERAMIDE
SYNTHASE
YOR171CLCB4Long chain base kinase, involved inSPH + ATP -> DHSP + ADPlcb4_1
sphingolipid metabolism
YLR260WLCB5Long chain base kinase, involved inSPH + ATP -> DHSP + ADPlcb5_1
sphingolipid metabolism
YOR171CLCB4Long chain base kinase, involved inPSPH + ATP -> PHSP + ADPlcb4_2
sphingolipid metabolism
YLR260WLCB5Long chain base kinase, involved inPSPH + ATP -> PHSP + ADPlcb5_2
sphingolipid metabolism
YJL134WLCB3Sphingoid base-phosphate phosphatase,DHSP -> SPH + PIlcb3
putative regulator of sphingolipid metabolism
and stress response
YKR053CYSR3Sphingoid base-phosphate phosphatase,DHSP -> SPH + PIysr3
putative regulator of sphingolipid metabolism
and stress response
YDR294CDPL1Dihydrosphingosine-1-phosphate lyaseDHSP -> PETHM + C16Adpl1
Sterol biosynthesis
YML126C4.1.3.5HMGS3-hydroxy-3-methylglutaryl coenzyme AH3MCOA + COA <-> ACCOA + AACCOAhmgs
synthase
YLR450W1.1.1.34hmg23-hydroxy-3-methylglutaryl-coenzyme AMVL + COA + 2 NADP <-> H3MCOA + 2hmg2
(HMG-CoA) reductase isozymeNADPH
YML075C1.1.1.34hmg13-hydroxy-3-methylglutaryl-coenzyme AMVL + COA + 2 NADP <-> H3MCOA + 2hmg1
(HMG-CoA) reductase isozymeNADPH
YMR208W2.7.1.36erg12mevalonate kinaseATP + MVL -> ADP + PMVLerg12_1
YMR208W2.7.1.36erg12mevalonate kinaseCTP + MVL -> CDP + PMVLerg12_2
YMR208W2.7.1.36erg12mevalonate kinaseGTP + MVL -> GDP + PMVLerg12_3
YMR208W2.7.1.36erg12mevalonate kinaseUTP + MVL -> UDP + PMVLerg12_4
YMR220W2.7.4.2ERG848 kDa Phosphomevalonate kinaseATP + PMVL -> ADP + PPMVLerg8
YNR043W4.1.1.33MVD1Diphosphomevalonate decarboxylaseATP + PPMVL -> ADP + PI + IPPP + CO2mvd1
YPL117C5.3.3.2idi1Isopentenyl diphosphate:dimethylallylIPPP <-> DMPPidi1
diphosphate isomerase (IPP isomerase)
YJL167W2.5.1.1ERG20prenyltransferaseDMPP + IPPP -> GPP + PPIerg20_1
YJL167W2.5.1.10ERG20Farnesyl diphosphate synthetase (FPPGPP + IPPP -> FPP + PPIerg20_2
synthetase)
YHR190W2.5.1.21ERG9Squalene synthase.2 FPP + NADPH -> NADP + SQLerg9
YGR175C1.14.99.7ERG1Squalene monooxygenaseSQL + O2 + NADP -> S23E + NADPHerg1
YHR072W5.4.99.7ERG72,3-oxidosqualene-lanosterol cyclaseS23E -> LNSTerg7
YHR007c1.14.14.1erg11cytochrome P450 lanosterol 14a-demethylaseLNST + RFP + O2 -> IGST + OFPerg11_1
YNL280c1.—.—.—ERG24C-14 sterol reductaseIGST + NADPH -> DMZYMST + NADPerg24
YGR060w1.—.—.—ERG25C-4 sterol methyl oxidase3 O2 + DMZYMST -> IMZYMSTerg25_1
YGL001c5.3.3.1ERG26C-3 sterol dehydrogenase (C-4 decarboxylase)IMZYMST -> IIMZYMST + CO2erg26_1
YLR100CYLR100CC-3 sterol keto reductaseIIMZYMST + NADPH -> MZYMST + NADPerg11_2
YGR060w1.—.—.—ERG25C-4 sterol methyl oxidase3 O2 + MZYMST -> IZYMSTerg25_2
YGL001c5.3.3.1ERG26C-3 sterol dehydrogenase (C-4 decarboxylase)IZYMST -> IIZYMST + CO2erg26_2
YLR100CYLR100CC-3 sterol keto reductaseIIZYMST + NADPH -> ZYMST + NADPerg11_3
YML008c2.1.1.41erg6S-adenosyl-methionine delta-24-sterol-c-ZYMST + SAM -> FEST + SAHerg6
methyltransferase
YMR202WERG2C-8 sterol isomeraseFEST -> EPSTerg2
YLR056w1.—.—.—ERG3C-5 sterol desaturaseEPST + O2 + NADPH -> NADP + ERTROLerg3
YMR015c1.14.14.—ERG5C-22 sterol desaturaseERTROL + O2 + NADPH -> NADP + ERTEOLerg5
YGL012w1.—.—.—ERG4sterol C-24 reductaseERTEOL + NADPH -> ERGOST + NADPerg4
LNST + 3 O2 + 4 NADPH + NAD -> MZYMST +unkrxn3
CO2 + 4 NADP + NADH
MZYMST + 3 O2 + 4 NADPH + NAD -> ZYMST +unkrxn4
CO2 + 4 NADP + NADH
5.3.3.5Cholestenol delta-isomeraseZYMST + SAM -> ERGOST + SAHcdisoa
Nucleotide Metabolism
Histidine Biosynthesis
YOL061W2.7.6.1PRS5ribose-phosphate pyrophosphokinaseR5P + ATP <-> PRPP + AMPprs5
YBL068W2.7.6.1PRS4ribose-phosphate pyrophosphokinase 4R5P + ATP <-> PRPP + AMPprs4
YER099C2.7.6.1PRS2ribose-phosphate pyrophosphokinase 2R5P + ATP <-> PRPP + AMPprs2
YHL011C2.7.6.1PRS3ribose-phosphate pyrophosphokinase 3R5P + ATP <-> PRPP + AMPprs3
YKL181W2.7.6.1PRS1ribose-phosphate pyrophosphokinaseR5P + ATP <-> PRPP + AMPprs1
YIR027C3.5.2.5dal1allantoinaseATN <-> ATTdal1
YIR029W3.5.3.4dal2allantoicaseATT <-> UGC + UREAdal2
YIR032C3.5.3.19dal3ureidoglycolate hydrolaseUGC <-> GLX + 2 NH3 + CO2dal3
Purine metabolism
YJL005W4.6.1.1CYR1adenylate cyclaseATP -> cAMP + PPIcyr1
YDR454C2.7.4.8GUK1guanylate kinaseGMP + ATP <-> GDP + ADPguk1_1
YDR454C2.7.4.8GUK1guanylate kinaseDGMP + ATP <-> DGDP + ADPguk1_2
YDR454C2.7.4.8GUK1guanylate kinaseGMP + DATP <-> GDP + DADPguk1_3
YMR300C2.4.2.14ade4phosphoribosylpyrophosphate amidotransferasePRPP + GLN -> PPI + GLU + PRAMade4
YGL234W6.3.4.13ade5,7glycinamide ribotide synthetase andPRAM + ATP + GLY <-> ADP + PI + GARade5
aminoimidazole ribotide syntbetase
YDR408C2.1.2.2ade8glycinamide ribotide transformylaseGAR + FTHF -> THF + FGARade8
YGR061C6.3.5.3ade65′-phosphoribosylformyl glycinamidineFGAR + ATP + GLN -> GLU + ADP + PI +ade6
synthetaseFGAM
YGL234W6.3.3.1ade5,7Phosphoribosylformylglycinamide cyclo-ligaseFGAM + ATP -> ADP + PI + AIRade7
YOR128C4.1.1.21ade2phosphoribosylamino-imidazole-carboxylaseCAIR <-> AIR + CO2ade2
YAR015W6.3.2.6ade1phosphoribosyl aminoCAIR + ATP + ASP <-> ADP + PI + SAICARade1
imidazolesuccinocarbozamide synthetase
YLR359W4.3.2.2ADE135′-Phosphoribosyl-4-(N-succinocarboxamide)-SAICAR <-> FUM + AICARade13_1
5-aminoimidazole lyase
YLR028C2.1.2.3ADE165-aminoimidazole-4-carboxamideAICAR + FTHF <-> THF + PRFICAade16_1
ribonucleotide (AICAR) transformylase\/IMP
cyclohydrolase
YMR120C2.1.2.3ADE175-aminoimidazole-4-carboxamideAICAR + FTHF <-> THF + PRFICAade17_1
ribonucleotide (AICAR) transfonnylase\/IMP
cyclohydrolase
YLR028C3.5.4.10ADE165-aminoimidazole-4-carboxamidePRFICA <-> IMPade16_2
ribonucleotide (AICAR) transformylase\/IMP
cyclohydrolase
YMR120C2.1.2.3ADE17IMP cyclohydrolasePRFICA <-> IMPade17_2
YNL220W6.3.4.4ade12adenylosuccinate synthetaseIMP + GTP + ASP -> GDP + PI + ASUCade12
YLR359W4.3.2.2ADE13Adenylosuccinate LyaseASUC <-> FUM + AMPade13_2
YAR073W1.1.1.205fun63putative inosine-5′-monophosphateIMP + NAD -> NADH + XMPfun63
dehydrogenase
YHR216W1.1.1.205pur5purine excretionIMP + NAD -> NADH + XMPpur5
YML056C1.1.1.205IMD4probable inosine-5′-monophosphateIMP + NAD -> NADH + XMPprm5
dehydrogenase (IMP
YLR432W1.1.1.205IMD3probable inosine-5′-monophosphateIMP + NAD -> NADH + XMPprm4
dehydrogenase (IMP
YAR075W1.1.1.205YAR075WProtein with strong similarity to inosine-5′-IMP + NAD -> NADH + XMPprm6
monophosphate dehydrogenase, frameshifted
from YAR073W, possible pseudogene
YMR217W6.3.5.2,GUA1GMP synthaseXMP + ATP + GLN -> GLU + AMP + PPI + GMPgua1
6.3.4.1
YML035C3.5.4.6amd1AMP deaminaseAMP -> IMP + NH3amd1
YGL248W3.1.4.17PDE13′,5′-Cyclic-nucleotide phosphodiesterase, lowcAMP -> AMPpde1
affinity
YOR360C3.1.4.17pde23′,5′-Cyclic-nucleotide phosphodiesterase, highcAMP -> AMPpde2_1
affinity
YOR360C3.1.4.17pde2cdAMP -> DAMPpde2_2
YOR360C3.1.4.17pde2cIMP -> IMPpde2_3
YOR360C3.1.4.17pde2cGMP -> GMPpde2_4
YOR360C3.1.4.17pde2cCMP -> CMPpde2_5
YDR530C2.7.7.53APA25′,5′″-P-1,P-4-tetraphosphate phosphorylase IIADP + ATP -> PI + ATRPapa2
YCL050C2.7.7.53apa15′,5′″-P-1,P-4-tetraphosphate phosphorylase IIADP + GTP -> PI + ATRPapa1_1
YCL050C2.7.7.53apa15′,5′″-P-1,P-4-tetraphosphate phosphorylase IIGDP + GTP -> PI + GTRPapa1_3
Pyrimidine metabolism
YJL130C2.1.3.2ura2Aspartate-carbamoyltransferaseCAP + ASP -> CAASP + PIura2_1
YLR420W3.5.2.3ura4dihydroorataseCAASP <-> DOROAura4
YKL216W1.3.3.1ura1dihydroorotate dehydrogenaseDOROA + O2 <-> H2O2 + OROAura1_1
YKL216W1.3.3.1PYRDDihydroorotate dehydrogenaseDOROA + Qm <-> QH2m + OROAura1_2
YML106W2.4.2.10URA5Orotate phosphoribosyltransferase 1OROA + PRPP <-> PPI + OMPura5
YMR271C2.4.2.10URA10Orotate phosphoribosyltransferase 2OROA + PRPP <-> PPI + OMPura10
YEL021W4.1.1.23ura3orotidine-5′-phosphate decarboxylaseOMP -> CO2 + UMPura3
YKL024C2.7.4.14URA6Nucleoside-phosphate kinaseATP + UMP <-> ADP + UDPnpk
YHR128W2.4.2.9fur1UPRTase, Uracil phosphoribosyltransferaseURA + PRPP -> UMP + PPIfur1
YPR062W3.5.4.1FCY1cytosine deaminaseCYTS -> URA + NH3fcy1
—2.7.1.21Thymidine (deoxyuridine) kinaseDU + ATP -> DUMP + ADPtdk1
—2.7.1.21Thymidine (deoxyuridine) kinaseDT + ATP -> ADP + DTMPtdk2
YNR012W2.7.1.48URK1Uridine kinaseURI + GTP -> UMP + GDPurk1_1
YNR012W2.7.1.48URK1Cytodine kinaseCYTD + GTP -> GDP + CMPurk1_2
YNR012W2.7.1.48URK1Uridine kinase, converts ATP and uridine toURI + ATP -> ADP + UMPurk1_3
ADP and UMP
YLR209C2.4.2.4PNP1Protein with similarity to human purineDU + PI <-> URA + DR1Pdeoa1
nucleoside phosphorylase, Thymidine
(deoxyuridine) phosphorylase, Purine
nucleotide phosphorylase
YLR209C2.4.2.4PNP1Protein with similarity to human purineDT + PI <-> THY + DR1Pdeoa2
nucleoside phosphorylase, Thymidine
(deoxyuridine) phosphorylase
YLR245C3.5.4.5CDD1Cytidine deaminaseCYTD -> URI + NH3cdd1_1
YLR245C3.5.4.5CDD1Cytidine deaminaseDC -> NH3 + DUcdd1_2
YJR057W2.7.4.9cdc8dTMP kinaseDTMP + ATP <-> ADP + DTDPcdc8
YDR353W1.6.4.5TRR1Thioredoxin reductaseOTHIO + NADPH -> NADP + RTHIOtrr1
YHR106W1.6.4.5TRR2mitochondrial thioredoxin reductaseOTHIOm + NADPHm -> NADPm + RTHIOmtrr2
YBR252W3.6.1.23DUT1dUTP pyrophosphatase (dUTPase)DUTP -> PPI + DUMPdut1
YOR074C2.1.1.45cdc21Thymidylate synthaseDUMP + METTHF -> DHF + DTMPcdc21
—2.7.4.14Cytidylate kinaseDCMP + ATP <-> ADP + DCDPcmka1
—2.7.4.14Cytidylate kinaseCMP + ATP <-> ADP + CDPcmka2
YHR144C3.5.4.12DCD1dCMP deaminaseDCMP <-> DUMP + NH3dcd1
YBL039C6.3.4.2URA7CTP synthase, highly homologus to URA8UTP + GLN + ATP -> GLU + CTP + ADP + PIura7_1
CTP synthase
YJR103W6.3.4.2URA8CTP synthaseUTP + GLN + ATP -> GLU + CTP + ADP + PIura8_1
YBL039C6.3.4.2URA7CTP synthase, highly homologus to URA8ATP + UTP + NH3 -> ADP + PI + CTPura7_2
CTP synthase
YJR103W6.3.4.2URA8CTP synthaseATP + UTP + NH3 -> ADP + PI + CTPura8_2
YNL292W4.2.1.70PUS4Pseudouridine synthaseURA + R5P <-> PURI5Ppus4
YPL212C4.2.1.70PUS1intranuclear protein which exhibits aURA + R5P <-> PURI5Ppus1
nucleotide-specific intron-dependent tRNA
pseudouridine synthase activity
YGL063W4.2.1.70PUS2pseudouridine synthase 2URA + R5P <-> PURI5Ppus2
YFL001W4.2.1.70deg1Similar to rRNA methyltransferaseURA + R5P <-> PURI5Pdeg1
( Caenorhabditis elegans ) and hypothetical 28K
protein (alkaline endoglucanase gene 5′ region)
from Bacillus sp.
Salvage Pathways
YML022W2.4.2.7APT1Adenine phosphoribosyltransferaseAD + PRPP -> PPI + AMPapt1
YDR441C2.4.2.7APT2similar to adenine phosphoribosyltransferaseAD + PRPP -> PPI + AMPapt2
YNL141W3.5.4.4AAH1adenine aminohydrolase (adenine deaminase)ADN -> INS + NH3aah1a
YNL141W3.5.4.4AAH1adenine aminohydrolase (adenine deaminase)DA -> DIN + NH3aah1b
YLR209C2.4.2.1PNP1Purine nucleotide phosphorylase, XanthosineDIN + PI <-> HYXN + DR1Pxapa1
phosphorylase
YLR209C2.4.2.1PNP1Xanthosine phosphorylase, Purine nucleotideDA + PI <-> AD + DR1Pxapa2
phosphorylase
YLR209C2.4.2.1PNP1Xanthosine phosphorylaseDG + PI <-> GN + DR1Pxapa3
YLR209C2.4.2.1PNP1Xanthosine phosphorylase, Purine nucleotideHYXN + RIP <-> INS + PIxapa4
phosphorylase
YLR209C2.4.2.1PNP1Xanthosine phosphorylase, Purine nucleotideAD + R1P <-> PI + ADNxapa5
phosphorylase
YLR209C2.4.2.1PNP1Xanthosine phosphorylase, Purine nucleotideGN + R1P <-> PI + GSNxapa6
phosphorylase
YLR209C2.4.2.1PNP1Xanthosine phosphorylase, Purine nucleotideXAN + R1P <-> PI + XTSINExapa7
phosphorylase
YJR133W2.4.2.22XPT1Xanthine-guanine phosphoribosyltransferaseXAN + PRPP -> XMP + PPIgpt1
YDR400W3.2.2.1urh1Purine nucleosidaseGSN -> GN + RIBpur21
YDR400W3.2.2.1urh1Purine nucleosidaseADN -> AD + RIBpur11
YJR105W2.7.1.20YJR105WAdenosine kinaseADN + ATP -> AMP + ADPprm2
YDR226W2.7.4.3adk1cytosolic adenylate kinaseATP + AMP <-> 2 ADPadk1_1
YDR226W2.7.4.3adk1cytosolic adenylate kinaseGTP + AMP <-> ADP + GDPadk1_2
YDR226W2.7.4.3adk1cytosolic adenylate kinaseITP + AMP <-> ADP + IDPadk1_3
YER170W2.7.4.3ADK2Adenylate kinase (mitochondrial GTP:AMPATPm + AMPm <-> 2 ADPmadk2_1
phosphotransferase)
YER170W2.7.4.3adk2Adenylate kinase (mitochondrial GTP:AMPGTPm + AMPm <-> ADPm + GDPmadk2_2
phosphotransferase)
YER170W2.7.4.3adk2Adenylate kinase (mitochondrial GTP:AMPITPm + AMPm <-> ADPm + IDPmadk2_3
phosphotransferase)
YGR180C1.17.4.1RNR4ribonucleotide reductase, small subunit (alt),
beta chain
YIL066C1.17.4.1RNR3Ribonucleotide reductase (ribonucleoside-ADP + RTHIO -> DADP + OTHIOrnr3
diphosphate reductase) large subunit, alpha
chain
YJL026W1.17.4.1rnr2small subunit of ribonucleotide reductase, beta
chain
YKL067W2.7.4.6YNK1Nucleoside-diphosphate kinaseUDP + ATP <-> UTP + ADPynk1_1
YKL067W2.7.4.6YNK1Nucleoside-diphosphate kinaseCDP + ATP <-> CTP + ADPynk1_2
YKL067W2.7.4.6YNK1Nucleoside-diphosphate kinaseDGDP + ATP <-> DGTP + ADPynk1_3
YKL067W2.7.4.6YNK1Nucleoside-diphosphate kinaseDUDP + ATP <-> DUTP + ADPynk1_4
YKL067W2.7.4.6YNK1Nucleoside-diphosphate kinaseDCDP + ATP <-> DCTP + ADPynk1_5
YKL067W2.7.4.6YNK1Nucleoside-diphosphate kinaseDTDP + ATP <-> DTTP + ADPynk1_6
YKL067W2.7.4.6YNK1Nucleoside-diphosphate kinaseDADP + ATP <-> DATP + ADPynk1_7
YKL067W2.7.4.6YNK1Nucleoside diphosphate kinaseGDP + ATP <-> GTP + ADPynk1_8
YKL067W2.7.4.6YNK1Nucleoside diphosphate kinaseIDP + ATP <-> ITP + IDPynk1_9
—2.7.4.11Adenylate kinase, dAMP kinaseDAMP + ATP <-> DADP + ADPdampk
YNL141W3.5.4.2AAH1Adenine deaminaseAD -> NH3 + HYXNyicp
—2.7.1.73Inosine kinaseINS + ATP -> IMP + ADPgsk1
—2.7.1.73Guanosine kinaseGSN + ATP -> GMP + ADPgsk2
YDR399W2.4.2.8HPT1Hypoxanthine phosphoribosyltransferaseHYXN + PRPP -> PPI + IMPhpt1_1
YDR399W2.4.2.8HPT1Hypoxanthine phosphoribosyltransferaseGN + PRPP -> PPI + GMPhpt1_2
—2.4.2.3Uridine phosphorylaseURI + PI <-> URA + R1Pudp
YKL024C2.1.4.—URA6Uridylate kinaseUMP + ATP <-> UDP + ADPpyrh1
YKL024C2.1.4.—URA6Uridylate kinaseDUMP + ATP <-> DUDP + ADPpyrh2
—3.2.2.10CMP glycosylaseCMP -> CYTS + R5Pcmpg
YHR144C3.5.4.13DCD1dCTP deaminaseDCTP -> DUTP + NH3dcd
—3.1.3.55′-NucleotidaseDUMP -> DU + PIusha1
—3.1.3.55′-NucleotidaseDTMP -> DT + PIusha2
—3.1.3.55′-NucleotidaseDAMP -> DA + PIusha3
—3.1.3.55′-NucleotidaseDGMP -> DG + PIusha4
—3.1.3.55′-NucleotidaseDCMP -> DC + PIusha5
—3.1.3.55′-NucleotidaseCMP -> CYTD + PIusha6
—3.1.3.55′-NucleotidaseAMP -> PI + ADNusha7
—3.1.3.55′-NucleotidaseGMP -> PI + GSNusha8
—3.1.3.55′-NucleotidaseIMP -> PI + INSusha9
—3.1.3.55′-NucleotidaseXMP -> PI + XTSINEusha12
—3.1.3.55′-NucleotidaseUMP -> PI + URIusha11
YER070W1.17.4.1RNR1Ribonucleoside-diphosphate reductaseADP + RTHIO -> DADP + OTHIOrnr1_1
YER070W1.17.4.1RNR1Ribonucleoside-diphosphate reductaseGDP + RTHIO -> DGDP + OTHIOrnr1_2
YER070W1.17.4.1RNR1Ribonucleoside-diphosphate reductaseCDP + RTHIO -> DCDP + OTHIOrnr1_3
YER070W1.17.4.1RNR1Ribonucleoside-diphosphate reductaseUDP + RTHIO -> OTHIO + DUDPrnr1_4
—1.17.4.2Ribonucleoside-triphosphate reductaseATP + RTHIO -> DATP + OTHIOnrdd1
—1.17.4.2Ribonucleoside-triphosphate reductaseGTP + RTHIO -> DGTP + OTHIOnrdd2
—1.17.4.2Ribonucleoside-triphosphate reductaseCTP + RTHIO -> DCTP + OTHIOnrdd3
—1.17.4.2Ribonucleoside-tiphosphate reductaseUTP + RTHIO -> OTHIO + DUTPnrdd4
3.6.1.—Nucleoside triphosphataseGTP -> GSN + 3 PImutt1
3.6.1.—Nucleoside triphosphataseDGTP -> DG + 3 PImutt2
YML035C3.2.2.4AMD1AMP deaminaseAMP -> AD + R5Pamn
YBR284W3.2.2.4YBR284WProtein with similarity to AMP deaminaseAMP -> AD + R5Pamn1
YJL070C3.2.2.4YJL070CProtein with similarity to AMP-deaminaseAMP -> AD + R5Pamn2
Amino Acid Metabolism
Glutamate Metabolism (Aminosugars met)
YMR250W4.1.1.15GAD1Glutamate decarboxylase BGLU -> GABA + CO2btn2
YGR019W2.6.1.19uga1Aminobutyrate aminotransaminase 2GABA + AKG -> SUCCSAL + GLUuga1
YBR006w1.2.1.16YBR006wSuccinate semialdehyde dehydrogenase-SUCCSAL + NADP -> SUCC + NADPHgabda
NADP
YKL104C2.6.1.16GFA1Glutamine_fructose-6-phosphateF6P + GLN -> GLU + GA6Pgfa1
amidotransferase (glucoseamine-6-phosphate
synthase)
YFL017C2.3.1.4GNA1Glucosamine-phosphate N-acetyltransferaseACCOA + GA6P <-> COA + NAGA6Pgna1
YEL058W5.4.2.3PCM1Phosphoacetylglucosamine MutaseNAGA1P <-> NAGA6Ppcm1a
YDL103C2.7.7.23QRI1N-Acetylglucosamine-1-phosphate-UTP + NAGA1P <-> UDPNAG + PPIqri1
uridyltransferase
YBR023C2.4.1.16chs3chitin synthase 3UDPNAG -> CHIT + UDPchs3
YBR038W2.4.1.16CHS2chitin synthase 2UDPNAG -> CHIT + UDPchs2
YNL192W2.4.1.16CHS1chitin synthase 2UDPNAG -> CHIT + UDPchs1
YHR037W1.5.1.12put2delta-1-pyrroline-5-carboxylate dehydrogenaseGLUGSALm + NADPm -> NADPHm + GLUmput2_1
P5Cm + NADm -> NADHm + GLUmput2
YDL171C1.4.1.14GLT1Glutamate synthase (NADH)AKG + GLN + NADH -> NAD + 2 GLUglt1
YDL215C1.4.1.4GDH2glutamate dehydrogenaseGLU + NAD -> AKG + NH3 + NADHgdh2
YAL062W1.4.1.4GDH3NADP-linked glutamate dehydrogenaseAKG + NH3 + NADPH <-> GLU + NADPgdh3
YOR375C1.4.1.4GDH1NADP-specific glutamate dehydrogenaseAKG + NH3 + NADPH <-> GLU + NADPgdh1
YPR035W6.3.1.2gln1glutamine synthetaseGLU + NH3 + ATP -> GLN + ADP + PIgln1
YEL058W5.4.2.3PCM1Phosphoglucosamine mutaseGA6P <-> GA1Ppcm1b
—3.5.1.2Glutaminase AGLN -> GLU + NH3glnasea
—3.5.1.2Glutaminase BGLN -> GLU + NH3glnaseb
Glucosamine
—5.3.1.10Glucosamine-6-phosphate deaminaseGA6P -> F6P + NH3nagb
Arabinose
YBR149W1.1.1.117ARA1D-arabinose 1-dehydrogenase (NAD(P)+).ARAB + NAD -> ARABLAC + NADHara1_1
YBR149W1.1.1.117ARA1D-arabinose 1-dehydrogenase (NAD(P)+).ARAB + NADP -> ARABLAC + NADPHara1_2
Xylose
YGR194C2.7.1.17XKS1XylulokinaseXUL + ATP -> X5P + ADPxks1
Mannitol
—1.1.1.17Mannitol-1-phosphate 5-dehydrogenaseMNT6P + NAD <-> F6P + NADHmtld
Alanine and Aspartate Metabolism
YKL106W2.6.1.1AAT1Asparate transaminaseOAm + GLUm <-> ASPm + AKGmaat1_1
YLR027C2.6.1.1AAT2Asparate transaminaseOA + GLU <-> ASP + AKGaat2_1
YAR035W2.3.1.7YAT1Carnitine O-acetyltransferaseCOAm + ACARm -> ACCOAm + CARmyat1
YML042W2.3.1.7CAT2Carnitine O-acetyltransferaseACCOA + CAR -> COA + ACARcat2
YDR111C2.6.1.2YDR111Cputative alanine transaminasePYR + GLU <-> AKG + ALAalab
YLR089C2.6.1.2YLR089Calanine aminotransferase, mitochondrialPYRm + GLUm <-> AKGm + ALAmcfx2
precursor (glutamic--
YPR145W6.3.5.4ASN1asparagine synthetaseASP + ATP + GLN -> GLU + ASN + AMP + PPIasn1
YGR124W6.3.5.4ASN2asparagine synthetaseASP + ATP + GLN -> GLU + ASN + AMP + PPIasn2
YLL062C2.1.1.10MHT1Putative cobalamin-dependent homocysteine S-SAM + HCYS -> SAH + METmht1
methyltransferase, Homocysteine S-
methyltransferase
YPL273W2.1.1.10SAM4Putative cobalamin-dependent homocysteine S-SAM + HCYS -> SAH + METsam4
methyltransferase
Asparagine
YCR024c6.1.1.22YCR024casn-tRNA synthetase, mitochondrialATPm + ASPm + TRNAm -> AMPm + PPIm +rnas
ASPTRNAm
YHR019C6.1.1.23DED81asn-tRNA synthetaseATP + ASP + TRNA -> AMP + PPI + ASPTRNAded81
YLR155C3.5.1.1ASP3-1Asparaginase, extracellularASN -> ASP + NH3asp3_1
YLR157C3.5.1.1ASP3-2Asparaginase, extracellularASN -> ASP + NH3asp3_2
YLR158C3.5.1.1ASP3-3Asparaginase, extracellularASN -> ASP + NH3asp3_3
YLR160C3.5.1.1ASP3-4Asparaginase, extracellularASN -> ASP + NH3asp3_4
YDR321W3.5.1.1asp1AsparaginaseASN -> ASP + NH3asp1
Glycine, serine and threonine metabolism
YER081W1.1.1.95ser3Phosphoglycerate dehydrogenase3PG + NAD -> NADH + PHPser3
YIL074C1.1.1.95ser33Phosphoglycerate dehydrogenase3PG + NAD -> NADH + PHPser33
YOR184W2.6.1.52ser1phosphoserine transaminasePHP + GLU -> AKG + 3PSERser1_1
YGR208W3.1.3.3ser2phosphoserine phosphatase3PSER -> PI + SERser2
YBR263W2.1.2.1SHM1Glycine hydroxymethyltransferaseTHFm + SERm <-> GLYm + METTHFmshm1
YLR058C2.1.2.1SHM2Glycine hydroxymethyltransferaseTHF + SER <-> GLY + METTHFshm2
YFL030W2.6.1.44YFL030WPutative alanine glyoxylate aminotransferaseALA + GLX <-> PYR + GLYagt
(serine pyruvate aminotransferase)
YDR019C2.1.2.10GCV1glycine cleavage T protein (T subunit ofGLYm + THFm + NADm -> METTHFm +gcv1_1
glycine decarboxylase complexNADHm + CO2 + NH3
YDR019C2.1.2.10GCV1glycine cleavage T protein (T subunit ofGLY + THF + NAD -> METTHF + NADH + CO2 +gcv1_2
glycine decarboxylase complexNH3
YER052C2.7.2.4hom3Aspartate kinase, Aspartate kinase I, II, IIIASP + ATP -> ADP + BASPhom3
YDR158W1.2.1.11hom2aspartic beta semi-aldehyde dehydrogenase,BASP + NADPH -> NADP + PI + ASPSAhom2
Aspartate semialdehyde dehydrogenase
YJR139C1.1.1.3hom6Homoserine dehydrogenase IASPSA + NADH -> NAD + HSERhom6_1
YJR139C1.1.1.3hom6Homoserine dehydrogenase IASPSA + NADPH -> NADP + HSERhom6_2
YHR025W2.7.1.39thr1homoserine kinaseHSER + ATP -> ADP + PHSERthr1
YCR053W4.2.99.2thr4threonine synthasePHSER -> PI + THRthr4_1
YGR155W4.2.1.22CYS4Cystathionine beta-synthaseSER + HCYS -> LLCTcys4
YEL046C4.1.2.5GLY1Threonine AldolaseGLY + ACAL -> THRgly1
YMR189W1.4.4.2GCV2Glycine decarboxylase complex (P-subunit),GLYm + LIPOm <-> SAPm + CO2mgcv2
glycine synthase (P-subunit), Glycine cleavage
system (P-subunit)
YCL064C4.2.1.16cha1threonine deaminaseTHR -> NH3 + OBUTchal_1
YER086W4.2.1.16ilv1L-Serine dehydrataseTHRm -> NH3m + OBUTmilv1
YCL064C4.2.1.13cha1catabolic serine (threonine) dehydrataseSER -> PYR + NH3cha1_2
YIL167W4.2.1.13YIL167Wcatabolic serine (threonine) dehydrataseSER -> PYR + NH3sdl1
—1.1.1.103Threonine dehydrogenaseTHR + NAD -> GLY + AC + NADHtdh1c
Methionine metabolism
YFR055W4.4.1.8YFR055WCystathionine-b-lyaseLLCT -> HCYS + PYR + NH3metc
YER043C3.3.1.1SAH1putative S-adenosyl-L-homocysteine hydrolaseSAH -> HCYS + ADNsah1
YER091C2.1.1.14met6vitamin B12-(cobalamin)-independent isozymeHCYS + MTHPTGLU -> THPTGLU + METmet6
of methionine synthase (also called N5-
methyltetrahydrofolate homocysteine
methyltransferase or 5-methyltetrahydropteroyl
triglutamate homocysteine methyltransferase)
—2.1.1.13Methionine synthaseHCYS + MTHF -> THF + METmet6_2
YAL012W4.4.1.1cys3cystathionine gamma-lyaseLLCT -> CYS + NH3 + OBUTcys3
YNL277W2.3.1.31met2homoserine O-trans-acetylaseACCOA + HSER <-> COA + OAHSERmet2
YLR303W4.2.99.10MET17O-Acetylhomoserine (thiol)-lyaseOAHSER + METH -> MET + ACmet17_1
YLR303W4.2.99.8MET17O-Acetylhomoserine (thiol)-lyaseOAHSER + H2S -> AC + HCYSmet17_2
YLR303W4.2.99.8,met17O-acetylhomoserine sulfhydrylase (OAHOAHSER + H2S -> AC + HCYSmet17_3
4.2.99.10SHLase); converts O-acetylhomoserine into
homocysteine
YML082W4.2.99.9YML082Wputative cystathionine gamma-synthaseOSLHSER <-> SUCC + OBUT + NH4met17h
YDR502C2.5.1.6sam2S-adenosylmethionine synthetaseMET + ATP -> PPI + PI + SAMsam2
YLR180W2.5.1.6sam1S-adenosylmethionine synthetaseMET + ATP -> PPI + PI + SAMsam1
YLR172C2.1.1.98DPH5Diphthine synthaseSAM + CALH -> SAH + DPTHdph5
Cysteine Biosynthesis
YJR010W2.7.7.4met3ATP sulfurylaseSLF + ATP -> PPI + APSmet3
YKL001C2.7.1.25met14adenylylsulfate kinaseAPS + ATP -> ADP + PAPSmet14
YFR030W1.8.1.2met10sulfite reductaseH2SO3 + 3 NADPH <-> H2S + 3 NADPmet10
—2.3.1.30Serine transacetylaseSER + ACCOA -> COA + ASERcys1
YGR012W4.2.99.8YGR012Wputative cysteine synthase (O-acetylserineASER + H2S -> AC + CYSsul11
sulfhydrylase) (O-
YOL064C3.1.3.7MET223′-5′ Bisphosphate nucleotidasePAP -> AMP + PImet22
YPR167C1.8.99.4MET16PAPS ReductasePAPS + RTHIO -> OTHIO + H2SO3 + PAPmet16
YCL050C2.7.7.5apa1diadenosine 5′,5′″-P1,P4-tetraphosphateADP + SLF <-> PI + APSapa1_2
phosphorylase I
Branched Chain Amino Acid Metabolism (Valine, Leucine and Isoleucine)
YHR208W2.6.1.42BAT1Branched chain amino acid aminotransferaseOICAPm + GLUm <-> AKGm + LEUmbat1_1
YHR208W2.6.1.42BAT1Branched chain amino acid aminotransferaseOMVALm + GLUm <-> AKGm + ILEmbat1_2
YJR148W2.6.1.42BAT2branched-chain amino acid transaminase,OMVAL + GLU <-> AKG + ILEbat2_1
highly similar to mammalian ECA39, which is
regulated by the oncogene myc
YJR148W2.6.1.42BAT2Branched chain amino acid aminotransferaseOIVAL + GLU <-> AKG + VALbat2_2
YJR148W2.6.1.42BAT2branched-chain amino acid transaminase,OICAP + GLU <-> AKG + LEUbat2_3
highly similar to mammalian ECA39, which is
regulated by the oncogene myc
YMR108W4.1.3.18ilv2Acetolactate synthase, large subunitOBUTm + PYRm -> ABUTm + CO2milv2_1
YCL009C4.1.3.18ILV6Acetolactate synthase, small subunit
YMR108W4.1.3.18ilv2Acetolactate synthase, large subunit2 PYRm -> CO2m + ACLACmilv2_2
YCL009C4.1.3.18ILV6Acetolactate synthase, small subunit
YLR355C1.1.1.86ilv5Keto-acid reductoisomeraseACLACm + NADPHm -> NADPm + DHVALmilv5_1
YLR355C1.1.1.86ilv5Keto-acid reductoisomeraseABUTm + NADPHm -> NADPm + DHMVAmilv5_2
YJR016C4.2.1.9ilv3Dihydroxy acid dehydrataseDHVALm -> OIVALmilv3_1
YJR016C4.2.1.9ilv3Dihydroxy acid dehydrataseDHMVAm -> OMVALmilv3_2
YNL104C4.1.3.12LEU4alpha-isopropylmalate synthase (2-ACCOAm + OIVALm -> COAm + IPPMALmleu4
isopropylmalate Synthase)
YGL009C4.2.1.33leu1Isopropylmalate isomeraseCBHCAP <-> IPPMALleu1_1
YGL009C4.2.1.33leu1isopropylmalate isomerasePPMAL <-> IPPMALleu1_2
YCL018W1.1.1.85leu2beta-IPM (isopropylmalate) dehydrogenaseIPPMAL + NAD -> NADH + OICAP + CO2leu2
Lysine biosynthesis/degradation
—4.2.1.792-Methylcitrate dehydrataseHCITm <-> HACNmlys3
YDR234W4.2.1.36lys4Homoaconitate hydrataseHICITm <-> HACNmlys4
YIL094C1.1.1.155LYS12Homoisocitrate dehydrogenaseHICITm + NADm <-> OXAm + CO2m +lys12
(Strathern: 1.1.1.87)NADHm
—non-enzymaticOXAm <-> CO2m + AKAmlys12b
—2.6.1.392-Aminoadipate transaminaseAKA + GLU <-> AMA + AKGamit
YBR115C1.2.1.31lys2L-Aminoadipate-semialdehyde dehydrogenase,AMA + NADPH + ATP -> AMASA + NADP +lys2_1
large subunitAMP + PPI
YGL154C1.2.1.31lys5L-Aminoadipate-semialdehyde dehydrogenase,
small subunit
YBR115C1.2.1.31lys2L-Aminoadipate-semialdehyde dehydrogenase,AMA + NADH + ATP -> AMASA + NAD + AMP +lys2_2
large subunitPPI
YGL154C1.2.1.31lys5L-Aminoadipate-semialdehyde dehydrogenase,
small subunit
YNR050C1.5.1.10lys9Saccharopine dehydrogenase (NADP+, L-GLU + AMASA + NADPH <-> SACP + NADPlys9
glutamate forming)
YIR034C1.5.1.7lys1Saccharopine dehydrogenase (NAD+, L-lysineSACP + NAD <-> LYS + AKG + NADHlys1a
forming)
YDR037W6.1.1.6krs1lysyl-tRNA synthetase, cytosolicATP + LYS + LTRNA -> AMP + PPI + LLTRNAkrs1
YNL073W6.1.1.6msk1lysyl-tRNA synthetase, mitochondrialATPm + LYSm + LTRNAm -> AMPm + PPIm +msk1
LLTRNAm
YDR368W1.1.1.—YPR1similar to aldo-keto reductase
Arginine metabolism
YMR062C2.3.1.1ECM40Amino-acid N-acetyltransferaseGLUm + ACCOAm -> COAm + NAGLUmecm40_1
YER069W2.7.2.8arg5Acetylglutamate kinaseNAGLUm + ATPm -> ADPm + NAGLUPmarg6
YER069W1.2.1.38arg5N-acetyl-gamma-glutamyl-phosphate reductaseNAGLUPm + NADPHm -> NADPm + PIm +arg5
and acetylglutamate kinaseNAGLUSm
YOL140W2.6.1.11arg8Acetylornithine aminotransferaseNAGLUSm + GLUm -> AKGm + NAORNmarg8
YMR062C2.3.1.35ECM40Glutamate N-acetyltransferaseNAORNm + GLUm -> ORNm + NAGLUmecm40_2
YJL130C6.3.5.5ura2carbamoyl-phophate synthetase, aspartateGLN + 2 ATP + CO2 -> GLU + CAP + 2 ADP +ura2_2
transcarbamylase, and glutaminePI
amidotransferase
YJR109C6.3.5.5CPA2carbamyl phosphate synthetase, large chainGLN + 2 ATP + CO2 -> GLU + CAP + 2 ADP +cpa2
PI
YOR303W6.3.5.5cpa1Carbamoyl phosphate synthetase, samll chain,
arginine specific
YJL088W2.1.3.3arg3Ornithine carbamoyltransferaseORN + CAP -> CITR + PIarg3
YLR438W2.6.1.13car2Ornithine transaminaseORN + AKG -> GLUGSAL + GLUcar2
YOL058W6.3.4.5arg1arginosuccinate synthetaseCITR + ASP + ATP <-> AMP + PPI + ARGSUCCarg1
YHR018C4.3.2.1arg4argininosuccinate lyaseARGSUCC <-> FUM + ARGarg4
YKL184W4.1.1.17spe1Ornithine decarboxylaseORN -> PTRSC + CO2spe1
YOL052C4.1.1.50spe2S-adenosylmethionine decarboxylaseSAM <-> DSAM + CO2spe2
YPR069C2.5.1.16SPE3putrescine aminopropyltransferase (spermidinePTRSC + SAM -> SPRMD + 5MTAspe3
synthase)
YLR146C2.5.1.22SPE4Spermine synthaseDSAM + SPRMD -> 5MTA + SPRMspe4
YDR242W3.5.1.4AMD2AmidaseGBAD -> GBAT + NH3amd2_1
YMR293C3.5.1.4YMR293CProbable AmidaseGBAD -> GBAT + NH3amd
YPL111W3.5.3.1car1arginaseARG -> ORN + UREAcar1
YDR341C6.1.1.19YDR341Carginyl-tRNA synthetaseATP + ARG + ATRNA -> AMP + PPI + ALTRNAatrna
YHR091C6.1.1.19MSR1arginyl-tRNA synthetaseATP + ARG + ATRNA -> AMP + PPI + ALTRNAmsr1
YHR068W1.5.99.6DYS1deoxyhypusine synthaseSPRMD + Qm -> DAPRP + QH2mdys1
Histidine metabolism
YER055C2.4.2.17his1ATP phosphoribosyltransferasePRPP + ATP -> PPI + PRBATPhis1
YCL030C3.6.1.31his4phosphoribosyl-AMP cyclohydrolase/PRBATP -> PPI + PRBAMPhis4_1
phosphoribosyl-ATP pyrophosphohydrolase/
histidinol dehydrogenase
YCL030C3.5.4.19his4histidinol dehydrogenasePRBAMP -> PRFPhis4_2
YIL020C5.3.1.16his6phosphoribosyl-5-amino-1-phosphoribosyl-4-PRFP -> PRLPhis6
imidazolecarboxiamide isomerase
YOR202W4.2.1.19his3imidazoleglycerol-phosphate dehydrataseDIMGP -> IMACPhis3
YIL116W2.6.1.9his5histidinol-phosphate aminotransferaseIMACP + GLU -> AKG + HISOLPhis5
YFR025C3.1.3.15his2HistidinolphosphataseHISOLP -> PI + HISOLhis2
YCL030C1.1.1.23his4phosphoribosyl-AMP cyclohydrolase/HISOL + 2 NAD -> HIS + 2 NADHhis4_3
phosphoribosyl-ATP pyrophosphohydrolase/
histidinol dehydrogenase
YBR248C2.4.2.—his7glutamine amidotransferase:cyclasePRLP + GLN -> GLU + AICAR + DIMGPhis7
YPR033C6.1.1.21hts1histidyl-tRNA synthetaseATP + HIS + HTRNA -> AMP + PPI + HHTRNAhts1
YBR034C2.1.1.—hmt1hnRNP arginine N-methyltransferaseSAM + HIS -> SAH + MHIShmt1
YCL054W2.1.1.—spb1putative RNA methyltransferase
YML110C2.1.1.—coq5ubiquinone biosynthesis methlytransferase
COQ5
YOR201C2.1.1.—pet56rRNA (guanosine-2′-O-)-methyltransferase
YPL266W2.1.1.—dim1dimethyladenosine transferase
Phenylalanine, tyrosine and tryptophan biosynthesis (Aromatic Amino Acids)
YBR249C4.1.2.15ARO43-deoxy-D-arabino-heptulosonate 7-phosphateE4P + PEP -> PI + 3DDAH7Paro4
(DAHP) synthase isoenzyme
YDR035W4.1.2.15ARO3DAHP synthase\; a.k.a. phospho-2-dehydro-3-E4P + PEP -> PI + 3DDAH7Paro3
deoxyheptonate aldolase, phenylalanine-
inhibited\; phospho-2-keto-3-deoxyheptonate
aldolase\; 2-dehydro-3-deoxyphosphoheptonate
aldolase\; 3-deoxy-D-arabine-heptulosonate-7-
phosphate synthase
YDR127W4.6.1.3aro1pentafunctional arom polypeptide (contains: 3-3DDAH7P -> DQT + PIaro1_1
dehydroquinate synthase, 3-dehydroquinate
dehydratase (3-dehydroquinase), shikimate 5-
dehydrogenase, shikimate kinase, and epsp
synthase)
YDR127W4.2.1.10aro13-Dehydroquinate dehydrataseDQT -> DHSKaro1_2
YDR127W1.1.1.25aro1Shikimate dehydrogenaseDHSK + NADPH -> SME + NADParo1_3
YDR127W2.7.1.71aro1Shikimate kinase I, IISME + ATP -> ADP + SME5Paro1_4
YDR127W2.5.1.19aro13-Phosphoshikimate-1-carboxyvinyltransferaseSME5P + PEP -> 3PSME + PIaro1_5
YGL148W4.6.1.4aro2Chorismate synthase3PSME -> PI + CHORaro2
YPR060C5.4.99.5aro7Chorismate mutaseCHOR -> PHENaro7
YNL316C4.2.1.51pha2prephenate dehydratasePHEN -> CO2 + PHPYRpha2
YHR137W2.6.1.—ARO9putative aromatic amino acid aminotransferasePHPYR + GLU <-> AKG + PHEaro9_1
II
YBR166C1.3.1.13tyr1Prephenate dehydrogenase (NADP+)PHEN + NADP -> 4HPP + CO2 + NADPHtyr1
YGL202W2.6.1.—ARO8aromatic amino acid aminotransferase I4HPP + GLU -> AKG + TYRaro8
YHR137W2.6.1.—ARO9aromatic amino acid aminotransferase II4HPP + GLU -> AKG + TYRaro9_2
—1.3.1.12Prephanate dehydrogenasePHEN + NAD -> 4HPP + CO2 + NADHtyra2
YER090W4.1.3.27trp2Anthranilate synthaseCHOR + GLN -> GLU + PYR + ANtrp2_1
YKL211C4.1.3.27trp3Anthranilate synthaseCHOR + GLN -> GLU + PYR + ANtrp3_1
YDR354W2.4.2.18trp4anthranilate phosphoribosyl transferaseAN + PRPP -> PPI + NPRANtrp4
YDR007W5.3.1.24trp1n-(5′-phosphoribosyl)-anthranilate isomeraseNPRAN -> CPAD5Ptrp1
YKL211C4.1.1.48trp3Indoleglycerol phosphate synthaseCPAD5P -> CO2 + IGPtrp3_2
YGL026C4.2.1.20trp5tryptophan synthetaseIGP + SER -> T3P1 + TRPtrp5
YDR256C1.11.1.6CTA1catalase A2 H2O2 -> O2cta1
YGR088W1.11.1.6CTT1cytoplasmic catalase T2 H2O2 -> O2ctt1
YKL106W2.6.1.1AAT1Asparate aminotransferase4HPP + GLU <-> AKG + TYRaat1_2
YLR027C2.6.1.1AAT2Asparate aminotransferase4HPP + GLU <-> AKG + TYRaat2_2
YMR170C1.2.1.5ALD2Cytosolic aldeyhde dehydrogenaseACAL + NAD -> NADH + ACald2
YMR169C1.2.1.5ALD3strong similarity to aldehyde dehydrogenaseACAL + NAD -> NADH + ACald3
YOR374W1.2.1.3ALD4mitochondrial aldehyde dehydrogenaseACALm + NADm -> NADHm + ACmald4_1
YOR374W1.2.1.3ALD4mitochondrial aldehyde dehydrogenaseACALm + NADPm -> NADPHm + ACmald4_2
YER073W1.2.1.3ALD5mitochondrial Aldehyde DehydrogenaseACALm + NADPm -> NADPHm + ACmald5_1
YPL061W1.2.1.3ALD6Cytosolic Aldehyde DehydrogenaseACAL + NADP -> NADPH + ACald6
YJR078W1.13.11.11YJR078WProtein with similarity to indoleamine 2,3-TRP + O2 -> FKYNtdo2
dioxygenases, which catalyze conversion of
tryptophan and other indole derivatives into
kynurenines, Tryptophan 2,3-dioxygenase
—3.5.1.9Kynurenine formamidaseFKYN -> FOR + KYNkfor
YLR231C3.7.1.3YLR231Cprobable kynureninase (L-kynurenineKYN -> ALA + ANkynu_1
hydrolase)
YBL098W1.14.13.9YBL098WKynurenine 3-hydroxylase, NADPH-dependentKYN + NADPH + O2 -> HKYN + NADPkmo
flavin monooxygenase that catalyzes the
hydroxylation of kynurenine to 3-
hydroxykynurenine in tryptophan degradation
and nicotinic acid synthesis, Kynurenine 3-
monooxygenase
YLR231C3.7.1.3YLR231Cprobable kynureninase (L-kynurenineHKYN -> HAN + ALAkynu_2
hydrolase)
YJR025C1.13.11.6BNA13-hydroxyanthranilate 3,4-dioxygenase (3-HAN + O2 -> CMUSAbna1
HAO) (3-hydroxyanthranilic acid
dioxygenase) (3-
hydroxyanthranilatehydroxyanthranilic acid
dioxygenase) (3-hydroxyanthranilate
oxygenase)
—4.1.1.45Picolinic acid decarboxylaseCMUSA -> CO2 + AM6SAaaaa
—1.2.1.32AM6SA + NAD -> AMUCO + NADHaaab
—1.5.1.—AMUCO + NADPH -> AKA + NADP + NH4aaac
—1.3.11.274-Hydroxyphenylpyruvate dioxygenase4HPP + O2 -> HOMOGEN + CO2tyrdega
—1.13.11.5Homogentisate 1,2-dioxygenaseHOMOGEN + O2 -> MACACtyrdegb
—5.2.1.2Maleyl-acetoacetate isomeraseMACAC -> FUACACtyrdegc
—3.7.1.2FumarylacetoacetaseFUACAC -> FUM + ACTACtrydegd
YDR268w6.1.1.2MSW1tryptophanyl-tRNA synthetase, mitochondrialATPm + TRPm + TRNAm -> AMPm + PPIm +msw1
TRPTRNAm
YDR242W3.5.1.4AMD2putative amidasePAD -> PAC + NH3amd2_2
YDR242W3.5.1.4AMD2putative amidaseIAD -> IAC + NH3amd2_3
—2.6.1.29Diamine transaminaseSPRMD + ACCOA -> ASPERMD + COAspra
—1.5.3.11Polyamine oxidaseASPERMD + O2 -> APRUT + APROA + H2O2sprb
—1.5.3.11Polyamine oxidaseAPRUT + O2 -> GABAL + APROA + H2O2sprc
—2.6.1.29Diamine transaminaseSPRM + ACCOA -> ASPRM + COAsprd
—1.5.3.11Polyamine oxidaseASPRM + O2 -> ASPERMD + APROA + H2O2spre
Proline biosynthesis
YDR300C2.7.2.11pro1gamma-glutamyl kinase, glutamate kinaseGLU + ATP -> ADP + GLUPpro1
YOR323C1.2.1.41PRO2gamma-glutamyl phosphate reductaseGLUP + NADH -> NAD + PI + GLUGSALpro2_1
YOR323C1.2.1.41pro2gamma-glutamyl phosphate reductaseGLUP + NADPH -> NADP + PI + GLUGSALpro2_2
—spontaneous conversion (Strathern)GLUGSAL <-> P5Cgps1
—spontaneous conversion (Strathern)GLUGSALm <-> P5Cmgps2
YER023W1.5.1.2pro3Pyrroline-5-carboxylate reductaseP5C + NADPH -> PRO + NADPpro3_1
YER023W1.5.1.2pro3Pyrroline-5-carboxylate reductasePHC + NADPH -> HPRO + NADPpro3_3
YER023W1.5.1.2pro3Pyrroline-5-carboxylate reductasePHC + NADH -> HPRO + NADpro3_4
YLR142W1.5.3.—PUT1Proline oxidasePROm + NADm -> P5Cm + NADHmpro3_5
Metabolism of Other Amino Acids
beta-Alanine metabolism
1.2.1.3aldehyde dehydrogenase, mitochondrial 1GABALm + NADm -> GABAm + NADHmald1
YER073W1.2.1.3ALD5mitochondrial Aldehyde DehydrogenaseLACALm + NADm <-> LLACm + NADHmald5_2
Cyanoamino acid metabolism
YJL126W3.5.5.1NIT2NITRILASEAPROP -> ALA + NH3nit2_1
YJL126W3.5.5.1NIT2NITRILASEACYBUT -> GLU + NH3nit2_2
Proteins, Peptides and Aminoacids Metabolism
YLR195C2.3.1.97nmt1Glycylpeptide N-tetradecanoyltransferaseTCOA + GLP -> COA + TGLPnmt1
YDL040C2.3.1.88nat1Peptide alpha-N-acetyltransferaseACCOA + PEPD -> COA + APEPnat1
YGR147C2.3.1.88NAT2Peptide alpha-N-acetyltransferaseACCOA + PEPD -> COA + APEPnat2
Glutathione Biosynthesis
YJL101C6.3.2.2GSH1gamma-glutamylcysteine synthetaseCYS + GLU + ATP -> GC + PI + ADPgsh1
YOL049W6.3.2.3GSH2Glutathione SynthetaseGLY + GC + ATP -> RGT + PI + ADPgsh2
YBR244W1.11.1.9GPX2Glutathione peroxidase2 RGT + H2O2 <-> OGTgpx2
YIR037W1.1.1.1.9HYR1Glutathione peroxidase2 RGT + H2O2 <-> OGThyr1
YKL026C1.11.1.9GPX1Glutathione peroxidase2 RGT + H2O2 <-> OGTgpx1
YPL091W1.6.4.2GLR1Glutathione oxidoreductaseNADPH + OGT -> NADP + RGTglr1
YLR299W2.3.2.2ECM38gamma-glutamyltranspeptidaseRGT + ALA -> CGLY + ALAGLYecm38
Metabolism of Complex Carbohydrates
Starch and sucrose metabolism
YGR032W2.4.1.34GSC21,3-beta-Glucan synthaseUDPG -> 13GLUCAN + UDPgsc2
YLR342W2.4.1.34FKS11,3-beta-Glucan synthaseUDPG -> 13GLUCAN + UDPfks1
YGR306W2.4.1.34FKS3Protein with similarity to Fks1p and Gsc2pUDPG -> 13GLUCAN + UDPfks3
YDR261C3.2.1.58exg2Exo-1,3-b-glucanase13GLUCAN -> GLCexg2
YGR282C3.2.1.58BGL2Cell wall endo-beta-1,3-glucanase13GLUCAN -> GLCbgl2
YLR300W3.2.1.58exg1Exo-1,3-beta-glucanase13GLUCAN -> GLCexg1
YOR190W3.2.1.58spr1sporulation-specific exo-1,3-beta-glucanase13GLUCAN -> GLCspr1
Glycoprotein Biosynthesis/Degradation
YMR013C2.7.1.108sec59Dolichol kinaseCTP + DOL -> CDP + DOLPsec59
YPR183W2.4.1.83DPM1Dolichyl-phosphate beta-D-GDPMAN + DOLP -> GDP + DOLMANPdpm1
mannosyltransferase
YAL023C2.4.1.109PMT2Dolichyl-phosphate-mannose--proteinDOLMANP -> DOLP + MANNANpmt2
mannosyltransferase
YDL093W2.4.1.109PMT5Dolichyl-phosphate-mannose--proteinDOLMANP -> DOLP + MANNANpmt5
mannosyltransferase
YDL095W2.4.1.109PMT1Dolichyl-phosphate-mannose--proteinDOLMANP -> DOLP + MANNANpmt1
mannosyltransferase
YGR199W2.4.1.109PMT6Dolichyl-phosphate-mannose--proteinDOLMANP -> DOLP + MANNANpmt6
mannosyltransferase
YJR143C2.4.1.109PMT4Dolichyl-phosphate-mannose--proteinDOLMANP -> DOLP + MANNANpmt4
mannosyltransferase
YOR321W2.4.1.109PMT3Dolichyl-phosphate-mannose--proteinDOLMANP -> DOLP + MANNANpmt3
mannosyltransferase
YBR199W2.4.1.131KTR4Glycolipid 2-alpha-mannosyltransferaseMAN2PD + 2 GDPMAN -> 2 GDP + 2MANPDktr4
YBR205W2.4.1.131KTR3Glycolipid 2-alpha-mannosyltransferaseMAN2PD + 2 GDPMAN -> 2 GDP + 2MANPDktr3
YDR483W2.4.1.131kre2Glycolipid 2-alpha-mannosyltransferaseMAN2PD + 2 GDPMAN -> 2 GDP + 2MANPDkre2
YJL139C2.4.1.131yur1Glycolipid 2-alpha-mannosyltransferaseMAN2PD + 2 GDPMAN -> 2 GDP + 2MANPDyur1
YKR061W2.4.1.131KTR2Glycolipid 2-alpha-mannosyltransferaseMAN2PD + 2 GDPMAN -> 2 GDP + 2MANPDktr2
YOR099W2.4.1.131KTR1Glycolipid 2-alpha-mannosyltransferaseMAN2PD + 2 GDPMAN -> 2 GDP + 2MANPDktr1
YPL053C2.4.1.131KTR6Glycolipid 2-alpha-mannosyltransferaseMAN2PD + 2 GDPMAN -> 2 GDP + 2MANPDktr6
Aminosugars metabolism
YER062C3.1.3.21HOR2DL-glycerol-3-phosphataseGL3P -> GL + PIhor2
YIL053W3.1.3.21RHR2DL-glycerol-3-phosphataseGL3P -> GL + PIrhr2
YLR307W3.5.1.41CDA1Chitin DeacetylaseCHIT -> CHITO + ACcda1
YLR308W3.5.1.41CDA2Chitin DeacetylaseCHIT -> CHITO + ACcda2
Metabolism of Complex Lipids
Glycerol (Glycerolipid metabolism)
YFL053W2.7.1.29DAK2dihydroxyacetone kinaseGLYN + ATP -> T3P2 + ADPdak2
YML070W2.7.1.29DAK1putative dihydroxyacetone kinaseGLYN + ATP -> T3P2 + ADPdak1
YDL022W1.1.1.8GPD1glycerol-3-phosphate dehydrogenase (NAD)T3P2 + NADH -> GL3P + NADgpd1
YOL059W1.1.1.8GPD2glycerol-3-phosphate dehydrogenase (NAD)T3P2 + NADH -> GL3P + NADgpd2
YHL032C2.7.1.30GUT1glycerol kinaseGL + ATP -> GL3P + ADPgut1
YIL155C1.1.99.5GUT2glycerol-3-phosphate dehydrogenaseGL3P + FADm -> T3P2 + FADH2mgut2
DAGLY + 0.017 C100ACP + 0.062 C120ACP +daga
0.100 C140ACP + 0.270 C160ACP + 0.169
C161ACP + 0.055 C180ACP + 0.235 C181ACP +
0.093 C182ACP -> TAGLY + ACP
Metabolism of Cofactors, Vitamins, and Other Substances
Thiamine (Vitamin B1) metabolism
YOR143C2.7.6.2THI80Thiamin pyrophosphokinaseATP + THIAMIN -> AMP + TPPthi80_1
YOR143C2.7.6.2THI80Thiamin pyrophosphokinaseATP + TPP -> AMP + TPPPthi80_2
—thiC proteinAIR -> AHMthic
YOL055C2.7.1.49THI20Bipartite protein consisting of N-terminalAHM + ATP -> AHMP + ADPthi20
hydroxymethylpyrimidine phosphate (HMP-P)
kinase domain, needed for thiamine
biosynthesis, fused to C-terminal Pet18p-like
domain of indeterminant function
YPL258C2.7.1.49THI21Bipartite protein consisting of N-terminalAHM + ATP -> AHMP + ADPthi21
hydroxymethylpyrimidine phosphate (HMP-P)
kinase domain, needed for thiamine
biosynthesis, fused to C-terminal Pet18p-like
domain of indeterminant function
YPR121W2.7.1.49THI22Bipartite protein consisting of N-terminalAHM + ATP -> AHMP + ADPthi22
hydroxymethylpyrimidine phosphate (HMP-P)
kinase domain, needed for thiamine
biosynthesis, fused to C-terminal Pet18p-like
domain of indeterminant function
YOL055C2.7.4.7THI20HMP-phosphate kinaseAHMP + ATP -> AHMPP + ADPthid
—HypotheticalT3P1 + PYR -> DTPunkrxn1
—thiG proteinDTP + TYR + CYS -> THZ + HBA + CO2thig
—thiE proteinDTP + TYR + CYS -> THZ + HBA + CO2thie
—thiF proteinDTP + TYR + CYS -> THZ + HBA + CO2thif
—thiH proteinDTP + TYR + CYS -> THZ + HBA + CO2thih
YPL214C2.7.1.50THI6Hydroxyethylthiazole kinaseTHZ + ATP -> THZP + ADPthim
YPL214C2.5.1.3THI6TMP pyrophosphorylase, hydroxyethylthiazoleTHZP + AHMPP -> THMP + PPIthi6
kinase
—2.7.4.16Thiamin phosphate kinaseTHMP + ATP <-> TPP + ADPthi1
3.1.3.—(DL)-glycerol-3-phosphatase 2THMP -> THIAMIN + PIunkrxn8
Riboflavin metabolism
YBL033C3.5.4.25rib1GTP cyclohydrolase IIGTP -> D6RP5P + FOR + PPIrib1
YBR153W3.5.4.26RIB7HTP reductase, second step in the riboflavinD6RP5P -> A6RP5P + NH3ribd1
biosynthesis pathway
YBR153W1.1.1.193rib7Pyrimidine reductaseA6RP5P + NADPH -> A6RP5P2 + NADPrib7
—Pyrimidine phosphataseA6RP5P2 -> A6RP + PIprm
—3,4 Dihydroxy-2-butanone-4-phosphateRL5P -> DB4P + FORribb
synthase
YBR256C2.5.1.9RIB5Riboflavin biosynthesis pathway enzyme, 6,7-DB4P + A6RP -> D8RL + PIrib5
dimethyl-8-ribityllumazine synthase, apha
chain
YOL143C2.5.1.9RIB4Riboflavin biosynthesis pathway enzyme, 6,7-
dimethyl-8-ribityllumazine synthase, beta chain
YAR071W3.1.3.2pho11Acid phosphataseFMN -> RIBFLAV + PIpho11
YDR236C2.7.1.26FMN1Riboflavin kinaseRIBFLAV + ATP -> FMN + ADPfmn1_1
YDR236C2.7.1.26FMN1Riboflavin kinaseRIBFLAVm + ATPm -> FMNm + ADPmfmn1_2
YDL045C2.7.7.2FAD1FAD synthetaseFMN + ATP -> FAD + PPIfad1
2.7.7.2FAD synthetaseFMNm + ATPm -> FADm + PPImfad1b
Vitamin B6 (Pyridoxine) Biosynthesis metabolism
—2.7.1.35Pyridoxine kinasePYRDX + ATP -> P5P + ADPpdxka
—2.7.1.35Pyridoxine kinasePDLA + ATP -> PDLA5P + ADPpdxkb
—2.7.1.35Pyridoxine kinasePL + ATP -> PL5P + ADPpdxkc
YBR035C1.4.3.5PDX3Pyridoxine 5′-phosphate oxidasePDLA5P + O2 -> PL5P + H2O2 + NH3pdx3_1
YBR035C1.4.3.5PDX3Pyridoxine 5′-phosphate oxidaseP5P + O2 <-> PL5P + H2O2pdx3_2
YBR035C1.4.3.5PDX3Pyridoxine 5′-phosphate oxidasePYRDX + O2 <-> PL + H2O2pdx3_3
YBR035C1.4.3.5PDX3Pyridoxine 5′-phosphate oxidasePL + O2 + NH3 <-> PDLA + H2O2pdx3_4
YBR035C1.4.3.5PDX3Pyridoxine 5′-phosphate oxidasePDLA5P + O2 -> PL5P + H2O2 + NH3pdx3_5
YOR184W2.6.1.52ser1Hypothetical transaminase/phosphoserineOHB + GLU <-> PHT + AKGser1_2
transaminase
YCR053W4.2.99.2thr4Threonine synthasePHT -> 4HLT + PIthr4_2
3.1.3.—Hypothetical EnzymePDLA5P -> PDLA + PIhor2b
Pantothenate and CoA biosynthesis
—3 MALCOA -> CHCOA + 2 COA + 2 CO2bio1
—2.3.1.478-Amino-7-oxononanoate synthaseALA + CHCOA <-> CO2 + COA + AONAbiof
YNR058W2.6.1.62BIO37,8-diamino-pelargonic acid aminotransferaseSAM + AONA <-> SAMOB + DANNAbio3
(DAPA) aminotransferase
YNR057C6.3.3.3BIO4dethiobiotin synthetaseCO2 + DANNA + ATP <-> DTB + PI + ADPbio4
YGR286C2.8.1.6BIO2Biotin synthaseDTB + CYS <-> BTbio2
Folate biosynthesis
YGR267C3.5.4.16fol2GTP cyclohydrolase IGTP -> FOR + AHTDfol2
—3.6.1.—Dihydroneopterin triphosphateAHTD -> PPI + DHPPntpa
pyrophosphorylase
YDR481C3.1.3.1pho8Glycerophosphatase, Alkaline phosphatase;AHTD -> DHP + 3 PIpho8
Nucleoside triphosphatase
YDL100C3.6.1.—YDL100CDihydroneopterin monophosphateDHPP -> DHP + PIdhdnpa
dephosphorylase
YNL256W4.1.2.25fol1Dihydroneopterin aldolaseDHP -> AHHMP + GLALfol1_1
YNL256W2.7.6.3fol16-Hydroxymethyl-7,8 dihydropterinAHHMP + ATP -> AMP + AHHMDfol1_2
pyrophosphokinase
YNR033W4.1.3.—ABZ1Aminodeoxychorismate synthaseCHOR + GLN -> ADCHOR + GLUabz1
—4.—.—.—Aminodeoxychorismate lyaseADCHOR -> PYR + PABApabc
YNL256W2.5.1.15fol1Dihydropteroate synthasePABA + AHHMD -> PPI + DHPTfol1_3
YNL256W2.5.1.15fol1Dihydropteroate synthasePABA + AHHMP -> DHPTfol1_4
—6.3.2.12Dihydrofolate synthaseDHPT + ATP + GLU -> ADP + PI + DHFfolc
YOR236W1.5.1.3dfr1Dihydrofolate reductaseDHFm + NADPHm -> NADPm + THFmdfr1_1
YOR236W1.5.1.3dfr1Dihydrofolate reductaseDHF + NADPH -> NADP + THFdfr1_2
—6.3.3.25-Formyltetrahydrofolate cyclo-ligaseATPm + FTHFm -> ADPm + PIm + MTHFmftfa
—6.3.3.25-Formyltetrahydrofolate cyclo-ligaseATP + FTHF -> ADP + PI + MTHFftfb
YKL132C6.3.2.17RMA1Protein with similarity to folylpolyglutamateTHF + ATP + GLU <-> ADP + PI + THFGrma1
synthase; converts tetrahydrofolyl-[Glu(n)] +
glutamate to tetrahydrofolyl-[Glu(n + 1)]
YMR113W6.3.2.17FOL3Dihydrofolate synthetaseTHF + ATP + GLU <-> ADP + PI + THFGfol3
YOR241W6.3.2.17MET7Folylpolyglutamate synthetase, involved inTHF + ATP + GLU <-> ADP + PI + THFGmet7
methionine biosynthesis and maintenance of
mitochondrial genome
One carbon pool by folate [MAP: 00670]
YPL023C1.5.1.20MET12Methylene tetrahydrofolate reductaseMETTHFm + NADPHm -> NADPm + MTHFmmet12
YGL125W1.5.1.20met13Methylene tetrahydrofolate reductaseMETTHFm + NADPHm -> NADPm + MTHFmmet13
YBR084W1.5.1.5mis1the mitochondrial trifunctional enzyme C1-METTHFm + NADPm <-> METHFm + NADPHmmis1_1
tetrahydroflate synthase
YGR204W1.5.1.5ade3the cytoplasmic trifunctional enzyme C1-METTHF + NADP <-> METHF + NADPHade3_1
tetrahydrofolate synthase
YBR084W6.3.4.3mis1the mitochondrial trifunctional enzyme C1-THFm + FORm + ATPm -> ADPm + PIm +mis1_2
tetrahydroflate synthaseFTHFm
YGR204W6.3.4.3ade3the cytoplasmic trifunctional enzyme C1-THF + FOR + ATP -> ADP + PI + FTHFade3_2
tetrahydrofolate synthase
YBR084W3.5.4.9mis1the mitochondrial trifunctional enzyme C1-METHFm <-> FTHFmmis1_3
tetrahydroflate synthase
YGR204W3.5.4.9ade3the cytoplasmic trifunctional enzyme C1-METHF <-> FTHFade3_3
tetrahydrofolate synthase
YKR080W1.5.1.15MTD1NAD-dependent 5,10-METTHF + NAD -> METHF + NADHmtd1
methylenetetrahydrafolate dehydrogenase
YBL013W2.1.2.9fmt1Methionyl-tRNA TransformylaseFTHFm + MTRNAm -> THFm + FMRNAmfmt1
Coenzyme A Biosynthesis
YBR176W2.1.2.11ECM31Ketopentoate hydroxymethyl transferaseOIVAL + METTHF -> AKP + THFecm31
YHR063C1.1.1.169PAN5Putative ketopantoate reductase (2-AKP + NADPH -> NADP + PANTpane
dehydropantoate 2-reductase) involved in
coenzyme A synthesis, has similarity to Cbs2p,
Ketopantoate reductase
YLR355C1.1.1.86ilv5Ketol-acid reductoisomeraseAKPm + NADPHm -> NADPm + PANTmilv5_3
YIL145C6.3.2.1YIL145CPantoate-b-alanine ligatePANT + bALA + ATP -> AMP + PPI + PNTOpanca
YDR531W2.7.1.33YDR531WPutative pantothenate kinase involved inPNTO + ATP -> ADP + 4PPNTOcoaa
coenzyme A biosynthesis, Pantothenate kinase
—6.3.2.5Phosphopantothenate-cysteine ligase4PPNTO + CTP + CYS -> CMP + PPI +pclig
4PPNCYS
—4.1.1.36Phosphopantothenate-cysteine decarboxylase4PPNCYS -> CO2 + 4PPNTEpcdc1
—2.7.7.3Phospho-pantethiene adenylyltransferase4PPNTE + ATP -> PPI + DPCOApatrana
—2.7.7.3Phospho-pantethiene adenylyltransferase4PPNTEm + ATPm -> PPIm + DPCOAmpatranb
—2.7.1.24DephosphoCoA kinaseDPCOA + ATP -> ADP + COAdphcoaka
—2.7.1.24DephosphoCoA kinaseDPCOAm + ATPm -> ADPm + COAmdphcoakb
—4.1.1.11ASPARTATE ALPHA-DECARBOXYLASEASP -> CO2 + bALApancb
YPL148C2.7.8.7PPT2Acyl carrier-protein synthase,COA -> PAP + ACPacps
phosphopantetheine protein transferase for
Acp1p
NAD Biosynthesis
YGL037C3.5.1.19PNC1NicotinamidaseNAM <-> NAC + NH3nadh
YOR209C2.4.2.11NPT1NAPRTaseNAC + PRPP -> NAMN + PPInpt1
1.4.3.—Aspartate oxidaseASP + FADm -> FADH2m + ISUCCnadb
1.4.3.16Quinolate synthaseISUCC + T3P2 -> PI + QAnada
YFR047C2.4.2.19QPT1Quinolate phosphoribosyl transferaseQA + PRPP -> NAMN + CO2 + PPInadc
YLR328W2.7.7.18YLR328WNicotinamide mononucleotide (NMN)NAMN + ATP -> PPI + NAADnadd1
adenylyltransferase
YHR074W6.3.5.1QNS1Deamido-NAD ammonia ligaseNAAD + ATP + NH3 -> NAD + AMP + PPInade
YJR049c2.7.1.23utr1NAD kinase, POLYPHOSPHATE KINASENAD + ATP -> NADP + ADPnadf_1
(EC 2.7.4.1)/NAD+ KINASE (EC 2.7.1.23)
YEL041w2.7.1.23YEL041wNAD kinase, POLYPHOSPHATE KINASENAD + ATP -> NADP + ADPnadf_2
(EC 2.7.4.1)/NAD+ KINASE (EC 2.7.1.23)
YPL188w2.7.1.23POS5NAD kinase, POLYPHOSPHATE KINASENAD + ATP -> NADP + ADPnadf_5
(EC 2.7.4.1)/NAD+ KINASE (EC 2.7.1.23)
3.1.2.—NADP phosphataseNADP -> NAD + PInadphps
3.2.2.5NAD -> NAM + ADPRIBnadi
2.4.2.1strong similarity to purine-nucleosideADN + PI <-> AD + RIPnadg1
phosphorylases
2.4.2.1strong similarity to purine-nucleosideGSN + PI <-> GN + RIPnadg2
phosphorylases
Nicotinic Acid synthesis from TRP
YFR047C2.4.2.19QPT1Quinolate phosphoribosyl transferaseQAm + PRPPm -> NAMNm + CO2m + PPImmnadc
YLR328W2.7.7.18YLR328WNAMN adenylyl transferaseNAMNm + ATPm -> PPIm + NAADmmnadd1
YLR328W2.7.7.18YLR328WNAMN adenylyl transferaseNMNm + ATPm -> NADm + PPImmnadd2
YHR074W6.3.5.1QNS1Deamido-NAD ammonia ligaseNAADm + ATPm + NH3m -> NADm + AMPm +mnade
PPIm
YJR049c2.7.1.23utr1NAD kinase, POLYPHOSPHATE KINASENADm + ATPm -> NADPm + ADPmmnadf_1
(EC 2.7.4.1)/NAD+ KINASE (EC 2.7.1.23)
YPL188w2.7.1.23POS5NAD kinase, POLYPHOSPHATE KINASENADm + ATPm -> NADPm + ADPmmnadf_2
(EC 2.7.4.1)/NAD+ KINASE (EC 2.7.1.23)
YEL041w2.7.1.23YEL041wNAD kinase, POLYPHOSPHATE KINASENADm + ATPm -> NADPm + ADPmmnadf_5
(EC 2.7.4.1)/NAD+ KINASE (EC 2.7.1.23)
—3.1.2.—NADP phosphataseNADPm -> NADm + PImmnadphps
YLR209C2.4.2.1PNP1strong similarity to purine-nucleosideADNm + PIm <-> ADm + RIPmmnadg1
phosphorylases
YLR209C2.4.2.1PNP1strong similarity to purine-nucleosideGSNm + PIm <-> GNm + RIPmmnadg2
phosphorylases
YGL037C3.5.1.19PNC1NicotinamidaseNAMm <-> NACm + NH3mmnadh
YOR209C2.4.2.11NPT1NAPRTaseNACm + PRPPm -> NAMNm + PPImmnpt1
3.2.2.5NADm -> NAMm + ADPRIBmmnadi
Uptake Pathways
Porphyrin and Chlorophyll Metabolism
YDR232W2.3.1.37hem15-Aminolevulinate synthaseSUCCOAm + GLYm -> ALAVm + COAm +hem1
CO2m
YGL040C4.2.1.24HEM2Aminolevulinate dehydratase2 ALAV -> PBGhem2
YDL205C4.3.1.8HEM3Hydroxymethylbilane synthase4 PBG -> HMB + 4 NH3hem3
YOR278W4.2.1.75HEM4Uroporphyrinogen-III synthaseHMB -> UPRGhem4
YDR047W4.1.1.37HEM12Uroporphyrinogen decarboxylaseUPRG -> 4 CO2 + CPPhem12
YDR044W1.3.3.3HEM13Coproporphyrinogen oxidase, aerobicO2 + CPP -> 2 CO2 + PPHGhem13
YER014W1.3.3.4HEM14Protoporphyrinogen oxidaseO2 + PPHGm -> PPIXmhem14
YOR176W4.99.1.1HEM15FerrochelatasePPIXm -> PTHmhem15
YGL245W6.1.1.17YGL245Wglutamyl-tRNA synthetase, cytoplasmicGLU + ATP -> GTRNA + AMP + PPIunrxn10
YOL033W6.1.1.17MSE1GLUm + ATPm -> GTRNAm + AMPm + PPImmse1
YKR069W2.1.1.107met1uroporphyrin-III C-methyltransferaseSAM + UPRG -> SAH + PC2met1
Quinone Biosynthesis
YKL211C4.1.3.27trp3anthranilate synthase Component II and indole-CHOR -> 4HBZ + PYRtrp3_3
3-phosphate (multifunctional enzyme)
YER090W4.1.3.27trp2anthranilate synthase Component ICHOR -> 4HBZ + PYRtrp2_2
YPR176C2.5.1.—BET2geranylgeranyltransferase type II beta subunit4HBZ + NPP -> N4HBZ + PPIbet2
YJL031C2.5.1.—BET4geranylgeranyltransferase type II alpha subunit
YGL155W2.5.1.—cdc43geranylgeranyltransferase type I beta subunit
YBR003W2.5.1.—COQ1Hexaprenyl pyrophosphate synthetase,4HBZ + NPP -> N4HBZ + PPIcoq1
catalyzes the first step in coenzyme Q
(ubiquinone) biosynthesis pathway
YNR041C2.5.1.—COQ2para-hydroxybenzoate--polyprenyltransferase4HBZ + NPP -> N4HBZ + PPIcoq2
YPL172C2.5.1.—COX10protoheme IX farnesyltransferase,4HBZ + NPP -> N4HBZ + PPIcox10
mitochondrial precursor
YDL090C2.5.1.—ram1protein farnesyltransferase beta subunit4HBZ + NPP -> N4HBZ + PPIram1
YKL019W2.5.1.—RAM2protein farnesyltransferase alpha subunit
YBR002C2.5.1.—RER2putative dehydrodolichyl diphospate synthetase4HBZ + NPP -> N4HBZ + PPIrer2
YMR101C2.5.1.—SRT1putative dehydrodolichyl diphospate synthetase4HBZ + NPP -> N4HBZ + PPIsrt1
YDR538W4.1.1.—PAD1Octaprenyl-hydroxybenzoate decarboxylaseN4HBZ -> CO2 + 2NPPPpad1_2
—1.13.14.—2-Octaprenylphenol hydroxylase2NPPP + O2 -> 2N6Hubib
YPL266W2.1.1.—DIM12N6H + SAM -> 2NPMP + SAHdim1
—1.14.13.—2-Octaprenyl-6-methoxyphenol hydroxylase2NPMPm + O2m -> 2NPMBmubih
YML110C2.1.1.—COQ52-Octaprenyl-6-methoxy-1,4-benzoquinone2NPMBm + SAMm -> 2NPMMBm + SAHmcoq5
methylase
YGR255C1.14.13.—COQ6COQ6 monooxygenase2NPMMBm + O2m -> 2NMHMBmcoq6b
YOL096C2.1.1.64COQ33-Dimethylubiquinone 3-methyltransferase2NMHMBm + SAMm -> QH2m + SAHmubig
Memberane Transport
Mitochondiral Membrane Transport
The followings diffuse through the inner mitochondiral membrane in a non-carrier-mediated manner:
O2 <-> O2mmo2
CO2 <-> CO2mmco2
ETH <-> ETHmmeth
NH3 <-> NH3mmnh3
MTHN <-> MTHNmmmthn
THFm <-> THFmthf
METTHFm <-> METTHFmmthf
SERm <-> SERmser
GLYm <-> GLYmgly
CBHCAPm <-> CBHCAPmcbh
OICAPm <-> OICAPmoicap
PROm <-> PROmpro
CMPm <-> CMPmcmp
ACm <-> ACmac
ACAR -> ACARmmacar —
CARm -> CARmcar —
ACLAC <-> ACLACmmaclac
ACTAC <-> ACTACmmactc
SLF -> SLFm + Hmmslf
THRm <-> THRmthr
AKAm -> AKAmaka
YMR056cAAC1ADP/ATP carrier protein (MCF)ADP + ATPm + PI -> Hm + ADPm +aac1
ATP + PIm
YBL030Cpet9ADP/ATP carrier protein (MCF)ADP + ATPm + PI -> Hm + ADPm +pet9
ATP + PIm
YBR085wAAC3ADP/ATP carrier protein (MCF)ADP + ATPm + PI -> Hm + ADPm +aac3
ATP + PIm
YJR077CMIR1phosphate carrierPI <-> Hm + PImmir1a
YER053CYER053Csimilarity to C. elegans mitochondrial phosphate carrierPI + OHm <-> PImmir1d
YLR348CDIC1dicarboxylate carrierMAL + SUCCm <-> MALm + SUCCdic1_1
YLR348CDIC1dicarboxylate carrierMAL + PIm <-> MALm + PIdic1_2
YLR348CDIC1dicarboxylate carrierSUCC + PIm -> SUCCm + PIdic1_3
MALT + PIm <-> MALTm + PImmlt
YKL120WOAC1Mitochondrial oxaloacetate carrierOA <-> OAm + Hmmoab
YBR291CCTP1citrate transport proteinCIT + MALm <-> CITm + MALctp1_1
YBR291CCTP1citrate transport proteinCIT + PEPm <-> CITm + PEPctp1_2
YBR291CCTP1citrate transport proteinCIT + ICITm <-> CITm + ICITctp1_3
IPPMAL <-> IPPMALmmpmalR
LAC <-> LACm + Hmmlac
pyruvate carrierPYR <-> PYRm + Hmpyrca
glutamate carrierGLU <-> GLUm + Hmgca
GLU + OHm -> GLUmgcb
YOR130CORT1ornithine carrierORN + Hm <-> ORNmort1
YOR100CCRC1carnitine carrierCARm + ACAR -> CAR + ACARmcrc1
OIVAL <-> OIVALmmoival
OMVAL <-> OMVALmmomval
YIL134WFLX1Protein involved in transport of FAD from cytosol intoFAD + FMNm -> FADm + FMNmfad
the mitochondrial matrix
RIBFLAV <-> RIBFLAVmmribo
DTB <-> DTBmmdtb
H3MCOA <-> H3MCOAmmmcoa
MVL <-> MVLmmmvl
PA <-> PAmmpa
4PPNTE <-> 4PPNTEmmppnt
AD <-> ADmmad
PRPP <-> PRPPmmprpp
DHF <-> DHFmmdhf
QA <-> QAmmqa
OPP <-> OPPmmopp
SAM <-> SAMmmsam
SAH <-> SAHmmsah
YJR095WSFC1Mitochondrial membrane succinate-fumarateSUCC + FUMm -> SUCCm + FUMsfc1
transporter, member of the mitochondrial carrier family
(MCF) of membrane transporters
YPL134CODC12-oxodicarboylate transporterAKGm + OXA <-> AKG + OXAmodc1
YOR222WODC22-oxodicarboylate transporterAKGm + OXA <-> AKG + OXAmodc2
Malate Aspartate Shuttle
Included elsewhere
Glycerol phosphate shuttle
T3P2m -> T3P2mt3p
GL3P -> GL3Pmmgl3p
Plasma Membrane Transport
Carbohydrates
YHR092cHXT4moderate- to low-affinity glucose transporterGLCxt -> GLChxt4
YLR081wGAL2galactose (and glucose) permeaseGLCxt -> GLCgal2_3
YOL156wHXT11low affinity glucose transport proteinGLCxt -> GLChxt11
YDR536Wstl1Protein member of the hexose transporter familyGLCxt -> GLCstl1_1
YHR094chxt1High-affinity hexose (glucose) transporterGLCxt -> GLChxt1_1
YOL156wHXT11Glucose permeaseGLCxt -> GLChxt11_1
YEL069cHXT13high-affinity hexose transporterGLCxt -> GLChxt13_1
YDL245cHXT15Hexose transporterGLCxt -> GLChxt15_1
YJR158wHXT16hexose permeaseGLCxt -> GLChxt16_1
YFL011wHXT10high-affinity hexose transporterGLCxt -> GLChxt10_1
YNR072wHXT17Putative hexose transporterGLCxt -> GLChxt17_1
YMR011wHXT2high affinity hexose transporter-2GLCxt -> GLChxt2_1
YHR092chxt4High-affinity glucose transporterGLCxt -> GLChxt4_1
YDR345chxt3Low-affinity glucose transporterGLCxt -> GLChxt3_1
YHR096cHXT5hexose transporterGLCxt -> GLChxt5_1
YDR343cHXT6Hexose transporterGLCxt -> GLChxt6_1
YDR342cHXT7Hexose transporterGLCxt -> GLChxt7_1
YJL214wHXT8hexose permeaseGLCxt -> GLChxt8_4
YJL219wHXT9hexose permeaseGLCxt -> GLChxt9_1
YLR081wgal2galactose permeaseGLACxt + HEXT -> GLACgal2_1
YFL011wHXT10high-affinity hexose transporterGLACxt + HEXT -> GLAChxt10_4
YOL156wHXT11Glucose permeaseGLACxt + HEXT -> GLAChxt11_4
YNL318cHXT14Member of the hexose transporter familyGLACxt + HEXT -> GLAChxt14
YJL219wHXT9hexose permeaseGLACxt + HEXT -> GLAChxt9_4
YDR536Wstl1Protein member of the hexose transporter familyGLACxt + HEXT -> GLACstl1_4
YFL055wAGP3Amino acid permease for serine, aspartate, andGLUxt + HEXT <-> GLUagp3_3
glutamate
YDR536Wstl1Protein member of the hexose transporter familyGLUxt + HEXT <-> GLUstl1_2
YKR039Wgap1General amino acid permeaseGLUxt + HEXT <-> GLUgap8
YCL025CAGP1Amino acid permease for most neutral amino acidsGLUxt + HEXT <-> GLUgap24
YPL265WDIP5Dicarboxylic amino acid permeaseGLUxt + HEXT <-> GLUdip10
YDR536Wstl1Protein member of the hexose transporter familyGLUxt + HEXT <-> GLUstl1_3
YHR094chxt1High-affinity hexose (glucose) transporterFRUxt + HEXT -> FRUhxt1_2
YFL011wHXT10high-affinity hexose transporterFRUxt + HEXT -> FRUhxt10_2
YOL156wHXT11Glucose permeaseFRUxt + HEXT -> FRUhxt11_2
YEL069cHXT13high-affinity hexose transporterFRUxt + HEXT -> FRUhxt13_2
YDL245cHXT15Hexose transporterFRUxt + HEXT -> FRUhxt15_2
YJR158wHXT16hexose permeaseFRUxt + HEXT -> FRUhxt16_2
YNR072wHXT17Putative hexose transporterFRUxt + HEXT -> FRUhxt17_2
YMR011wHXT2high affinity hexose transporter-2FRUxt + HEXT -> FRUhxt2_2
YDR345chxt3Low-affinity glucose transporterFRUxt + HEXT -> FRUhxt3_2
YHR092chxt4High-affinity glucose transporterFRUxt + HEXT -> FRUhxt4_2
YHR096cHXT5hexose transporterFRUxt + HEXT -> FRUhxt5_2
YDR343cHXT6Hexose transporterFRUxt + HEXT -> FRUhxt6_2
YDR342cHXT7Hexose transporterFRUxt + HEXT -> FRUhxt7_2
YJL214wHXT8hexose permeaseFRUxt + HEXT -> FRUhxt8_5
YJL219wHXT9hexose permeaseFRUxt + HEXT -> FRUhxt9_2
YHR094chxt1High-affinity hexose (glucose) transporterMANxt + HEXT -> MANhxt1_5
YFL011wHXT10high-affinity hexose transporterMANxt + HEXT -> MANhxt10_3
YOL156wHXT11Glucose permeaseMANxt + HEXT -> MANhxt11_3
YEL069cHXT13high-affinity hexose transporterMANxt + HEXT -> MANhxt13_3
YDL245cHXT15Hexose transporterMANxt + HEXT -> MANhxt15_3
YJR158wHXT16hexose permeaseMANxt + HEXT -> MANhxt16_3
YNR072wHXT17Putative hexose transporterMANxt + HEXT -> MANhxt17_3
YMR011wHXT2high affinity hexose transporter-2MANxt + HEXT -> MANhxt2_3
YDR345chxt3Low-affinity glucose transporterMANxt + HEXT -> MANhxt3_3
YHR092chxt4High-affinity glucose transporterMANxt + HEXT -> MANhxt4_3
YHR096cHXT5hexose transporterMANxt + HEXT -> MANhxt5_3
YDR343cHXT6Hexose transporterMANxt + HEXT -> MANhxt6_3
YDR342cHXT7Hexose transporterMANxt + HEXT -> MANhxt7_3
YJL214wHXT8hexose permeaseMANxt + HEXT -> MANhxt8_6
YJL219wHXT9hexose permeaseMANxt + HEXT -> MANhxt9_3
YDR497cITR1myo-inositol transporterMIxt + HEXT -> MIitr1
YOL103wITR2myo-inositol transporterMIxt + HEXT -> MIitr2
Maltase permeaseMLTxt + HEXT -> MLTmltup
YIL162W3.2.1.26SUC2invertase (sucrose hydrolyzing enzyme)SUCxt -> GLCxt + FRUxtsuc2
sucroseSUCxt + HEXT -> SUCsucup
YBR298cMAL31DicarboxylatesMALxt + HEXT <-> MALmal31
a-Ketoglutarate/malate translocatorMALxt + AKG <-> MAL + AKGxtakmup
a-methylglucosideAMGxt <-> AMGamgup
SorboseSORxt <-> SORsorup
Arabinose (low affinity)ARABxt <-> ARABarbup1
FucoseFUCxt + HEXT <-> FUCfucup
GLTLxt + HEXT -> GLTLgltlupb
GlucitolGLTxt + HEXT -> GLTgltup
GlucosamineGLAMxt + HEXT <-> GLAMgaup
YLL043WFPS1GlycerolGLxt <-> GLglup
YKL217WJEN1Lactate transportLACxt + HEXT <-> LAClacup1
MannitolMNTxt + HEXT -> MNTmntup
MelibioseMELIxt + HEXT -> MELImelup_1
N-AcetylglucosamineNAGxt + HEXT -> NAGnagup
RhamnoseRMNxt + HEXT -> RMNrmnup
RiboseRIBxt + HEXT -> RIBribup
TrehaloseTRExt + HEXT -> TREtreup_1
TRExt -> AATRE6Ptreup_2
XYLxt <-> XYLxylup
Amino Acids
YKR039Wgap1General amino acid permeaseALAxt + HEXT <-> ALAgap1_1
YPL265WDIP5Dicarboxylic amino acid permeaseALAxt + HEXT <-> ALAdip5
YCL025CAGP1Amino acid permease for most neutral amino acidsALAxt + HEXT <-> ALAgap25
YOL020WTAT2Tryptophan permeaseALAxt + HEXT <-> ALAtat5
YOR348CPUT4Proline permeaseALAxt + HEXT <-> ALAput4
YKR039Wgap1General amino acid permeaseARGxt + HEXT <-> ARGgap2
YEL063Ccan1Permease for basic amino acidsARGxt + HEXT <-> ARGcan1_1
YNL270CALP1Protein with strong similarity to permeasesARGxt + HEXT <-> ARGalp1
YKR039Wgap1General amino acid permeaseASNxt + HEXT <-> ASNgap3
YCL025CAGP1Amino acid permease for most neutral amino acidsASNxt + HEXT <-> ASNgap21
YDR508CGNP1Glutamine permease (high affinity)ASNxt + HEXT <-> ASNgnp2
YPL265WDIP5Dicarboxylic amino acid permeaseASNxt + HEXT <-> ASNdip6
YFL055WAGP3Amino acid permease for serine, aspartate, andASPxt + HEXT <-> ASPagp3_2
glutamate
YKR039Wgap1General amino acid permeaseASPxt + HEXT <-> ASPgap4
YPL265WDIP5Dicarboxylic amino acid permeaseASPxt + HEXT <-> ASPdip7
YKR039Wgap1General amino acid permeaseCYSxt + HEXT <-> CYSgap5
YDR508CGNP1Glutamine permease (high affinity)CYSxt + HEXT <-> CYSgnp3
YBR068CBAP2Branched chain amino acid permeaseCYSxt + HEXT <-> CYSbap2_1
YDR046CBAP3Branched chain amino acid permeaseCYSxt + HEXT <-> CYSbap3_1
YBR069CVAP1Amino acid permeaseCYSxt + HEXT <-> CYSvap7
YOL020WTAT2Tryptophan permeaseCYSxt + HEXT <-> CYStat7
YKR039Wgap1General amino acid permeaseGLYxt + HEXT <-> GLYgap6
YOL020WTAT2Tryptophan permeaseGLYxt + HEXT <-> GLYtat6
YPL265WDIP5Dicarboxylic amino acid permeaseGLYxt + HEXT <-> GLYdip8
YOR348CPUT4Proline permeaseGLYxt + HEXT <-> GLYput5
YKR039Wgap1General amino acid permeaseGLNxt + HEXT <-> GLNgap7
YCL025CAGP1Amino acid permease for most neutral amino acidsGLNxt + HEXT <-> GLNgap22
YDR508CGNP1Glutamine permease (high affinity)GLNxt + HEXT <-> GLNgnp1
YPL265WDIP5Dicarboxylic amino acid permeaseGLNxt + HEXT <-> GLNdip9
YGR191WHIP1Histidine permeaseHISxt + HEXT <-> HIShip1
YKR039Wgap1General amino acid permeaseHISxt + HEXT <-> HISgap9
YCL025CAGP1Amino acid permease for most neutral amino acidsHISxt + HEXT <-> HISgap23
YBR069CVAP1Amino acid permeaseHISxt + HEXT <-> HISvap6
YBR069CTAT1Amino acid permease that transports valine, leucine,ILExt + HEXT <-> ILEtat1_2
isleucine, tyrosine, tryptophan, and threonine
YKR039Wgap1General amino acid permeaseILExt + HEXT <-> ILEgap10
YCL025CAGP1Amino acid permease for most neutral amino acidsILExt + HEXT <-> ILEgap32
YBR068CBAP2Branched chain amino acid permeaseILExt + HEXT <-> ILEbap2_2
YDR046CBAP3Branched chain amino acid permeaseILExt + HEXT <-> ILEbap3_2
YBR069CVAP1Amino acid permeaseILExt + HEXT <-> ILEvap3
YBR069CTAT1Amino acid permease that transports valine, leucine,LEUxt + HEXT <-> LEUtat1_3
isleucine, tyrosine, tryptophan, and threonine
YKR039Wgap1General amino acid permeaseLEUxt + HEXT <-> LEUgap11
YCL025CAGP1Amino acid permease for most neutral amino acidsLEUxt + HEXT <-> LEUgap33
YBR068CBAP2Branched chain amino acid permeaseLEUxt + HEXT <-> LEUbap2_3
YDR046CBAP3Branched chain amino acid permeaseLEUxt + HEXT <-> LEUbap3_3
YBR069CVAP1Amino acid permeaseLEUxt + HEXT <-> LEUvap4
YDR508CGNP1Glutamine permease (high affinity)LEUxt + HEXT <-> LEUgnp7
YKR039Wgap1General amino acid permeaseMETxt + HEXT <-> METgap13
YCL025CAGP1Amino acid permease for most neutral amino acidsMETxt + HEXT <-> METgap26
YDR508CGNP1Glutamine permease (high affinity)METxt + HEXT <-> METgnp4
YBR068CBAP2Branched chain amino acid permeaseMETxt + HEXT <-> METbap2_4
YDR046CBAP3Branched chain amino acid permeaseMETxt + HEXT <-> METbap3_4
YGR055WMUP1High-affinity methionine permeaseMETxt + HEXT <-> METmup1
YHL036WMUP3Low-affinity methionine permeaseMETxt + HEXT <-> METmup3
YKR039Wgap1General amino acid permeasePHExt + HEXT <-> PHENgap14
YCL025CAGP1Amino acid permease for most neutral amino acidsPHExt + HEXT <-> PHENgap29
YOL020WTAT2Tryptophan permeasePHExt + HEXT <-> PHENtat4
YBR068CBAP2Branched chain amino acid permeasePHExt + HEXT <-> PHENbap2_5
YDR046CBAP3Branched chain amino acid permeasePHExt + HEXT <-> PHENbap3_5
YKR039Wgap1General amino acid permeasePROxt + HEXT <-> PROgap15
YOR348CPUT4Proline permeasePROxt + HEXT <-> PROput6
YBR069CTAT1Amino acid permease that transports valine, leucine,TRPxt + HEXT <-> TRPtat1_6
isleucine, tyrosine, tryptophan, and threonine
YKR039Wgap1General amino acid permeaseTRPxt + HEXT <-> TRPgap18
YBR069CVAP1Amino acid permeaseTRPxt + HEXT <-> TRPvap2
YOL020WTAT2Tryptophan permeaseTRPxt + HEXT <-> TRPtat3
YBR068CBAP2Branched chain amino acid permeaseTRPxt + HEXT <-> TRPbap2_6
YDR046CBAP3Branched chain amino acid permeaseTRPxt + HEXT <-> TRPbap3_6
YBR069CTAT1Amino acid permease that transports valine, leucine,TYRxt + HEXT <-> TYRtat1_7
isleucine, tyrosine, tryptophan, and threonine
YKR039Wgap1General amino acid permeaseTYRxt + HEXT <-> TYRgap19
YCL025CAGP1Amino acid permease for most neutral amino acidsTYRxt + HEXT <-> TYRgap28
YBR068CBAP2Branched chain amino acid permeaseTYRxt + HEXT <-> TYRbap2_7
YBR069CVAP1Amino acid permeaseTYRxt + HEXT <-> TYRvap1
YOL020WTAT2Tryptophan permeaseTYRxt + HEXT <-> TYRtat2
YDR046CBAP3Branched chain amino acid permeaseTYRxt + HEXT <-> TYRbap3_7
YKR039Wgap1General amino acid permeaseVALxt + HEXT <-> VALgap20
YCL025CAGP1Amino acid permease for most neutral amino acidsVALxt + HEXT <-> VALgap31
YDR046CBAP3Branched chain amino acid permeaseVALxt + HEXT <-> VALbap3_8
YBR069CVAP1Amino acid permeaseVALxt + HEXT <-> VALvap5
YBR068CBAP2Branched chain amino acid permeaseVALxt + HEXT <-> VALbap2_8
YFL055WAGP3Amino acid permease for serine, aspartate, andSERxt + HEXT <-> SERagp3_1
glutamate
YCL025CAGP1Amino acid permease for most neutral amino acidsSERxt + HEXT <-> SERgap27
YDR508CGNP1Glutamine permease (high affinity)SERxt + HEXT <-> SERgnp5
YKR039Wgap1General amino acid permeaseSERxt + HEXT <-> SERgap16
YPL265WDIP5Dicarboxylic amino acid permeaseSERxt + HEXT <-> SERdip11
YBR069CTAT1Amino acid permease that transports valine, leucine,THRxt + HEXT <-> THRtat1_1
isleucine, tyrosine, tryptophan, and threonine
YCL025CAGP1Amino acid permease for most neutral amino acidsTHRxt + HEXT <-> THRgap30
YKR039Wgap1General amino acid permeaseTHRxt + HEXT <-> THRgap17
YDR508CGNP1Glutamine permease (high affinity)THRxt + HEXT <-> THRgnp6
YNL268WLYP1Lysine specific permease (high affinity)LYSxt + HEXT <-> LYSlyp1
YKR039Wgap1General amino acid permeaseLYSxt + HEXT <-> LYSgap12
YLL061WMMP1High affinity S-methylmethionine permeaseMMETxt + HEXT -> MMETmmp1
YPL274WSAM3High affinity S-adenosylmethionine permeaseSAMxt + HEXT -> SAMsam3
YOR348CPUT4Proline permeaseGABAxE + HEXT -> GABAput7
YDL210Wuga4Amino acid permease with high specificity for GABAGABAxt + HEXT -> GABAuga4
YBR132CAGP2Plasma membrane carnitine transporterCARxt <-> CARagp2
YGL077CHNM1Choline permeaseCHOxt + HEXT -> METhnm1
YNR056CBIO5transmembrane regulator of KAPA/DAPA transportBIOxt + HEXT -> BIObio5a
YDL210Wuga4Amino acid permease with high specificity for GABAALAVxt + HEXT -> ALAVuga5
YKR039Wgap1General amino acid permeaseORNxt + HEXT <-> ORNgap1b
YEL063Ccan1Permease for basic amino acidsORNxt + HEXT <-> ORNcan1b
PutrescinePTRSCxt + HEXT -> PTRSCptrup
Spermidine & putrescineSPRMDxt + HEXT -> SPRMDsprup1
YKR093WPTR2DipeptideDIPEPxt + HEXT -> DIPEPptr2
YKR093WPTR2OligopeptideOPEPxt + HEXT -> OPEPptr3
YKR093VVPTR2PeptidePEPTxt + HEXT -> PEPTptr4
YBR021WFUR4UracilURAxt + HEXT -> URAuraup1
Nicotinamide mononucleotide transporterNMNxt + HEXT -> NMNnmnup
YER056CFCY2Cytosine purine permeaseCYTSxt + HEXT -> CYTSfcy2_1
YER056CFCY2AdenineADxt + HEXT -> ADfcy2_2
YER056CFCY2GuanineGNxt + HEXT <-> GNfcy2_3
YER060WFCY21Cytosine purine permeaseCYTSxt + HEXT -> CYTSfcy21_1
YER060WFCY21AdenineADxt + HEXT -> ADfcy21_2
YER060WFCY21GuanineGNxt + HEXT <-> GNfcy21_3
YER060W-AFCY22Cytosine purine permeaseCYTSxt + HEXT -> CYTSfcy22_1
YER060W-AFCY22AdenineADxt + HEXT -> ADfcy22_2
YER060W-AFCY22GuanineGNxt + HEXT <-> GNfcy22_3
YGL186CYGL186CCytosine purine permeaseCYTSxt + HEXT -> CYTScytup1
YGL186CYGL186CAdenineADxt + HEXT -> ADadup1
YGL186CYGL186CGuanineGNxt + HEXT <-> GNgnup
G-systemADNxt + HEXT -> ADNncgup1
G-systemGSNxt + HEXT -> GSNncgup3
YBL042CFUI1Uridine permease, G-systemURIxt + HEXT -> URIuriup
G-systemCYTDxt + HEXT -> CYTDncgup4
G-system (transports all nucleosides)INSxt + HEXT -> INSncgup5
G-systemXTSINExt + HEXT -> XTSINEncgup6
G-systemDTxt + HEXT -> DTncgup7
G-systemDINxt + HEXT -> DINncgup8
G-systemDGxt + HEXT -> DGncgup9
G-systemDAxt + HEXT -> DAncgup10
G-systemDCxt + HEXT -> DCncgup11
G-systemDUxt + HEXT -> DUncgup12
C-systemADNxt + HEXT -> ADNnccup1
YBL042CFUI1Uridine permease, C-systemURIxt + HEXT -> URInccup2
C-systemCYTDxt + HEXT -> CYTDnccup3
C-systemDTxt + HEXT -> DTnccup4
C-systemDAxt + HEXT -> DAnccup5
C-systemDCxt + HEXT -> DCnccup6
C-systemDUxt + HEXT -> DUnccup7
Nucleosides and deoxynucleosideADNxt + HEXT -> ADNncup1
Nucleosides and deoxynucleosideGSNxt + HEXT -> GSNncup2
YBL042CFUI1Uridine permease, Nucleosides and deoxynucleosideURIxt + HEXT -> URIncup3
Nucleosides and deoxynucleosideCYTDxt + HEXT -> CYTDncup4
Nucleosides and deoxynucleosideINSxt + HEXT -> INSncup5
Nucleosides and deoxynucleosideDTxt + HEXT -> DTncup7
Nucleosides and deoxynucleosideDINxt + HEXT -> DINncup8
Nucleosides and deoxynucleosideDGxt + HEXT -> DGncup9
Nucleosides and deoxynucleosideDAxt + HEXT -> DAncup10
Nucleosides and deoxynucleosideDCxt + HEXT -> DCncup11
Nucleosides and deoxynucleosideDUxt + HEXT -> DUncup12
HypoxanthineHYXNxt + HEXT <-> HYXNhyxnup
XanthineXANxt <-> XANxanup
Metabolic By-Products
YCR032WBPH1Probable acetic acid export pump, Acetate transportACxt + HEXT <-> ACacup
Formate transportFORxt <-> FORforup
Ethanol transportETHxt <-> ETHethup
Succinate transportSUCCxt + HEXT <-> SUCCsuccup
YKL217WJEN1Pyruvate lactate proton symportPYRxt + HEXT -> PYRjen1_1
Other Compounds
YHL016Cdur3Urea active transportUREAxt + 2 HEXT <-> UREAdur3
YGR121CMEP1Ammonia transportNH3xt <-> NH3mep1
YNL142WMEP2Ammonia transport, low capacity high affinityNH3xt <-> NH3mep2
YPR138CMEP3Ammonia transport, high capacity low affinityNH3xt <-> NH3mep3
YJL129Ctrk1Potassium transporter of the plasma membrane, highKxt + HEXT <-> Ktrk1
affinity, member of the potassium transporter (TRK)
family of membrane transporters
YBR294WSUL1Sulfate permeaseSLFxt -> SLFsul1
YLR092WSUL2Sulfate permeaseSLFxt -> SLFsul2
YGR125WYGR125WSulfate permeaseSLFxt -> SLFsulup
YML123Cpho84inorganic phosphate transporter, transmembrane proteinPIxt + HEXT <-> PIpho84
CitrateCITxt + HEXT <-> CITcitup
DicarboxylatesFUMxt + HEXT <-> FUMfumup
Fatty acid transportC140xt -> C140faup1
Fatty acid transportC160xt -> C160faup2
Fatty acid transportC161xt -> C161faup3
Fatty acid transportC180xt -> C180faup4
Fatty acid transportC181xt -> C181faup5
a-KetoglutarateAKGxt + HEXT <-> AKGakgup
YLR138WNHA1Putative Na+/H+ antiporterNAxt <-> NA + HEXTnha1
YCR028CFEN2PantothenatePNTOxt + HEXT <-> PNTOfen2
ATP drain flux for constant maintanence requirementsATP -> ADP + PIatpmt
YCR024c-aPMP1H+-ATPase subunit, plasma membraneATP -> ADP + PI + HEXTpmp1
YEL017c-aPMP2H+-ATPase subunit, plasma membraneATP -> ADP + PI + HEXTpmp2
YGL008cPMA1H+-transporting P-type ATPase, major isoform, plasmaATP -> ADP + PI + HEXTpma1
membrane
YPL036wPMA2H+-transporting P-type ATPase, minor isoform, plasmaATP -> ADP + PI + HEXTpma2
membrane
Glyceraldehyde transportGLALxt <-> GLALglaltx
Acetaldehyde transportACALxt <-> ACALacaltx
YLR237WTHI7Thiamine transport proteinTHMxt + HEXT -> THIAMINthm1
YOR071CYOR071CProbable low affinity thiamine transporterTHMxt + HEXT -> THIAMINthm2
YOR192CYOR192CProbable low affinity thiamine transporterTHMxt + HEXT -> THIAMINthm3
YJR028Wdal4ATNxt -> ATNdal4
YJR152Wdal5ATTxt -> ATTdal5
MTHNxt <-> MTHNmthup
PAPxt <-> PAPpapx
DTTPxt <-> DTTPdttpx
THYxt <-> THY + HEXTthyx
GA6Pxt <-> GA6Pga6pup
YGR065CVHT1H+/biotin symporter and member of the allantoateBTxt + HEXT <-> BTbtup
permease family of the major facilitator superfamily
AONAxt + HEXT <-> AONAkapaup
DANNAxt + HEXT <-> DANNAdapaup
OGTxt -> OGTogtup
SPRMxt -> SPAMsprmup
PIMExt -> PIMEpimeup
Oxygen transportO2xt <-> O2o2tx
Carbon dioxide transportCO2xt <-> CO2co2tx
YOR011WAUS1ERGOSTxt <-> ERGOSTergup
YOR011WAUS1Putative sterol transporterZYMSTxt <-> ZYMSTzymup
RFLAVxt + HEXT -> RIBFLAVrflup
TABLE 3
AbbreviationMetabolite
13GLUCAN1,3-beta-D-Glucan
13PDG3-Phospho-D-glyceroyl phosphate
23DAACP2,3-Dehydroacyl-[acyl-carrier-protein]
23PDG2,3-Bisphospho-D-glycerate
2HDACPHexadecenoyl-[acp]
2MANPD(“alpha”-D-mannosyl)(,2)-“beta”-D-
mannosyl-diacetylchitobiosyldiphosphod olichol
2N6H2-Nonaprenyl-6-hydroxyphenol
2NMHMB3-Demethylubiquinone-9
2NMHMBm3-Demethylubiquinone-9M
2NPMBm2-Nonaprenyl-6-methoxy-1,4-benzoquinoneM
2NPMMBm2-Nonaprenyl-3-methyl-6-methoxy-1,4-benzoquinoneM
2NPMP2-Nonaprenyl-6-methoxyphenol
2NPMPm2-Nonaprenyl-6-methoxyphenolM
2NPPP2-Nonaprenylphenol
2PG2-Phospho-D-glycerate
3DDAH7P2-Dehydro-3-deoxy-D-arabino-heptonate 7-phosphate
3HPACP(3R)-3-Hydroxypalmitoyl-[acyl-carrier protein]
3PG3-Phospho-D-glycerate
3PSER3-Phosphoserine
3PSME5-O-(1-Carboxyvinyl)-3-phosphoshikimate
4HBZ4-Hydroxybenzoate
4HLT4-Hydroxy-L-threonine
4HPP3-(4-Hydroxyphenyl)pyruvate
4PPNCYS(R)-4′-Phosphopantothenoyl-L-cysteine
4PPNTEPantetheine 4′-phosphate
4PPNTEmPantetheine 4′-phosphateM
4PPNTOD-4′-Phosphopantothenate
5MTA5′-Methylthioadenosine
6DGLCD-Gal alpha 1->6D-Glucose
A6RP5-Amino-6-ribitylamino-2,4 (1H,3H)-pyrimidinedione
A6RP5P5-Amino-6-(5′-phosphoribosylamino)uracil
A6RP5P25-Amino-6-(5′-phosphoribitylamino)uracil
AACCOAAcetoacetyl-CoA
AACPAcyl-[acyl-carrier-protein]
AATRE6Palpha,alpha′-Trehalose 6-phosphate
ABUTm2-Aceto-2-hydroxy butyrateM
ACAcetate
ACACPAcyl-[acyl-carrier protein]
ACACPmAcyl-[acyl-carrier protein]M
ACALAcetaldehyde
ACALmAcetaldehydeM
ACARO-Acetylcarnitine
ACARmO-AcetylcarnitineM
ACCOAAcetyl-CoA
ACCOAmAcetyl-CoAM
ACLAC2-Acetolactate
ACLACm2-AcetolactateM
ACmAcetateM
ACNL3-Indoleacetonitrile
ACOAAcyl-CoA
ACPAcyl-carrier protein
ACPmAcyl-carrier proteinM
ACTACAcetoacetate
ACTACmAcetoacetateM
ACYBUTgamma-Amino-gamma-cyanobutanoate
ADAdenine
ADCHOR4-amino-4-deoxychorismate
ADmAdenineM
ADNAdenosine
ADNmAdenonsineM
ADPADP
ADPmADPM
ADPRIBADPribose
ADPRIBmADPriboseM
AGL3PAcyl-sn-glycerol 3-phosphate
AHHMD2-Amino-7,8-dihydro-4-hydroxy-6-
(diphosphooxymethyl)pteridine
AHHMP2-Amino-4-hydroxy-6-hydroxymethyl-7,8-
dihydropteridine
AHM4-Amino-5-hydroxymethyl-2-methylpyrimidine
AHMP4-Amino-2-methyl-5-phosphomethylpyrimidine
AHMPP2-Methyl-4-amino-5-hydroxymethylpyrimidine
diphosphate
AHTD2-Amino-4-hydroxy-6-(erythro-1,2,3-
trihydroxypropyl)-dihydropteridine triphosphate
AICAR1-(5′-Phosphoribosyl)-5-amino-4-imidazolecarboxamide
AIRAminoimidazole ribotide
AKA2-Oxoadipate
AKAm2-OxoadipateM
AKG2-Oxoglutarate
AKGm2-OxoglutarateM
AKP2-Dehydropantoate
AKPm2-DehydropantoateM
ALAL-Alanine
ALAGLYR-S-Alanylglycine
ALAmL-AlanineM
ALAV5-Aminolevulinate
ALAVm5-AminolevulinateM
ALTRNAL-Arginyl-tRNA(Arg)
AM6SA2-Aminomuconate 6-semialdehyde
AMAL-2-Aminoadipate
AMASAL-2-Aminoadipate 6-semialdehyde
AMGMethyl-D-glucoside
AMPAMP
AMPmAMPM
AMUCO2-Aminomuconate
ANAnthranilate
AONA8-Amino-7-oxononanoate
APEPNalpha-Acetylpeptide
APROA3-Aminopropanal
APROPalpha-Aminopropiononitrile
APRUTN-Acetylputrescine
APSAdenylylsulfate
ARABD-Arabinose
ARABLACD-Arabinono-1,4-lactone
ARGL-Arginine
ARGSUCCN-(L-Arginino)succinate
ASERO-Acetyl-L-serine
ASNL-Asparagine
ASPL-Aspartate
ASPERMDN1-Acetylspermidine
ASPmL-AspartateM
ASPRMN1-Acetylspermine
ASPSAL-Aspartate 4-semialdehyde
ASPTRNAL-Asparaginyl-tRNA(Asn)
ASPTRNAmL-Asparaginyl-tRNA(Asn)M
ASUCN6-(1,2-Dicarboxyethyl)-AMP
AT3P2Acyldihydroxyacetone phosphate
ATNAllantoin
ATPATP
ATPmATPM
ATRNAtRNA(Arg)
ATRPP1,P4-Bis(5′-adenosyl) tetraphosphate
ATTAllantoate
bALAbeta-Alanine
BASP4-Phospho-L-aspartate
bDG6Pbeta-D-Glucose 6-phosphate
bDGLCbeta-D-Glucose
BIOBiotin
BTBiotin
C100ACPDecanoyl-[acp]
C120ACPDodecanoyl-[acyl-carrier protein]
C120ACPmDodecanoyl-[acyl-carrier protein]M
C140Myristic acid
C140ACPMyristoyl-[acyl-carrier protein]
C140ACPmMyristoyl-[acyl-carrier protein]M
C141ACPTetradecenoyl-[acyl-carrier protein]
C141ACPmTetradecenoyl-[acyl-carrier protein]M
C160Palmitate
C160ACPHexadecanoyl-[acp]
C160ACPmHexadecanoyl-[acp]M
C1611-Hexadecene
C161ACPPalmitoyl-[acyl-carrier protein]
C161ACPmPalmitoyl-[acyl-carrier protein]M
C16AC16_aldehydes
C180Stearate
C180ACPStearoyl-[acyl-carrier protein]
C180ACPmStearoyl-[acyl-carrier protein]M
C1811-Octadecene
C181ACPOleoyl-[acyl-carrier protein]
C181ACPmOleoyl-[acyl-carrier protein]M
C182ACPLinolenoyl-[acyl-carrier protein]
C182ACPmLinolenoyl-[acyl-carrier protein]M
CAASPN-Carbamoyl-L-aspartate
CAIR1-(5-Phospho-D-ribosyl)-5-amino-
4-imidazolecarboxylate
CALH2-(3-Carboxy-3-aminopropyl)-L-histidine
cAMP3′,5′-Cyclic AMP
CAPCarbamoyl phosphate
CARCarnitine
CARmCarnitineM
CBHCAP3-Isopropylmalate
CBHCAPm3-IsopropylmalateM
cCMP3′,5′-Cyclic CMP
cdAMP3′,5′-Cyclic dAMP
CDPCDP
CDPCHOCDPcholine
CDPDGCDPdiacylglycerol
CDPDGmCDPdiacylglycerolM
CDPETNCDPethanolamine
CER2Ceramide-2
CER3Ceramide-3
CGLYCys-Gly
cGMP3′,5′-Cyclic GMP
CHCOA6-Carboxyhexanoyl-CoA
CHITChitin
CHITOChitosan
CHOCholine
CHORChorismate
cIMP3′,5′-Cyclic IMP
CITCitrate
CITmCitrateM
CITRL-Citrulline
CLmCardiolipinM
CMPCMP
CMPmCMPM
CMUSA2-Amino-3-carboxymuconate semialdehyde
CO2CO2
CO2mCO2M
COACoA
COAmCoAM
CPAD5P1-(2-Carboxyphenylamino)-1-deoxy-
D-ribulose 5-phosphate
CPPCoproporphyrinogen
CTPCTP
CTPmCTPM
CYSL-Cysteine
CYTDCytidine
CYTSCytosine
D45PI1-Phosphatidyl-D-myo-inositol 4,5-bisphosphate
D6PGC6-Phospho-D-gluconate
D6PGLD-Glucono-1,5-lactone 6-phosphate
D6RP5P2,5-Diamino-6-hydroxy-4-(5′-phosphoribosyl-
amino)-pyrimidine
D8RL6,7-Dimethyl-8-(1-D-ribityl)lumazine
DADeoxyadenosine
DADPdADP
DAGLYDiacylglycerol
DAMPdAMP
dAMPdAMP
DANNA7,8-Diaminononanoate
DAPRP1,3-Diaminopropane
DATPdATP
DB4PL-3,4-Dihydroxy-2-butanone 4-phosphate
DCDeoxycytidine
DCDPdCDP
DCMPdCMP
DCTPdCTP
DFUCalpha-D-Fucoside
DGDeoxyguanosine
DGDPdGDP
DGMPdGMP
DGPPDiacylglycerol pyrophosphate
DGTPdGTP
DHFDihydrofolate
DHFmDihydrofolateM
DHMVAm(R)-2,3-dihydroxy-3-methylbutanoateM
DHP2-Amino-4-hydroxy-6-(D-erythro-1,2,3-
trihydroxypropyl)-7,8-dihydropteridine
DHPPDihydroneopterin phosphate
DHPTDihydropteroate
DHSK3-Dehydroshikimate
DHSPSphinganine 1-phosphate
DHSPH3-Dehydrosphinganine
DHVALm(R)-3-Hydroxy-3-methyl-2-oxobutanoateM
DIMGPD-erythro-1-(Imidazol-4-yl)glycerol 3-phosphate
DINDeoxyinosine
DIPEPDipeptide
DISAC1P2,3-bis(3-hydroxytetradecanoyl)-D-glucosaminyl-
1,6-beta-D-2,3-bis(3-hydroxytetra-decanoyl)-beta-D-
glucosaminyl 1-phosphate
DLIPOmDihydrolipoamideM
DMPPDimethylallyl diphosphate
DMZYMST4,4-Dimethylzymosterol
DOLDolichol
DOLMANPDolichyl beta-D-mannosyl phosphate
DOLPDolichyl phosphate
DOLPPDehydrodolichol diphosphate
DOROA(S)-Dihydroorotate
DPCOADephospho-CoA
DPCOAmDephospho-CoAM
DPTH2-[3-Carboxy-3-(methylammonio)propyl]-L-histidine
DQT3-Dehydroquinate
DR1PDeoxy-ribose 1-phosphate
DR5P2-Deoxy-D-ribose 5-phosphate
DRIBDeoxyribose
DSAMS-Adenosylmethioninamine
DTThymidine
DTBDethiobiotin
DTBmDethiobiotinM
DTDPdTDP
DTMPdTMP
DTP1-Deoxy-d-threo-2-pentulose
DTTPdTTP
DUDeoxyuridine
DUDPdUDP
DUMPdUMP
DUTPdUTP
E4PD-Erythrose 4-phosphate
EPMEpimelibiose
EPSTEpisterol
ER4P4-Phospho-D-erythronate
ERGOSTErgosterol
ERTEOLErgosta-5,7,22,24(28)-tetraenol
ERTROLErgosta-5,7,24(28)-trienol
ETHEthanol
ETHmEthanolM
ETHMEthanolamine
F1PD-Fructose 1-phosphate
F26PD-Fructose 2,6-bisphosphate
F6Pbeta-D-Fructose 6-phosphate
FADFAD
FADH2mFADH2M
FADmFADM
FALDFormaldehyde
FDPbeta-D-Fructose 1,6-bisphosphate
FERImFerricytochrome cM
FEROmFerrocytochrome cM
FESTFecosterol
FGAM2-(Formamido)-N1-(5′-phosphoribosyl)acetamidine
FGAR5′-Phosphoribosyl-N-formylglycinamide
FGTS-Formylglutathione
FKYNL-Formylkynurenine
FMNFMN
FMNmFMNM
FMRNAmN-Formylmethionyl-tRNAM
FORFormate
FORmFormateM
FPPtrans,trans-Farnesyl diphosphate
FRUD-Fructose
FTHF10-Formyltetrahydrofolate
FTHFm10-FormyltetrahydrofolateM
FUACAC4-Fumarylacetoacetate
FUCbeta-D-Fucose
FUMFumarate
FUMmFumarateM
G1PD-Glucose 1-phosphate
G6Palpha-D-Glucose 6-phosphate
GA1PD-Glucosamine 1-phosphate
GA6PD-Glucosamine 6-phosphate
GABA4-Aminobutanoate
GABAL4-Aminobutyraldehyde
GABALm4-AminobutyraldehydeM
GABAm4-AminobutanoateM
GAL1PD-Galactose 1-phosphate
GAR5′-Phosphoribosylglycinamide
GBAD4-Guanidino-butanamide
GBAT4-Guanidino-butanoate
GCgamma-L-Glutamyl-L-cysteine
GDPGDP
GDPmGDPM
GDPMANGDPmannose
GGLGalactosylglycerol
GLGlycerol
GL3Psn-Glycerol 3-phosphate
GL3Pmsn-Glycerol 3-phosphateM
GLACD-Galactose
GLACL1-alpha-D-Galactosyl-myo-inositol
GLALGlycolaldehyde
GLAMGlucosamine
GLCalpha-D-Glucose
GLCNGluconate
GLNL-Glutamine
GLPGlycylpeptide
GLTL-Glucitol
GLUL-Glutamate
GLUGSALL-Glutamate 5-semialdehyde
GLUGSALmL-Glutamate 5-semialdehydeM
GLUmGlutamateM
GLUPalpha-D-Glutamyl phosphate
GLXGlyoxylate
GLYGlycine
GLYCOGENGlycogen
GLYmGlycineM
GLYNGlycerone
GMPGMP
GNGuanine
GNmGuanineM
GPPGeranyl diphosphate
GSNGuanosine
GSNmGuanosineM
GTPGTP
GTPmGTPM
GTRNAL-Glutamyl-tRNA(Glu)
GTRNAmL-Glutamyl-tRNA(Glu)M
GTRPP1,P4-Bis(5′-guanosyl) tetraphosphate
H2O2H2O2
H2SHydrogen sulfide
H2SO3Sulfite
H3MCOA(S)-3-Hydroxy-3-methylglutaryl-CoA
H3MCOAm(S)-3-Hydroxy-3-methylglutaryl-CoAM
HACNmBut-1-ene-1,2,4-tricarboxylateM
HACOA(3S)-3-Hydroxyacyl-CoA
HAN3-Hydroxyanthranilate
HBA4-Hydroxy-benzyl alcohol
HCIT2-Hydroxybutane-1,2,4-tricarboxylate
HCITm2-Hydroxybutane-1,2,4-tricarboxylateM
HCYSHomocysteine
HEXTH + EXT
HHTRNAL-Histidyl-tRNA(His)
HIB(S)-3-Hydroxyisobutyrate
HIBCOA(S)-3-Hydroxyisobutyryl-CoA
HICITmHomoisocitrateM
HISL-Histidine
HISOLL-Histidinol
HISOLPL-Histidinol phosphate
HKYN3-Hydroxykynurenine
HmH+M
HMBHydroxymethylbilane
HOMOGENHomogentisate
HPROtrans-4-Hydroxy-L-proline
HSERL-Homoserine
HTRNAtRNA(His)
HYXANHypoxanthine
IACIndole-3-acetate
IADIndole-3-acetamide
IBCOA2-Methylpropanoyl-CoA
ICITIsocitrate
ICITmIsocitrateM
IDPIDP
IDPmIDPM
IGPIndoleglycerol phosphate
IGST4,4-Dimethylcholesta-8,14,24-trienol
IIMZYMSTIntermediate_Methylzymosterol_II
IIZYMSTIntermediate_Zymosterol_II
ILEL-Isoleucine
ILEmL-IsoleucineM
IMACP3-(Imidazol-4-yl)-2-oxopropyl phosphate
IMPIMP
IMZYMSTIntermediate_Methylzymosterol_I
INACIndoleacetate
INSInosine
IPCInositol phosphorylceramide
IPPMAL2-Isopropylmalate
IPPMALm2-IsopropylmalateM
IPPPIsopentenyl diphosphate
ISUCCa-Iminosuccinate
ITCCOAmItaconyl-CoAM
ITCmItaconateM
ITPITP
ITPmITPM
IVCOA3-Methylbutanoyl-CoA
IZYMSTIntermediate_Zymosterol_I
KPotassium
KYNL-Kynurenine
LAC(R)-Lactate
LACALm(S)-LactaldehydeM
LACm(R)-LactateM
LCCAa Long-chain carboxylic acid
LEUL-Leucine
LEUmL-LeucineM
LGT(R)—S-Lactoylglutathione
LGTm(R)—S-LactoylglutathioneM
LIPIV2,3,2′,3′-tetrakis(3-hydroxytetradecanoyl)-D-
glucosaminyl-1,6-beta-D-
glucosamine 1,4′-bisphosphate
LIPOmLipoamideM
LIPXLipid X
LLACm(S)-LactateM
LLCTL-Cystathionine
LLTRNAL-lysyl-tRNA(Lys)
LLTRNAmL-lysyl-tRNA(Lys)M
LNSTLanosterol
LTRNAtRNA(Lys)
LTRNAmtRNA(Lys)M
LYSL-Lysine
LYSmL-LysineM
MAACOAa-Methylacetoacetyl-CoA
MACAC4-Maleylacetoacetate
MACOA2-Methylprop-2-enoyl-CoA
MALMalate
MALACPMalonyl-[acyl-carrier protein]
MALACPmMalonyl-[acyl-carrier protein]M
MALCOAMalonyl-CoA
MALmMalateM
MALTMalonate
MALTmMalonateM
MANalpha-D-Mannose
MAN1Palpha-D-Mannose 1-phosphate
MAN2PDbeta-D-Mannosyldiacetylchitobiosyldiphosphodolichol
MAN6PD-Mannose 6-phosphate
MANNANMannan
MBCOAMethylbutyryl-CoA
MCCOA2-Methylbut-2-enoyl-CoA
MCRCOA2-Methylbut-2-enoyl-CoA
MDAPMeso-diaminopimelate
MELIMelibiose
MELTMelibiitol
METL-Methionine
METHMethanethiol
METHF5,10-Methenyltetrahydrofolate
METHFm5,10-MethenyltetrahydrofolateM
METTHF5,10-Methylenetetrahydrofolate
METTHFm5,10-MethylenetetrahydrofolateM
MGCOA3-Methylglutaconyl-CoA
MHISN(pai)-Methyl-L-histidine
MHVCOAa-Methyl-b-hydroxyvaleryl-CoA
MImyo-Inositol
MI1P1L-myo-Inositol 1-phosphate
MIP2CInositol-mannose-P-inositol-P-ceramide
MIPCMannose-inositol-P-ceramide
MKMenaquinone
MLTMaltose
MMCOAMethylmalonyl-CoA
MMETS-Methylmethionine
MMS(S)-Methylmalonate semialdehyde
MNTD-Mannitol
MNT6PD-Mannitol 1-phosphate
MTHF5-Methyltetrahydrofolate
MTHFm5-MethyltetrahydrofolateM
MTHGXLMethylglyoxal
MTHNMethane
MTHNmMethaneM
MTHPTGLU5-Methyltetrahydropteroyltri-L-glutamate
MTRNAmL-Methionyl-tRNAM
MVL(R)-Mevalonate
MVLm(R)-MevalonateM
MYOImyo-Inositol
MZYMST4-Methylzymsterol
N4HBZ3-Nonaprenyl-4-hydroxybenzoate
NASodium
NAADDeamino-NAD+
NAADmDeamino-NAD+M
NACNicotinate
NACmNicotinateM
NADNAD+
NADHNADH
NADHmNADHM
NADmNAD+M
NADPNADP+
NADPHNADPH
NADPHmNADPHM
NADPmNADP+M
NAGN-Acetylglucosamine
NAGA1PN-Acetyl-D-glucosamine 1-phosphate
NAGA6PN-Acetyl-D-glucosamine 6-phosphate
NAGLUmN-Acetyl-L-glutamateM
NAGLUPmN-Acetyl-L-glutamate 5-phosphateM
NAGLUSmN-Acetyl-L-glutamate 5-semialdehydeM
NAMNicotinamide
NAMmNicotinamideM
NAMNNicotinate D-ribonucleotide
NAMNmNicotinate D-ribonucleotideM
NAORNmN2-Acetyl-L-ornithineM
NH3NH3
NH3mNH3M
NH4NH4+
NPPall-trans-Nonaprenyl diphosphate
NPPmall-trans-Nonaprenyl diphosphateM
NPRANN-(5-Phospho-D-ribosyl)anthranilate
O2Oxygen
O2mOxygenM
OAOxaloacetate
OACOA3-Oxoacyl-CoA
OAHSERO-Acetyl-L-homoserine
OAmOxaloacetateM
OBUT2-Oxobutanoate
OBUTm2-0xobutanoateM
OFPOxidized flavoprotein
OGTOxidized glutathione
OHB2-Oxo-3-hydroxy-4-phosphobutanoate
OHmHO-M
OICAP3-Carboxy-4-methyl-2-oxopentanoate
OICAPm3-Carboxy-4-methyl-2-oxopentanoateM
OIVAL(R)-2-Oxoisovalerate
OIVALm(R)-2-OxoisovalerateM
OMPOrotidine 5′-phosphate
OMVAL3-Methyl-2-oxobutanoate
OMVALm3-Methyl-2-oxobutanoateM
OPEPOligopeptide
ORNL-Ornithine
ORNmL-OrnithineM
OROAOrotate
OSLHSERO-Succinyl-L-homoserine
OSUCOxalosuccinate
OSUCmOxalosuccinateM
OTHIOOxidized thioredoxin
OTHIOmOxidized thioredoxinM
OXAOxaloglutarate
OXAmOxaloglutarateM
P5C(S)-1-Pyrroline-5-carboxylate
P5Cm(S)-1-Pyrroline-5-carboxylateM
P5PPyridoxine phosphate
PAPhosphatidate
PABA4-Aminobenzoate
PACPhenylacetic acid
PAD2-Phenylacetamide
PALCOAPalmitoyl-CoA
PAmPhosphatidateM
PANT(R)-Pantoate
PANTm(R)-PantoateM
PAPAdenosine 3′,5′-bisphosphate
PAPS3′-Phosphoadenylylsulfate
PBGPorphobilinogen
PCPhosphatidylcholine
PC2Sirohydrochlorin
PCHOCholine phosphate
PDLAPyridoxamine
PDLA5PPyridoxamine phosphate
PDMEPhosphatidyl-N-dimethylethanolamine
PEPhosphatidylethanolamine
PEmPhosphatidylethanolamineM
PEPPhosphoenolpyruvate
PEPDPeptide
PEPmPhosphoenolpyruvateM
PEPTPeptide
PETHMEthanolamine phosphate
PGmPhosphatidylglycerolM
PGPmPhosphatidylglycerophosphateM
PHCL-1-Pyrroline-3-hydroxy-5-carboxylate
PHEL-Phenylalanine
PHENPrephenate
PHP3-Phosphonooxypyruvate
PHPYRPhenylpyruvate
PHSERO-Phospho-L-homoserine
PHSPPhytosphingosine 1-phosphate
PHTO-Phospho-4-hydroxy-L-threonine
PIOrthophosphate
PImOrthophosphateM
PIMEPimelic Acid
PINS1-Phosphatidyl-D-myo-inositol
PINS4P1-Phosphatidyl-1D-myo-inositol 4-phosphate
PINSP1-Phosphatidyl-1D-myo-inositol 3-phosphate
PLPyridoxal
PL5PPyridoxal phosphate
PMMEPhosphatidyl-N-methylethanolamine
PMVL(R)-5-Phosphomevalonate
PNTO(R)-Pantothenate
PPHGProtoporphyrinogen IX
PPHGmProtoporphyrinogen IXM
PPIPyrophosphate
PPImPyrophosphateM
PPIXmProtoporphyrinM
PPMAL2-Isopropylmaleate
PPMVL(R)-5-Diphosphomevalonate
PRAM5-Phosphoribosylamine
PRBAMPN1-(5-Phospho-D-ribosyl)-AMP
PRBATPN1-(5-Phospho-D-ribosyl)-ATP
PRFICA1-(5′-Phosphoribosyl)-5-formamido-4-
imidazolecarboxamide
PRFP5-(5-Phospho-D-ribosylaminoformimino)-1-
(5-phosphoribosyl)-imidazole-4-carboxamide
PRLPN-(5′-Phospho-D-1′-ribulosylformimino)-5-amino-
1-(5″-phospho-D-ribosyl)-4-imidazolecarboxamide
PROL-Proline
PROmL-ProlineM
PROPCOAPropanoyl-CoA
PRPP5-Phospho-alpha-D-ribose 1-diphosphate
PRPPm5-Phospho-alpha-D-ribose 1-diphosphateM
PSPhosphatidylserine
PSmPhosphatidylserineM
PSPHPhytosphingosine
PTHmHemeM
PTRCPutrescine
PTRSCPutrescine
PUR15PPseudouridine 5′-phosphate
PYRPyruvate
PYRDXPyridoxine
PYRmPyruvateM
QUbiquinone-9
QAPyridine-2,3-dicarboxylate
QAmPyridine-2,3-dicarboxylateM
QH2Ubiquinol
QH2mUbiquinolM
QmUbiquinone-9M
R1PD-Ribose 1-phosphate
R5PD-Ribose 5-phosphate
RADP4-(1-D-Ribitylamino)-5-amino-2,6-dihydroxypyrimidine
RAFRaffinose
RFPReduced flavoprotein
RGTGlutathione
RGTmGlutathioneM
RIBD-Ribose
RIBFLAVmRiboflavinM
RIBOFLAVRiboflavin
RIPmalpha-D-Ribose 1-phosphateM
RL5PD-Ribulose 5-phosphate
RMND-Rhamnose
RTHIOReduced thioredoxin
RTHIOmReduced thioredoxinM
SSulfur
S17PSedoheptulose 1,7-bisphosphate
S23E(S)-2,3-Epoxysqualene
S7PSedoheptulose 7-phosphate
SACPN6-(L-1,3-Dicarboxypropyl)-L-lysine
SAHS-Adenosyl-L-homocysteine
SAHmS-Adenosyl-L-homocysteineM
SAICAR1-(5′-Phosphoribosyl)-5-amino-4-(N-
succinocarboxamide)-imidazole
SAMS-Adenosyl-L-methionine
SAMmS-Adenosyl-L-methionineM
SAMOBS-Adenosyl-4-methylthio-2-oxobutanoate
SAPmS-AminomethyldihydrolipoylproteinM
SERL-Serine
SERmL-SerineM
SLFSulfate
SLFmSulfateM
SMEShikimate
SME5PShikimate 3-phosphate
SORSorbose
SOR1PSorbose 1-phosphate
SOTD-Sorbitol
SPHSphinganine
SPMDSpermidine
SPRMSpermine
SPRMDSpermidine
SQLSqualene
SUCSucrose
SUCCSuccinate
SUCCmSuccinateM
SUCCOAmSuccinyl-CoAM
SUCCSALSuccinate semialdehyde
T3P1D-Glyceraldehyde 3-phosphate
T3P2Glycerone phosphate
T3P2mGlycerone phosphateM
TAG16PD-Tagatose 1,6-bisphosphate
TAG6PD-Tagatose 6-phosphate
TAGLYTriacylglycerol
TCOATetradecanoyl-CoA
TGLPN-Tetradecanoylglycylpeptide
THFTetrahydrofolate
THFGTetrahydrofolyl-[Glu](n)
THFmTetrahydrofolateM
THIAMINThiamin
THMPThiamin monophosphate
THPTGLUTetrahydropteroyltri-L-glutamate
THRL-Threonine
THRmL-ThreonineM
THYThymine
THZ5-(2-Hydroxyethyl)-4-methylthiazole
THZP4-Methyl-5-(2-phosphoethyl)-thiazole
TPID-myo-inositol 1,4,5-trisphosphate
TPPThiamin diphosphate
TPPPThiamin triphosphate
TREalpha,alpha-Trehalose
TRE6Palpha,alpha′-Trehalose 6-phosphate
TRNAtRNA
TRNAGtRNA(Glu)
TRNAGmtRNA(Glu)M
TRNAmtRNAM
TRPL-Tryptophan
TRPmL-TryptophanM
TRPTRNAmL-Tryptophanyl-tRNA(Trp)M
TYRL-Tyrosine
UDPUDP
UDPGUDPglucose
UDPG23AUDP-2,3-bis(3-hydroxytetradecanoyl)glucosamine
UDPG2AUDP-3-O-(3-hydroxytetradecanoyl)-D-glucosamine
UDPG2AAUDP-3-O-(3-hydroxytetradecanoyl)-N-acetylglucosamine
UDPGALUDP-D-galactose
UDPNAGUDP-N-acetyl-D-galactosamine
UDPPUndecaprenyl diphosphate
UGC(−)-Ureidoglycolate
UMPUMP
UPRGUroporphyrinogen III
URAUracil
UREAUrea
UREACUrea-1-carboxylate
URIUridine
UTPUTP
VALL-Valine
X5PD-Xylose-5-phosphate
XANXanthine
XMPXanthosine 5′-phosphate
XTSINEXanthosine
XTSNXanthosine
XULD-Xylulose
XYLD-Xylose
ZYMSTZymosterol
TABLE 6 — Defined Medium #The isoenyzme Pyk2p is glucose repressed, and cannot sustain growth on glucose. *Model predicts single deletion mutant to be (highly) growth retarded. $ Growth of single deletion mutant is inhibited by glucose. & Different hypotheses exist for why Pgi1p deficient mutants do not grow on glucose, e.g. the pentose phosphate pathway in S. cerevisiae is insufficient to support growth and cannot supply the EMP pathway with sufficient amounts of fructose-6-phosphate and glyceraldehydes-3-phosphate (Boles, 1997). || The isoenzymes Gpm2p and Gpm3p cannot sustain growth on glucose. They only show residual in vivo activity when they are expressed from a foreign promoter (Heinisch et al., 1998). ## Gnd1p accounts for 80% of the enzyme activity. A mutant deleted in GND1 accumulates gluconate-6-phosphate, which is toxic to the cell (Schaaff-Gerstenschläger and Miosga, 1997). $$ ENO1 plays central role in gluconeogenesis whereas ENO2 is used in glycolysis (Müller and Entian, 1997).
CompleteMinimalMinimalMinimal
Carbon Source
GlucoseGlucoseAcetateEthanol
in silico/in silico/in silico/in silico/References:
Genein vivoin vivoin vivoin vivo(Minimal media)
ACO1+/+−/−(Gangloff et al., 1990)
CDC19#+/−+/−(Boles et al., 1998)
CIT1+/++/+(Kim et al., 1986)
CIT2+/++/+(Kim et al., 1986)
CIT3+/+
DAL7+/++/++/++/+(Hartig et al., 1992)
ENO1+/+
ENO2 $$+/−+/−
FBA1*+/−+/−
FBP1+/++/+−/−(Sedivy and Fraenkel, 1985;
Gancedo and Delgado, 1984)
FUM1+/+
GLK1+/+
GND1 ##+/−+/−
GND2+/+
GPM1 ||+/−+/−
GPM2+/+
GPM3+/+
HXK1+/+
HXK2+/+
ICL1+/++/+(Smith et al., 1996)
IDH1+/++/+(Cupp and McAlister-Henn,
1992)
IDH2+/++/+(Cupp and McAlister-Henn,
1992)
IDP1+/++/+(Loftus et al., 1994)
IDP2+/++/+(Loftus et al., 1994)
IDP3+/+
KGD1+/++/+(Repetto and Tzagoloff, 1991)
KGD2+/++/+(Repetto and Tzagoloff, 1991)
LPD1+/+
LSC1+/++/++/+(Przybyla-Zawislak et al., 1998)
LSC2+/++/++/+(Przybyla-Zawislak et al., 1998)
MAE1+/++/++/+(Boles et al., 1998)
MDH1+/++/++/−(McAlister-Henn and Thompson,
1987)
MDH2+/++/−+/−(McAlister-Henn and Thompson,
1987)
MDH3+/+
MLS1+/++/++/++/+(Hartig et al., 1992)
OSM1+/+
PCK1+/+
PDC1+/++/+(Flikweert et al., 1996)
PDC5+/++/+(Flikweert et al., 1996)
PDC6+/++/+(Flikweert et al., 1996)
PFK1+/++/+(Clifton and Fraenkel, 1982)
PFK2+/++/+(Clifton and Fraenkel, 1982)
PGI1* &+/−+/−(Clifton et al., 1978)
PGK1*+/−+/−
PGM1+/++/+(Boles et al., 1994)
PGM2+/++/+(Boles et al., 1994)
PYC1+/++/++/−+/−(Wills and Melham, 1985)
PYC2+/+
PYK2+/++/++/+(Boles et al., 1998; McAlister-
Henn and Thompson, 1987)
RKI1−/−
RPE1+/+
SOL1+/+
SOL2+/+
SOL3+/+
SOL4+/+
TAL1+/++/+(Schaaff-Gerstenschläger and
Zimmermann, 1993)
TDH1+/+
TDH2+/+
TDH3+/+
TKL1+/++/+(Schaff-Gerstenschläger and
Zimmermann, 1993)
TKL2+/+
TPI1* ,$+/−
ZWF1+/++/+(Schaaff-Gerstenschläger and
Zimmermann, 1993)
+/− Growth/no growth
TABLE 7 — Genes involved in dead end
Simulation12pathways3
Number of deletion599599530
Predicted Total509526475
True positive48149651445
True negative2830030
False positive63591742
False negative2714113
Overall Prediction85.0%87.8%89.6%
Positive Prediction88.4%89.4%91.4%
Negative Prediction50.9%68.2%69.8%

Claims as granted

15 claims

Log in to read the claims of this application.

Log in to unlock

Classifications

12 codes
IPC · International Patent Classification
Section C — Chemistry; metallurgy
  • C12Q1/68
Section G — Physics
  • G16B5/00
  • G16B20/00
  • G01N33/48
  • G06G7/58
  • G06F17/30
  • G06F7/60
USPC · US Patent Classification
703/11703/2702/20702/19435/6

Claim changes

Soon
Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this application are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoomApr 2010Jul 2010Oct 2010Jan 2011Apr 2011Jul 2011Oct 2011Jan 2012Apr 2012USPTOApplicantRestriction requirementNon-final rejectionResponse after non-finalNotice of allowance
USPTOApplicanthover for detail · click to open
Pendency
2.0 y
734 days filing → grant
Office actions
1
after a restriction
Responses
2
no RCE
Examiner
Shubo Zhou
art unit 1631 · TC 1600
Citations: 454 back · 1 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Log in to unlock

Documents

Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.

Log in to unlock

Chain of title

⤢ drag to zoom201420162018202020222024202620282030Owner 1
Titlehover for detail · click to open

See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.

Log in to unlock